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Summary 
Disseminated breast cancer cells have been found in the perivascular niche of 
lung, brain and bone marrow. Research has suggested that thrombospondin 1 (TSP1), 
an antiangiogenic protein secreted by endothelial cells, is involved in cancer dormancy. 
My research aims to clarify the role of TSP1 in cancer dormancy. On the other hand, 
breast tumours overexpress indoleamine 2,3-dioxygenase (IDO1) which degrades 
intracellular tryptophan, a key amino acid of TSP1. I aim to investigate whether cancer 
cells induce endothelial IDO1 expression and therefore limit TSP1 synthesis. I 
hypothesize that the decrease of TSP1 might enable cancer cell proliferation and 
angiogenesis. 
To evaluate whether endothelial cells can induce cancer dormancy, MDA-MB-
231 cells were cultured on the top of an endothelial monolayer or treated with endothelial 
conditioned medium. Ki67, p21 and cell cycle analysis showed that endothelial cells 
induce cell cycle arrest in MDA-MB-231 cells but not senescence. ki67 was also 
decreased when MDA-MB-231 cells were cultured with TSP1. MDA-MB-231 revealed to 
be more resistant to docetaxel, a breast cancer drug, when pre-cultured with TSP1.  
Conditioned medium experiments showed that MDA-MB-231 cells are capable of 
inducing endothelial IDO1 expression and it also increased tryptophan degradation, 
which was prevented by siRNA IDO1 knockdown. Interestingly, endothelial TSP1 
secretion was revealed to be decreased under low tryptophan concentration. 
Immunohistochemistry of breast cancer tissue showed that there was a negative 
correlation between vascular IDO1 and stromal TSP1. IFNγ, a potent inducer of IDO1, 
showed to be able to induce endothelial IDO1 and a decrease in endothelial TSP1.  
Taken together, the data presented here suggests that endothelial cells induce 
breast cancer dormancy and drug resistance via TSP1. My research also suggests that 
an IFNγ/IDO1 pathway might decrease TSP1 synthesis leading to cancer cell 
proliferation and angiogenesis. 
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Chapter I: Introduction 
 
2 
 
1.1 Breast cancer 
Breast cancer is the most frequent female cancer and the second cause of cancer 
related death for women worldwide (Druesne-Pecollo et al., 2012; Ferlay et al., 2015). In 
the US alone, the cost of cancer care in 2010 was 124.57 billion US dollars, among of 
which 16.50 billion US dollars was spent on female breast cancer care (Mariotto et al., 
2011). Yet, breast cancer is a highly heterogeneous disease, at both pathology and 
biological level, and the outcome is greatly influenced by the stage of the disease at 
diagnosis (Ferlay et al., 2015; Verma et al., 2012). 
1.1.1 Epidemiology, risk factors and prevention 
Breast cancer accounted for 1.67 million new cases worldwide in 2012, about 
25% of all cancer cases. The incidence rate varies worldwide. For instance, in the Middle 
Africa and Eastern Asia there were 27 cases diagnosed as breast cancer per 100,000 
women, while it raises to 96 in Western Europe. There was also less prevalence of breast 
cancer cases in women from less developed countries, as shown in Figure 1 (Ferlay et 
al., 2015).  
Breast cancer was responsible for 522.000 deaths in 2012 ranking as the fifth 
deadliest cancer overall. In undeveloped countries breast cancer is the leading cause of 
cancer related deaths in women (about 14.3% of total), while it was the second cause of 
death in more developed countries (15.4%) after lung cancer (Ferlay et al., 2015).  
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Figure 1: Estimated numbers of new cancer cases and deaths in more developed 
and less developed countries. Numbers are represented in thousands (Modified from 
(Ferlay et al., 2015). 
 
Breast cancer is a major public health burden and due to the fact that incidence 
is increasing in most countries, the number of new cases will keep rising for the next 20 
years (Arnold et al., 2015; Colditz and Bohlke, 2014; Eccles et al., 2013; Rahib et al., 
2014). In most countries, the number of females with breast cancer risk factors has been 
on the rise. The risk factors include the lower age of the first menstrual period, first 
pregnancy at a late age, fewer pregnancies, shorter or no breastfeeding periods, and 
late age of menopause. Many life styles, such as alcohol consumption, obesity, hormone 
replacement therapy and inactivity are correlated with the incidence of breast cancer 
(Colditz and Bohlke, 2014). Genetic inherent-related risk factors for breast cancer has 
also increased in the past years.  For instance, the breast cancer 2 (BRCA2) mutation 
has been estimated to have increased fourfold in Iceland over the last century 
(Tryggvadottir et al., 2006). Interestingly, the same study estimated that the incidence of 
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sporadic breast cancer in Iceland also increased fourfold in women under 70 years old 
(Tryggvadottir et al., 2006), suggesting that both familial and non-familial breast cancer 
risk factors have increased. 
In 2002, a study estimated that the incidence of breast cancer would drop from 
6.3 to 2.7 per 100 women under the age of 70 in developed countries, if women had 
more children and breastfed for longer periods (Collaborative Group on Hormonal 
Factors in Breast Cancer, 2002). Based on the effects of the current population growth, 
social, economic and health condition, current views suggest that women are not 
encouraged to increase the number of pregnancies or have earlier pregnancie However, 
breastfeeding may have preventative effects on breast cancer. Oestrogen is responsible 
for most reproductive risk factors for breast cancer, which can be reduced by an early 
oophorectomy, or by the inhibitors of oestrogen receptors, such as tamoxifen or 
raloxifene (Cuzick et al., 2013), or the inhibition of oestrogen synthesis [e.g., exemestane 
(Goss et al., 2011) and anastrozole (Brown, 2014; Cuzick et al., 2014)] Tamoxifen and 
raloxifene, which are cheap, safe and effective in antagonising oestrogen, are currently 
used in the NHS as preventive drugs for females with high risk of breast cancer. 
Prophylactic mastectomy is another preventive measure, although it is mostly intended 
for women from high risk families, for example families with inherited BRCA1 mutation 
(Domchek et al., 2010). 
The life style and environment are other important variables, and it has been 
estimated that 26.8% of new breast cancer cases in the UK were caused by these two 
variables (Parkin et al., 2011). So, a healthy and balanced diet, exercise, maintenance 
of a healthy weight, quitting smoking and drinking alcohol are considered preventive 
measures.   
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1.1.2 Histological classification and biomarkers 
Breast cancer can be catalogued into two major groups, carcinoma in situ and 
invasive carcinoma. The in situ carcinoma is subdivided into ductal carcinoma in situ 
(DCIS) when there are abnormal cells in the lining of the breast ducts or lobular 
carcinoma in situ (LCIS) when there are abnormal cells in the breast lobules. DCIS is the 
most common in situ breast carcinoma and has five subgroups of tumours (comedo, 
cribiform, micropapillary and solid). The five subgroups are very heterogeneous between 
them (Malhotra et al., 2010). The invasive carcinomas are also a heterogeneous group 
which is subdivided into infiltrating ductal, invasive lobular, ductal/lobular, mucinous, 
tubular, medullary and papillary carcinomas. Infiltrating ductal carcinoma accounts for 70 
to 80% of the invasive carcinoma (Li et al., 2005). The differentiation level of infiltrating 
ductal carcinoma is graded according to the glandular formation, mitotic index and 
nuclear pleomorphism (Lester et al., 2009). There are three ranks of differentiation grade 
including grade 1 (well-differentiated), grade 2 (moderately differentiated) and grade 3 
(poorly differentiated).  
The classification described above has been used for decades but merely based 
on the histology of the tumour. The advance in breast cancer therapy and in particular 
the recent surge of personalised medicine has increased the necessity to identify new 
biomarkers including molecular markers to stratify the patients with breast cancer by 
improving the knowledge of the tumour according to its biological behaviour, route and 
course to progression, recurrence risk, sensitivity intervention and therapy response.  
Breast cancer is subdivided according to its ER, PR and HER2/neu profile. These 
markers are well accepted for the characterization of infiltrating ductal carcinoma (Harris 
et al., 2007; Malhotra et al., 2010). As these markers can predict which patients are likely 
to respond to specific therapies, it is a helpful tool for clinical decision (Payne et al., 2008; 
Rakha et al., 2010). Ki67 and p53 are other two markers that have been extensively 
studied as prognostic and predictive tools in breast cancer (Nishimura et al., 2010; Ohara 
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et al., 2016). However, techniques and scoring methods have to be standardised to be 
used in everyday practice (Urruticoechea et al., 2005).  
Breast cancer is also graded according to the TNM staging system, which 
evaluates the tumour on the basis of primary tumour (T), lymph-node (N) and metastasis 
(M). It was first established by Pierre Denoix in the 1940s, and it was revised by the 
American Joint Committee on Cancer and International Union against Cancer in 2002 
(Table 1). The TNM classification of a tumour is based on a series of clinical 
examinations, including radiological imaging, biopsies and biochemical analysis (Greene 
and Sobin, 2002).  
1.1.3 Current therapy 
An appropriate evaluation of the tumour is crucial for the clinicians to choose the 
best treatment options. There are standard treatments that are currently available which 
includes surgery, radiation therapy, chemotherapy and hormone therapy. However, 
there are clinical trials that aim to test new drugs that target both conventional and new 
markers or innovative strategies, such as new devices and immunotherapies.  
There are different types of surgery that can be performed in breast cancer 
patients, including lumpectomy, the removal of the lump, mastectomy, the removal of the 
breast or radical mastectomy, the removal of the breast and some axillary lymph nodes. 
The type of surgery executed depends on the stage of the tumour, and each one of the 
approaches carries different risks (Sharma et al., 2010).  
Radiation therapy uses high energy X-rays or gamma rays to eliminate cancer 
cells. This method can be applied to the tumour before or after surgery. It is usually 
performed after the surgery and in particular for those with nodal involvement in order to 
kill any remaining cancer cells and it can last for up to seven weeks (Sharma et al., 2010). 
The use of chemotherapy agents to eliminate cancer cells is known as 
chemotherapy. Chemo agent selection is highly specific to the tumour and stage of the 
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tumour and biomarkers. Age, medical history and overall health are also taking into 
consideration (Sharma et al., 2010). Chemotherapy is usually done in cycles. The patient 
can be treated for a period of time, then a recovery period, followed by another treatment. 
Chemotherapy administrated after surgery is called adjuvant therapy and studies have 
shown that delaying adjuvant chemotherapy by over 12 weeks increases the risk of 
recurrence and a decrease in survival (Lohrisch et al., 2006). There are several drugs 
available to treat early stage breast cancer patients, such as doxorubicin, 
cyclophosphamide, fluorouracil, paclitaxel and methotrexate. While the advanced 
disease is treated with a combination of gemcitabine and taxanes (Ferguson et al., 2007; 
Gudena et al., 2008). For the past two decades, chemotherapy prior to surgery, one type 
of neoadjuvant therapy, has become a choice for a majority of the patients. This has 
been shown to reduce the risk of recurrence, improve the survival of the patients and 
reduce the scale of surgical intervention (Kaufmann et al., 2010; Mamounas et al., 2012; 
Mieog et al., 2007).  
Another type of cancer therapy involves removing or blocking the effect of hormones. 
Therefore, this kind of therapy is only used in a patient with hormone-receptor positive 
(ER or PR). Oestrogen is mainly produced in the ovaries and it stimulates the growth of 
some breast tumours. One strategy to reduce oestrogen production is to remove the 
ovaries by surgery (Coombes et al., 2007; Rao and Cobleigh, 2012). Oestrogen 
production can also be inhibited by aromatase inhibitors, such as anastrozole, 
exemestane or letrozole. These compounds inhibit the aromatase enzyme, which is 
responsible for the conversion of androgens to oestrogen (Miller and Larionov, 2012). 
Oestrogen receptors can also be blocked by tamoxifen (Coombes et al., 2007; Rao and 
Cobleigh, 2012), which directly binds to it and blocks the transcriptional activity of this 
receptor (Ali et al., 2016). Tamoxifen and aromatase inhibitors are effective therapies 
and they are less harmful when compared to chemotherapy. Although these therapies 
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improve the quality of life of ER-positive breast cancer patients, a large number of 
patients develop drug resistance (Jan 2012).  
 
Table 1: TNM grading system for breast cancer. A- Definition of the TNM 
categories. B- Stage grouping according to the categories. (Information from 
(American_Joint_Committee_on_Cancer, 2002). 
Definition of categories 
Primary tumour (T) 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: Intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple 
with no tumour 
T1 Tumour 2 cm or less in greatest dimension 
  T1a 0.5 cm or less in greatest dimension 
  T1b More than 0.5 cm but not more than 1 cm in greatest dimension 
  T1c More than 1 cm but not more than 2 cm in greatest dimension 
T2 Tumour more than 2 cm but not more than 5 cm in greatest dimension 
T3 Tumour more than 5 cm in greatest dimension 
T4 Tumour of any size with direct extension to chest wall or skin 
  T4a Extension to chest wall 
  T4b Edema (including peau d'orange) or ulceration of the skin of breast or satellite skin nodules confined to 
same breast 
  T4c Both T4a and T4b 
  T4d Inflammatory carcinoma 
Lymph node (N) 
Nx Regional lymph nodes cannot be assessed (e.g. previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral axillary lymph node(s) 
N2 Metastasis to ipsilateral axillary lymph node(s) fixed to one another or to other structures 
N3 Metastasis to ipsilateral internal mammary lymph node(s) 
Distant Metastasis (M) 
Mx Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis (includes metastasis to ipsilateral supraclavicular lymph node(s)) 
 
Stage grouping 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage IIA T0 N1 M0 
T1 N1* M0 
T2 N0 M0 
Stage IIB T2 N1 M0 
T3 N0 M0 
Stage IIIA T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0 
Stage IIIB T4 Any N M0 
 Any T N3 M0 
Stage IV Any T Any N M1 
*Note: The prognosis of patient with N1a is similar to that patient with pN0 
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1.2 Metastasis 
The formation of metastasis is a complex multi-step cascade where cancer cells 
migrate from the primary lesion to a distant organ. To metastasize, cancer cells have to 
go through a specific sequence of events: local invasion (including the basement and 
extracellular matrix), trans-endothelial migration into the bloodstream (intravasation), 
survival in the circulation, trans-endothelial migration into a new site (extravasation) and 
colonization of a distant tissue (Cristofanilli et al., 2004; Nguyen et al., 2009; Yang and 
Weinberg, 2008). They currently known that the primary tumour releases cancer cells 
into the circulation at early stages (Hüsemann et al., 2008) indicating that metastatic 
process may well start very early during cancer development and progression. Each one 
of these steps has natural barriers that cancer cells have to overcome, the metastatic 
cancer cells also have to fight against the established organisation and homeostasis of 
the target tissue (Gupta and Massagué, 2006). Thus, the metastatic cascade is highly 
inefficient. It has been estimated that 99.98% of disseminated tumour cells (DTCs) die 
before it forms a metastasis (Gupta and Massagué, 2006). Nevertheless, experimental 
studies have shown that even normal epithelial cells might be able to invade new tissues 
(Podsypanina et al., 2008; Rhim et al., 2012), less than 3% of cancer cells can survive 
in the new site (Kienast et al., 2010; Luzzi et al., 1998). Therefore, it is recognised that 
colonisation is the rate-limiting step in the metastatic process (Vanharanta et al., 2013).  
Cancer cells may face several fates once they reach the target organ: 1- cancer cells 
can die through spontaneous apoptosis or by the immune system; 2- DTCs can remain 
dormant; or 3- cancer cells can proliferate and develop early relapse.   
1.2.1 Breast cancer metastasis pattern 
Clinical observations have shown that different types of tumours have distinct 
patterns of metastatic spread, one example being their different preferential metastatic 
sites also known as organ tropism (Chiang and Massagué, 2008). This shows the 
importance of the microenvironment in developing a new metastasis. Breast cancer often 
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metastasizes to the bone, lung, liver and brain, which eventually leads to impaired 
function of those organs. Interestingly, the pattern of metastatic spread depends also on 
the subtype of the breast cancer (Kennecke et al., 2010). For instance, ER positive 
tumours exhibit initially the lowest incidence rate of metastasis, but the rate increases up 
to 40% after five years of follow-up. The preferable metastatic site of this subtype is the 
bone and the least is the brain.  However, the triple-negative subtype has the worst 
prognosis, having a high metastatic incidence rate within the first and second year after 
diagnosis (Dent et al., 2009; Kennecke et al., 2010). Brain and lung are the organs more 
often affected by triple-negative tumours. Another aggressive breast cancer subtype is 
the HER2 positive tumours. Anti-HER2 therapy has improved the prognosis and survival 
of patients with HER-2 breast tumours (Kennecke et al., 2010). However, the blood-brain 
barrier restricts the penetration of transtuzumab (anti-HER2 antibody) to the brain, 
therefore limiting its efficacy in the brain (Pestalozzi and Brignoli, 2000; Stemmler et al., 
2007) and trastuzumab-treated patient registered an increase in the incidence of brain 
metastasis (American_Cancer_Society_Cancer_Facts&Figures_2013", 2013; Tabouret 
et al., 2012; Wen and Loeffler, 1999).  
The mechanism underlying the pattern of metastatic spread of each tumour type 
or subtype remains unclear (Valastyan and Weinberg, 2011). In 1889, Sir Stephen Paget 
suggested the “seed-and-soil” theory, which proposed that disseminated tumour cells 
(seeds) lead to the formation of metastasis once they reach a tissue (soil) that allow them 
to survive and proliferate(Paget, 1889). Since then, many genes have been identified as 
beneficial to metastasis formation increasing metastasis in specific sites (Bos et al., 
2009; Hart and Fidler, 1980; Kang et al., 2003; Minn et al., 2005; Nguyen et al., 2009; 
Pencheva et al., 2012; Raz et al., 1980; Vanharanta et al., 2013), supporting the Paget 
hypothesis. The blood-metastasis can only explain this phenomenon in some tumour 
types, such as colon cancer. Colon cancer metastasis is more often observed in the liver 
and then in the lung via circulation (Gupta and Massagué, 2006). Breast cancer 
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metastasis are more common in bone (70.6%), followed by liver (54.5%) and lung 
(31.4%) (Savci-Heijink et al., 2015), which seems not fit into the previous blood stream 
theory.  
It has been shown a link between chemokines and metastasis sites (Klein et al., 
2002). For example, the stromal cell-derived factor 1 (SDF1/CXCL12), a cytokine 
secreted by bone, lungs, liver, lymph nodes and stromal fibroblasts in tumours, induced 
invasion and migration towards that SDF1 producing tissue by breast cancer cells that 
expressed the SDF1/XXL12 receptor, C-X-C chemokine receptor type 4 (CXCR4) 
(Müller et al., 2001). Interestingly, another study showed that high levels of CXCL12 and 
Insulin-like growth factor 1 (IGF1) in the bone promote survival of triple-negative breast 
cancer cells that highly colonises to the bone, compared to the lung and liver (Zhang et 
al., 2013). A better understanding of the site-specific signals responsible for attracting 
breast cancer cells could lead to more target therapies.  
1.2.2 Cancer dormancy 
As mentioned before, the treatment of metastasis is the main challenge of cancer 
treatment (Uhr and Pantel, 2011; Willis, 1952) due to the early dissemination of cancer 
cells from the primary tumour (Klein, 2011). The adjuvant therapy, which aims to prevent 
the relapse of the primary tumour and the development of metastasis, is often not 
efficient (Goss and Chambers, 2010) due to the ineffectiveness against disseminated 
tumour cells (DTC) (Klein, 2013).  The biology of cancer cells in the primary tumour and 
DTCs is very different. DTCs can go through a period of dormancy and be resistant to 
cancer drugs (Aguirre-Ghiso, 2007; Goss and Chambers, 2010; Klein, 2011, 2013). For 
instance, most chemotherapeutic drugs target metabolic pathways that are needed for 
DNA replication, and only effective to proliferating cells, failing to eliminate DTCs 
(Mitchison, 2012).  
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Clinical dormancy is common in several solid tumours, such as renal, breast, 
thyroid, prostate and melanoma (Uhr and Pantel, 2011). It is defined as the disease-free 
period of time that goes from the treatment of the primary tumour to the relapse of 
metastasis (Demicheli et al., 2005; Klein, 2011; Uhr and Pantel, 2011).   
Breast cancer is easier to treat when detected at an early stage, whilst the 
metastasised cancers are associated with a poor prognosis (Cardoso et al., 2009). 
However, a study showed that around 10% of patients who were metastasis-free at the 
diagnosis stage developed secondary tumours after breast cancer treatment (Noh et al., 
2011). Thus, uncovering the molecular mechanism behind the switch from clinical 
dormancy to the development of metastasis is currently one of the main focuses of breast 
cancer research.   
In the 1940s, Willis first time proposed cancer dormancy. In the 1950s Hadfield 
described it a transitory growth arrest (Willis, 1952) and mitotic arrest (HADFIELD, 1954). 
Current cancer dormancy is divided into three groups. Cellular dormancy refers to single 
or small groups of DTCs that are in the quiescent state, While angiogenic dormancy, is 
the situation the total volume of the micrometastasis is kept constant by a balance 
between dividing and apoptotic cells due to a lack of a good vascularisation system. In 
the immune-mediated dormancy, DTCs are proliferating but the total volume of the 
micrometastasis is kept constant due to the action of the immune system (Aguirre-Ghiso, 
2007). Different types of cancer dormancy may occur at the same time and some 
molecular mechanisms of the different cancer dormancy might be overlapped.  
It is estimated that only 3% of single dormant cells are able to grow into a 
micrometastasis, while only about 0.02% of dormant cells grow into clinically detectable 
metastasis (Luzzi et al., 1998). Cancer cells can come out of dormancy after years or 
even decades of the diagnosis of the primary tumour leading to a late relapse of the 
tumour. The cause of the regrowth of dormant cancer cells is not clear, but many factors 
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that control cancer dormancy, such as genetic changes, angiogenesis switch, the 
immune system and microenvironment, might be responsible for it.  
Genetic changes 
Genomic analysis showed that tumour cells from metastatic sites are 
homogeneous, while dormant DTCs from patients with no detectable metastasis were 
very heterogeneous (Klein et al., 2002; Klein et al., 1999; Schardt et al., 2005). Tumour 
genomic aberrations include mutations, loss of heterozygosity and polymorphisms. 
These findings suggest that DTCs might be originated from early stages of tumour 
progression and DTCs accumulate genetic changes over time that are required to 
metastasise. Although some studies have identified genes and molecular pathways that 
might be involved in tumour dormancy and the escape of DTCs from dormancy, further 
research is needed to identify a genetic signature that explains the outgrowth of dormant 
micrometastasis.  
Almog and colleagues developed a tumour dormancy in vivo model for breast 
carcinoma, liposarcoma, glioblastoma and osteosarcoma (Almog et al., 2009). The 
authors compared the gene expression pattern of dormant tumours and switched fast-
growing tumours by genome-wide transcriptional analysis. Their results showed that, in 
all tumour types studied, switch fast-growing tumours exhibited a downregulation of the 
expression of thrombospondin, an angiogenic inhibitor, and a decrease of the sensitivity 
to angiostatin, another natural angiogenic inhibitor (Almog et al., 2009). Their results 
suggested that tumour vascular niche plays a key role in the escape of dormancy.  
Other molecular pathways, such as tissue inhibitor of metalloproteinase-3, 
insulin-like growth factor receptor, KISS1 metastasis-suppressor, epidermal growth 
factor receptor (EGFR), have also been identified in the cellular processes of cancer 
dormancy (Steeg et al., 2003).  
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MicroRNAs have also been implicated in cancer dormancy. For instance, 16 
microRNAs were found to be overexpressed in dormant tumours and their 
downregulation was correlated with the switch of dormant status to growing malignancies 
(Almog et al., 2012).  
Epigenetic alterations are another type of gene regulation   in both dormant and 
proliferate cancer cells is. For instance, the expression of tissue inhibitor of 
metalloproteinases-3 (TIMP3) and E-cadherin (CDH1) was increased in dormant ovarian 
cancer cells and decreased in ovarian cancer cells transitioning to active growth. Both 
genes can be through promoter methylation (Lyu et al., 2013). Both TIMP3 and CDH1 
also function as anti-angiogenic molecules (Qi et al., 2003; Yi Kim et al., 2007) which 
suggest again that angiogenesis may be a central cellular mechanism in the escape of 
cancer dormancy.  
Angiogenesis  
Tumour growth is dependent on angiogenesis, which relies on a balance between 
pro- and anti- angiogenic factors. Rapidly growing cancer cells rely on their easy access 
to nutrients and oxygen, which is provided by angiogenesis (Folkman, 1990). Dormant 
micrometastases, however, have been shown to be avascular (Hanahan and Folkman, 
1996). Thus, micrometastases have to increase the secretion of pro-angiogenic factors 
and/or downregulate anti-angiogenic factors in order to grow and regrow.  
Glioma cells, angiogenic-dependent cancer cells, are much earlier to form 
tumours in mice than angiogenic-independent cancer cells, osteosarcoma cells. 
Intriguingly, there is no difference of proliferation rates between these two types of cancer 
cells, indicating that the tumour formations are related to the angiogenesis-induction 
capacity of cancer cells rather than the quiescence mechanisms (Naumov et al., 2006b). 
However, cancer cells can evolve to an angiogenic phenotype, this process is known as 
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angiogenic switch, which is characterised by an increased in the expression of pro-
angiogenic factors and a decrease in anti-angiogenic factors (Naumov et al., 2006a).  
In a series of in vivo and in vitro assays, Ghajar and collaborators showed that 
the vascular niche also might be involved in maintaining single cell dormancy (Ghajar et 
al., 2013). They demonstrated that a single breast cancer cell did not proliferate when in 
close association with a stable microtubule, while it divided when in the 
microenvironment of a sprouting vessel (Ghajar et al., 2013). They attributed this 
phenomenon, at least in part, to the presence of a high concentration of thrombospondin 
1 (TSP1) in the microenvironment of the stable vessel.  
Immune system 
The hypothesis of cancer immune-editing mechanism states that tumour 
development has to go through 3 stages: elimination, equilibrium and escape (Dunn et 
al., 2002).  The innate and adaptive immune system can detect and eradicate cancer 
cells. If this mechanism fails, cancer cells might reach an equilibrium for a long period of 
time. Some of the cancer cells can even escape the immune system (Dunn et al., 2002). 
The mechanism of how the immune system induces cancer dormancy is not 
established. Nevertheless, the following studies give some clues.  
Patients with breast cancer, who had DTCs in the bone marrow, had a higher 
number of CD4 T cells and CD56+CD8+ cells, when compared to healthy subjects 
(Feuerer et al., 2001). Also, depletion of CD4+ and CD8+ T cells in mouse models led to 
the escape of cancer cells from dormancy state (Teng et al., 2008). Interestingly, a study 
showed that cancer cells could overcome the effect of the immune system by 
overexpressing B7 homolog 1 (B7-H1), inhibiting the activation of T cells and the 
cytotoxic T lymphocyte (CTL) response (Ge et al., 2009).  
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 Also, many immune cells   within the tumour microenvironment, including T cells and 
macrophages, secrete many mitogens and pro-angiogenic factors, cytokines and MMPs 
(Ribatti and Crivellato, 2009). These molecules might help cancer cells to escape 
dormancy and induce angiogenesis. Despite these interesting observation, the interplay 
between immune cells, bone marrow, microenvironment and angiogenesis is far more 
complicated. For example, Bonapace and collaborators have shown that another 
targeting chemokine, CCL2, whilst can suppress the occurrence of metastasis, the 
withdraw of anti-CCL2 agents led to a dramatic increase in metastasis and accelerated 
death (Bonapace et al., 2014). The effects of the interruption of anti-CCL2 therapy were 
attributed to the release of monocytes from the bone marrow and cancer cells from the 
primary tumour.  
Microenvironment  
Once cancer cells reach a new tissue and survive in that microenvironment, they 
have to go through a dormancy state before a possible proliferative state (Heyn et al., 
2006; Murrell et al., 2014; Naumov et al., 2003). Interestingly, the higher numbers of 
DTCs are not necessarily correlated to the metastasis incidence in some organs than 
the others (Aguirre-Ghiso, 2007). For instance, gastric cancer patients have a high 
number of DTCs in the bone marrow. These DTCs have been shown to be non-
proliferative, and bone marrow metastasis are rare in this patients (Aguirre-Ghiso, 2007; 
Hüsemann et al., 2008; Klein, 2011; Pantel et al., 2009; Schardt et al., 2005). These 
findings suggest a crucial role of the microenvironment in the growth of DTCs. For this 
reason, the different microenvironments have been classified as dormancy-permissive 
or dormancy-restrictive (Aguirre-Ghiso et al., 2013; Bragado et al., 2013; Bragado et al., 
2012).  
Normal stromal cells in the bone marrow secrete BMP7, which induced ERK 
inhibition, p38 activation, leading to and the dormancy of prostate cancer cells that were 
injected into the bone (Kobayashi et al., 2011). Knockout of BMPR2, the BMP7 receptor, 
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caused the injected prostate cancer escaping from dormancy (Kobayashi et al., 2011). 
Consistently, bone metastasis in prostate patients was inversely correlated with BMPR2 
expression (Kobayashi et al., 2011), suggesting that the loss of BMPR2 might be a 
mechanism adapted by prostate cancer cells to escape dormancy in the bone marrow. 
The inhibition of BMP4, another BMPR2 ligand, secreted by lung, had a similar escaping 
effect on dormant breast DTCs in the lungs, indicating a similar role of BMPR2 in breast 
cancer cells. Other receptors in breast cancer cells have been linked to dormancy 
regulation, such as the lysophosphatidic acid receptor (EDG2) (Marshall et al., 2012).  
Other studies have shown that fibroblasts and endothelial tip secrete periostin, 
which, promote the cancer cells escaping of dormancy (Ghajar et al., 2013; Malanchi et 
al., 2011).  
Although the mechanisms of how cancer cells escape the dormancy still not clear, 
the above studies provide insight into the possible molecular mechanisms.  
1.3 Tumour stroma 
1.3.1 Cell-to-cell communication and angiogenesis 
Cell-to-cell communication is important for proper cell coordination and plays a 
central role in the development and function of animal tissues and organs. The failure of 
cell-to-cell communication has been demonstrated to lead to the development of 
diseases, for instance, immune disorders (Allen et al., 1993) and heart failure (De Mello, 
1996). Cells have different means of communication, cell communication can be through 
soluble factors, adhesion contacts, cell junctions or through vesicles, which can activate 
their own receptors (autocrine), reach a neighbouring cell (paracrine) or target distant 
cells (endocrine) (Camussi et al., 2010).  
Tumours are formed by a collection of different cell types, such as cancer cells, 
fibroblasts and macrophages. Stromal cells, the non-cancer cells residing within the 
tumour stroma, create a perfect microenvironment so cancer cells can grow to allow 
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tumour progression. Cell-to-cell communication is fundamental for cancer cells to attract 
and also to transform stromal cells. The inhibition of the cell communication within tumour 
microenvironment has been shown to reduce growth and aggressiveness of the tumour 
(Lin et al., 2013; Matsuda et al., 2014).  
Another type of stromal cells present in the tumour microenvironment are the 
endothelial cells. Tumour growth is dependent on a proper network of vessels; it has 
been shown that tumours do not grow beyond 2-3 mm in diameter without the proper 
vasculature support. Tumour Induced-angiogenesis – the formation of new blood vessels 
from an existing one, provides nutrients and oxygen to cancer and the other stromal cells 
allowing at the same time the removal of toxic metabolites. Tumour-endothelial cell 
communication is crucial to angiogenesis and the inhibition of those signals has shown 
to reduce tumour vasculature and tumour size (Vasudev and Reynolds, 2014). 
Tumour cells can indirectly communicate with endothelial cells via soluble factors, 
adhesion receptors, gap junctions or vesicles, in order to induce angiogenesis, Figure 2 
(reviewed in (Lopes-Bastos et al., 2016). Tumour cells can also attract and transform 
stromal cells, which in turn induce angiogenesis via secreting proteases leading to 
remodelling the extracellular matrix, or by other ways, such as changing the pH, 
temperature, or nutrient and oxygen availability, which have been shown to modify 
endothelial phenotype, Figure 2 (reviewed in (Lopes-Bastos et al., 2016)). 
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Figure 2: Schematic representation of the different types of cell-to-cell communication in order to cancer cells induce 
angiogenesis (Lopes-Bastos et al., 2016). 
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1.3.2 Extracellular matrix (ECM) 
The microenvironment of a tissue or organ is defined by their specific cell types 
and vesicles, proteins and other molecules secreted by those cells into the extracellular 
space. The denominated extracellular component is a tissue-specific extracellular matrix 
(ECM). ECM contains proteins such as fibronectin, laminins, collagens, glycoproteins 
and proteoglycans. These proteins give support to the cells and maintain the integrity 
and sustainability of the tissue. ECM is extremely important in embryonic development, 
but it is also essential in the homoeostasis of adult tissue. Although ECM provides a 
structure to tissues, its role goes beyond that. For instance, ECM proteins bind and 
activate surface receptors, which can promote essential cellular signalling for key cell 
behaviour, including cell growth/ survival and mobility (Chong et al., 2012). ECM can 
also bind soluble growth factors and other molecules, and modulate distribution and 
activation of these molecules, and their availability to cells (Hynes, 2009).   
The tumour ECM has been described as abnormal in composition and 
architecture. Cancer cells, but also infiltrating T-cells, macrophages and fibroblasts 
contribute to its composition, by matrix deposition and matrix modification. It is 
recognised that the tumour ECM is a crucial factor in cancer progression. For instance, 
tumours are composed of different subpopulations of cancer cells that are genetically 
heterogeneous. A study using a breast cancer model, demonstrated that a minor cancer 
cell subpopulation was responsible for the sustained growth of the tumour (Marusyk et 
al., 2014). The minor subpopulation of cells modulated the tumour microenvironment, 
including the organisation of the collagen (Marusyk et al., 2014). 
1.3.2.1 Thrombospondin family 
Thrombospondins (TSPs) are secreted proteins and are part of the ECM. 
However, TSPs do not have a role as a structural protein like most ECM proteins do. 
TSPs are denominated matricellular proteins with a wide range of functions. TSPs are 
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able to interact with several cell surface receptors but also with other ECM proteins, such 
as growth factors, proteases and collagens (Cockburn and Barnes, 1991; Greenaway et 
al., 2007; Gupta et al., 1999). 
The TSP family is composed of 5 members divided into two groups based on 
their domain structure. The TSP group A includes TSP-1 and TSP-2, while TSP-3, TSP-
4 and TSP-5 belong to group B (Adams, 2001; Adams and Lawler, 2004, 2011). TSP 
proteins in lower organism can be composed of only one protein or by multiple depending 
on the organism, but these proteins are very similar to human TSPs from the group B. 
Interestingly, the development of the vascular system coincides with the appearance of 
TSPs from group A, and these proteins evolve even more with the development of the 
cardiovascular and immune system (Bentley and Adams, 2010; Tucker et al., 2013) 
suggesting an important role of TSP group A in these processes.  
TSPs have a wide range of roles involved in many physiologic and pathological 
cellular processes, such as regulation of inflammation (Frolova et al., 2010; Lopez-Dee 
et al., 2011; Mustonen et al., 2012; Stenina-Adognravi, 2013; Vanhoutte et al., 2013), 
maintenance of the integrity and function of the myocardium (Chatila et al., 2007; 
Cingolani et al., 2011; Frolova et al., 2012; Lynch et al., 2012; Roberts et al., 2012; 
Schroen et al., 2004; Swinnen et al., 2009; van Almen et al., 2011), fibrosis regulation 
(Sweetwyne and Murphy-Ullrich, 2012), synaptogenesis (Risher and Eroglu, 2012), 
immune response modulation (Martin-Manso et al., 2012; Miller et al., 2013), 
angiogenesis and cancer progression (Lawler and Lawler, 2012).  
1.2.2.1.1 Thrombospondin 1 and angiogenesis 
Judah Folkman proposed in 1971 the existence of endogenous angiogenic 
inhibitors in order to counterbalance known pro-angiogenic molecules (Folkman, 1971). 
In 1990, thrombospondin 1 (TSP1) became the first known endogenous inhibitor of 
angiogenesis (Good et al., 1990). TSP1 is a 142,000 KDa glycoprotein that was first 
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isolated from human platelets (Lawler et al., 1978). Several cell types secrete TSP1, 
such as endothelial cells, adipocytes, smooth muscle cells, fibroblasts, monocytes, 
macrophages and also malignant cells (Naganuma et al., 2004; Wight et al., 1985). A 
fragment of TSP1, identified in hamster kidney cells (BHK21/cl12), was demonstrated to 
inhibit cell migration of endothelial cells and angiogenesis in the rat cornea. In the same 
year, several independent groups reported that TSP1 inhibits endothelial cell 
proliferation (Bagavandoss and Wilks, 1990) and also antagonizes the effects of basic 
fibroblast growth factor (bFGF) on endothelial cells (Taraboletti et al., 1990). Since then, 
many other proteins have been identified that contain an amino acid sequence of TSP1 
and TSP2 proteins called the thrombospondin type 1 repeat (TSR) sequence, such as 
the brain-specific angiogenesis inhibitor (BAI1) (Kaur et al., 2003). The identification of 
several endogenous inhibitors of angiogenesis led to the notion that angiogenesis in both 
physiological and pathological conditions is regulated by a controlled balance between 
pro- and anti- angiogenic proteins. “Angiogenic switch” (Hanahan and Folkman, 1996) 
indicates that the endothelial phenotype changes from quiescent to sprouting and also 
to changes in the endothelial microenvironment that triggers angiogenesis. It has been 
shown that the low level of TSP1 and TSP2 is a key factor in angiogenesis initiation, and 
the local TSP1 level has proven to be an efficient determinant of tumour growth 
(Zaslavsky et al., 2010). The discovery of angiogenic molecules initiated new therapeutic 
strategies of inhibition of angiogenesis, such as recombinant proteins and other cell-
based strategies to increase TSP1, especially in cancer (Zhang and Lawler, 2007).   
TSP1 domains 
TSP1 contains specific domains that allow it to bind to membrane proteins, such 
as integrins, and other proteins present in the matrix which are expressed by the cells in 
the microenvironment. The ability of TSP1 to bind to the proteins of the extracellular 
matrix allows it to be retained in the matrix, where TSP1 can fold and acquired its 3D 
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conformation (Bornstein, 1995; Tan and Lawler, 2009). This mechanism permits the cells 
to control the retention of TSP1 in their microenvironment (Sottile and Hocking, 2002).  
TSP1 is a large protein that contains 3 repeat domains (type I, II and III), a 
procollagen homology domain, and an amino and a carboxyl terminal which are globular 
(Lopez-Dee et al., 2011), as represented in Figure 3.  
TSP1 is involved in several molecular pathways, specially linked to anti-
angiogenic effects as summarised in Figure 4 and described along this subchapter.  
The NH2-terminal of TSP1 can interact with low-density lipoprotein receptor-
related protein (LRP1) releasing any metalloproteases bound to TSP1 modulating its 
enzymatic activity (Chen et al., 1996). TSP1 also binds to integrins and heparin sulphate 
proteoglycans via its NH2-termainal to regulate cell motility, chemotaxis adhesion and 
angiogenesis (Calzada et al., 2003). The thrombospondin structural homology repeats 
(TSRs), also called repeat domain I is only present in the TSP1 and TSP2 structure, 
while repeat domains II and III are present in all TSP members. The repeat domain type 
I is involved in the most well-known TSP1 pathway as an angiogenic inhibitor molecule, 
which interacts with the CD36 receptor in endothelial cells causing its dimerization which 
leads to endothelial apoptosis (Daviet et al., 1997; Jiménez et al., 2000). Other TSP1 
domains can modulate this process by interacting with their receptors.  
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Figure 3: Representation of the TSP1 structure (Lopez-Dee et al., 2011). 
 
TSP1 is the only TSP member that can activate TGFβ1. This cytokine is involved 
in key processes such as, cell proliferation, immune response, and wound healing and 
extracellular matrix formation. Mature TGFβ1 is found in the extracellular matrix in its 
latent form where is associated with latency-associated peptide (LAP). TSP1 binds to 
the latent TGFβ1-LAP complex which disrupts the complex turning TGFβ1 active (Young 
and Murphy-Ullrich, 2004). The amino acid sequence arginine-phenylalanine-lysine 
(RFK) is located in the TSR and it is responsible for the interaction between TSP1 and 
TGFβ1-LAP complex (Crawford et al., 1998; Schultz-Cherry et al., 1995; Young and 
Murphy-Ullrich, 2004).  
TSP1 can activate neutrophils by interacting with neutrophil elastase through 
TSP1 type III repeat domain (Hogg et al., 1993; Majluf-Cruz et al., 2000). The same 
domain is able to reduce angiogenesis by blocking the binding of fibroblast growth factor 
to endothelial cells (Margosio et al., 2008).  
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The TSP1 repeat domain II contain EGF-like repeats. Although these repeats 
domains are recognised by integrins, no biological function has been attributed to such 
interaction (Calzada et al., 2004).  
The TSP1 COOH-terminal also affects angiogenesis, immune response and cell 
proliferation by its ability to bind to CD47 (Kosfeld and Frazier, 1993), β1 and β2 integrins 
and proteoglycans (Calzada et al., 2003). The TSP1-CD47 interaction regulates nitric 
oxide (NO) modulating vasodilation and chemotaxis (Isenberg et al., 2006). Through a 
series of experiments using TSP1 and CD47 knockout mice or inhibiting the interaction 
between these two proteins, a research team has shown that TSP1-CD47 interaction is 
crucial in controlling angiogenesis (Isenberg et al., 2006). This study revealed much 
complex molecular mechanism has revealed to be much more complex, which indicating 
that CD47 can interact with VEGFR2 (Kaur et al., 2010), but the interaction between 
TSP1 and CD47 inhibits VEGFR2 phosphorylation and therefore angiogenesis (Kaur et 
al., 2014).  
Although, the majority of studies suggests an anti-angiogenic role of TSP1, it has 
been shown that TSP1 can induce angiogenesis. The pro-angiogenic activity of TSP1 
has been mainly described to be restricted to the N-terminal (BenEzra et al., 1993; 
Calzada et al., 2004; Chandrasekaran et al., 2000; Iruela-Arispe et al., 1999; Nicosia and 
Tuszynski, 1994), which should be taken into consideration when TSP1 peptide based 
therapy is being developed.  
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Figure 4: Schematic representation of the main TSP1 anti-angiogenic pathways that have been identified. 
 
 
27 
 
Regulation of TSP1 level in the ECM 
As mentioned before, several cell types secrete TSP1 (Naganuma et al., 2004; 
Wight et al., 1985). Several studies have described a differential regulation of the TSP1 
gene promoter in different cell types, suggesting tissue specific signals to modulate its 
expression. The activation of a promoter is not only dependent on the amino acid 
sequence, but also dependent on the availability of the target binding sites, transcription 
factors, cell signalling pathways to activate those transcription factors and protein co-
factors. One of the best studied TSP1 stimuli is glucose. Most cell types of the vascular 
wall, such as fibroblasts, smooth muscle cells and endothelial cells, up-regulate TSP1 
mRNA in response to high glucose (Stenina et al., 2003). Interestingly, the TSP1 up-
regulation occurs at different times, it happens much earlier in endothelial cells than   
smooth muscle cells. Studies revealed that endothelial cells and smooth muscle cells 
contains different transcriptional regulation mechanisms of the TSP1 gene in response 
to high glucose. In endothelial cells, TSP1 transcription was regulated by a proximal 
fragment of the promoter, while those in smooth muscle cells were required a proximal 
and a distal fragment of the promoter (Dabir et al., 2008; Raman et al., 2011).   
TSP1 is a significant protein in several metabolic disorders (Li et al., 2011; Moura 
et al., 2008), which leading to research on TSP1 regulation by leptin, a key hormone in 
diabetes and obesity. Leptin up-regulated TSP1 mRNA in a JAK/ERK/JNK dependent 
manner (Chavez et al., 2012).  
Erg-1, a transcription factor involved in inflammation mechanisms, induced TSP1 
transcription in combination with MYC, upon thrombin stimuli (McLaughlin et al., 2005). 
In inflammatory joint disease, a decrease in the orphan receptor 4A2 (NR4A2) led to a 
decrease in TSP1 expression suggesting a role of TSP1 in the resolution of the 
inflammation (McMorrow et al., 2013).  
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A series of experiments demonstrated that shorter TSP1 promoter deletion constructs 
have an inhibitory element (Dabir et al., 2008; Kang et al., 2004; Kang et al., 2003). A 
well-known human carcinogen, Nickel, decreased TSP1 promoter activity and 
downregulated its expression in hamster embryo cells. Nickel induced the expression of 
Activating Transcription Factor-1 (ATF-1) which was identified as the protein binding to 
the TSP1 promoter and repressing the promoter activity (Salnikow et al., 1994). The 
TSP1 promoter activity can be decreased by other proteins, such as c-Jun that interacts 
with YY-1 weakening the interaction of YY-1 to the TSP1 promoter (Kang et al., 2004).  
The inhibition of TSP1 expression is an effective and common control mechanism 
employed by cells once TSP1 protein and mRNA are both unstable resulting in rapid 
effects (Chavez et al., 2012; El Btaouri et al., 2011; McGray et al., 2011; Raman et al., 
2011; Raman et al., 2007).  
In melanoma, methylation of the TSP1 promoter is a powerful inhibitor of TSP1 
expression (Lindner et al. 2013), and reduced TSP1 expression has been associated 
with methylation of the TSP1 promoter in gastric carcinoma (Oue et al., 2003). 
The TSP1 level in the extracellular matrix can also be regulated by secretion. 
TSP1 can be stored inside the cells and its secretion is regulated by Ca2+ (Veliceasa et 
al., 2007). Platelet is a major source of extracellular matrix TSP1 and pre-synthesised 
TSP1 is only released after platelets activation (Dawes et al., 1983; Lawler and Slayter, 
1981). Cellular density can determine the secretion of TSP1. For instance, low density 
of endothelial cells, fibroblasts and smooth muscle cells secrete higher levels of TSP1 
without changing TSP1 synthesis (Mumby et al., 1984).  
TSP1 in cancer    
TSP1 is a key protein in angiogenesis. TSP1 has been extensively studied in 
cancer relating to tumour angiogenesis. Several studies have found a correlation 
between changes in the expression of TSP1 and tumour angiogenesis. A decrease in 
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TSP1 expression correlates with higher vascular density in colon cancer (Kawakami et 
al., 2001), glioma cells (Harada et al., 2003) and invasive cervical cancer (Cinatl et al., 
1999). An In vivo breast cancer study has shown that TSP1 inhibits angiogenesis 
constraining the growth of the primary tumour (Yee et al., 2009). TSP1 has been related 
to a decrease in angiogenesis and growth of the primary tumour, and metastasis 
(Incardona et al., 1995; Yee et al., 2009). Accordingly, many studies have presented low 
levels of TSP1 as a marker of poor prognosis in glioma (Perez-Janices et al., 2015), 
melanoma (Borsotti et al., 2015), ovarian and pancreatic carcinoma (Lyu et al., 2013; 
Nie et al., 2014; Pinessi et al., 2015).   
Studies showed that the suppression of TSP1 in cancer led to an increase in 
angiogenesis and tumour growth. Wilms’ tumour suppressor gene (WT1) has been 
shown to bind to the TSP1 promoter and inhibit TSP1 expression (Dejong et al., 1999). 
On the other hand, p53 induces the activity of the TSP1 promoter (Su et al., 2010). The 
transcription factor Id1 has also been identified as one of the regulators of TSP1 
expression (Volpert et al., 2002). Hypermethylation has also been identified as a 
mechanism employed by several tumours to prevent the activation of the TSP1 promoter 
(Kanai et al., 2001; Lindner et al., 2013; Liu et al., 2005; Yang et al., 2003).  
As an extracellular matrix protein, TSP1 interacting with many other proteins 
makes TSP1 difficulty to be studied. An in vivo study showed that the level of TSP1 was 
inversely correlated with tumour size, angiogenesis and the level of activated MMP-9 
(Rodriguez-Manzaneque et al., 2001). MMPs are enzymes that degrade a wide range of 
extracellular proteins and TSP1 can bind MMPs via its TSR domain (Bein and Simons, 
2000). The same study confirmed that in the presence of TSP1 there was a decrease in 
VEGF (Rodriguez-Manzaneque et al., 2001). This study concluded that TSP1 
suppressed angiogenesis by VEGF retention in the extracellular matrix which is possible 
by suppressing MMP activity.  
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TSP1 can also bind directly VEGF contributing to retention of VEGF in the matrix 
(Greenaway et al., 2007; Gupta et al., 1999). Interestingly, it has been shown that TSP1 
can be removed from the extracellular space by being transported into the cytosol. This 
cellular mechanism allows a fast decrease of extracellular TSP1, but also the reduction 
of proteins associated with TSP1, such as VEGF and MMPs. This process is regulated 
by low-density lipoprotein receptor-related protein (LRP) (Wang et al., 2004).  
The repeat domain type III of TSP1 also inhibits VEGF signal by blocking the 
VEGFR2 phosphorylation at the tyrosine-1175 (Zhang et al., 2009). CD36 is a receptor 
of TSP1 and an interaction between CD36 and VEGFR2 was observed in the same study 
(Zhang et al., 2009). Interestingly, the inhibition of VEGFR2 phosphorylation by TSP1 is 
also dependent on the association between CD36 and β1-integrin (Primo et al., 2005). 
The inhibitory effect of TSP1 on VEGFR2 appears to decrease Akt activation (Ren et al., 
2009). Other studies support this data showing that Akt signal is increased in the retinas 
of TSP1 knockout mice (Sun et al., 2009). Akt signalling pathway is involved in the 
survival and proliferation of endothelial cells (Wang et al., 2006). 
 
1.4. Tryptophan and Indoleamine 2,3-dioxygenase 1 
1.4.1 Amino acids 
Amino acids are essential molecules to life as they are the building blocks of 
proteins and peptides and are also a source of nitrogen for the synthesis of other amino 
acids and other nitrogenous compounds such as nucleotide bases. These organic 
molecules have a basic structure which is characterised by a carbon atom (C) attached 
to a carboxyl group (-COOH), a hydrogen (H), an amino group (-NH2) and a side-chain 
specific to each amino acid (R), as schematised in Figure 5. The R group confers the 
unique chemical properties of the amino acid (Lodish, 2000). 
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Figure 5: General structure of an amino acid (Lodish, 2000).  
 
There are 20 standard proteinogenic amino acids. Most microorganisms, for 
example, E. coli, can generate all of them. However, human beings can only synthesise 
11 amino acids. The amino acids that humans cannot synthesise, and therefore have to 
be supplied by the diet, primarily from plants, are known as essential amino acids (EAA; 
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan 
and valine). The remaining 9 amino acids are called nonessential amino acids (NEAA; 
alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, 
serine and tyrosine) (Berg JM, 2002).  
The essential amino acids are synthesised by complex reactions, whereas the 
synthesis of nonessential amino acids requires fewer and simpler reactions, as illustrated 
in Figure 6. Some nonessential amino acids, e.g. alanine and aspartate, are synthesised 
in only one step, while the formation of essential amino acids involves 5 to 16 steps (Berg 
JM, 2002). The reason that humans cannot synthesise essential amino acids has been 
attributed to the fact that humans do not have some of the enzymes required to catalyse 
some of the reactions (Berg JM, 2002).  
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Figure 6: Number of steps required to synthesise essential and nonessential 
amino acids (Berg JM, 2002).  
 
An adequate pool of amino acid is essential for growth, development, health and 
survival in humans and animals in general (Ren et al., 2012; Wu, 2009). For this reason, 
another important way of characterising amino acids has been discussed, which 
separates amino acids into 2 groups: nutritionally essential amino acids and 
nonessential.  
Nutritionally essential amino acids include amino acids that cannot be 
synthesised by humans but also amino acids that are not synthesised in enough quantity 
to assure an adequate development and growth of the organism (Wu, 2010). 
Nevertheless, nutritionally nonessential amino acids can be produced by human beings 
in sufficient amounts (Le Plénier et al., 2012; Liu et al., 2012; Obayashi et al., 2012).  
As mentioned before, amino acids are the building blocks of proteins which are 
obtained from the digestion of proteins in the intestine and the degradation of proteins 
within the cell. Many cellular proteins have a short half-life, being continually degraded 
N u m b e r o f  s te p s  in  p a th w a y s
N
u
m
b
e
r
 o
f 
a
m
in
o
 a
c
id
s
1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3 1 4 1 5 1 6
0
1
2
3
4
N o n e s s e n tia l
E s s e n tia l
33 
 
and for this reason cells have to resynthesize those proteins at the same rate to keep 
their physiological levels. Cells attach chains of small proteins, ubiquitin, to unnecessary 
or damaged proteins which are afterwards degraded by the proteasome, a large ATP-
dependent complex (Berg JM, 2002). 
Nevertheless, cells can store fatty acids and glucose; they cannot store or excrete 
surplus amino acids. Instead, excessive amino acids are used as metabolic fuel. The 
majority of surplus amino acids enter the urea cycle and their carbon skeletons are 
converted into a major metabolic intermediate, such as acetoacetyl-CoA, pyruvate, 
acetyl-CoA or a citric acid cycle intermediate. These molecules can be used to form fatty 
acids, ketone bodies, and glucose (Berg JM, 2002).  
Proteasome degradation has been extensively studied, and is important in 
controlling the degradation of regulatory, short-lived, damaged or misfolded proteins 
(Hershko and Ciechanover, 1998; Schwartz and Ciechanover, 2009). Apart from the 
well-studied functions described above, the ubiquitin- proteasome system also recycles 
amino acids. This process has been well studied in starving cells (Nakatogawa et al., 
2009). Autophagy and proteasomal degradation play a key role in the maintenance of an 
adequate pool of amino acids to support protein synthesis under severe nutrient 
deprivation conditions (Onodera and Ohsumi, 2005; Vabulas and Hartl, 2005). However, 
the importance of amino acid recycling by proteasomal degradation under physiological 
conditions is not clear. 
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1.3.2 Tryptophan 
Tryptophan (TRP) was isolated in 1901 by Hopkins and Cole, its name derived 
from the isolation method employed to digest casein, called tryptic digestion (Hopkins 
and Cole, 1901). Rose and colleagues showed in 1954 that tryptophan is an essential 
amino acid (ROSE et al., 1954a), they also demonstrated that only the L isoform of 
tryptophan is used to synthesise protein (ROSE et al., 1954b). Adults are required to 
obtain 3.5 mg/Kg of L-tryptophan every day and, for example in the United States, diet 
provides in average 0.7- 1 g of L-tryptophan (Wildman  and Medeiros, 2000).  
Tryptophan circulates in the plasma and blood mostly bound to albumin 
(Pardridge, 1979), which is estimated that only 10- 20% is albumin-free in the plasma. It 
remains debatable whether tryptophan bound to albumin changes the availability of 
tryptophan to protein synthesis or metabolism, but it has been reported that some drugs 
and non-esterified fatty acids change the binding of tryptophan to albumin (Pardridge, 
1979).  
Once L-tryptophan is ingested, it can be used in 4 different mechanisms: protein 
synthesis; the serotonin pathway; the kynurenine pathway; and decarboxylation to 
tryptamine (Richard et al., 2009). 
Tryptophan is involved in many metabolic processes, one of them being the 
precursor of serotonin (5-HT or 5-hydroxytryptamine). Serotonin is a neuromodulator 
which regulates appetite, haemodynamics, mood and gastrointestinal functions. Ninety-
five percentage of the mammalian serotonin is found in the gastrointestinal tract (Sanger, 
2008), and it has been estimated that only 3% of the tryptophan obtained from the diet 
is used for the body serotonin synthesis (van Praag HM and C, 1986). The conversion 
of tryptophan into serotonin is achieved in only two steps. The first step is catalysed by 
tryptophan hydroxylase (TPH) which converts tryptophan into 5-hydroxy-tryptophan, and 
this one is decarboxylated into serotonin which is dependent on vitamin B6.  
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Tryptamine is a molecule with several biological functions and has tryptophan as 
a precursor. Tryptophan is immediately decarboxylated resulting in very small amounts 
of tryptamine, being its primary role as a neuromodulator of serotonin (Jones, 1982). 
Animal studies have suggested that tryptamine can activate specific receptors, acting as 
an independent neurotransmitter from serotonin, however, its main function is as a 
modulator of serotonin function (Jones, 1982). 
Tryptophan is also involved in the kynurenine pathway being the first substrate of 
this metabolic process where tryptophan is converted, through a series of reactions, into 
quinolinic acid, niacin, kynurenic and xanthurenic acid. This pathway also generates 
many intermediate metabolites which have been shown to have several functional 
activities, e.g. N-formyl kynurenine and kynurenine. The first reaction, which converts 
tryptophan into N-formyl kynurenine, can be catalysed by 3 different enzymes: 
tryptophan 2,3-dioxygenase (TDO), indoleamine 2,3-dioxygenase 1 (IDO1) and 
indoleamine 2,3-dioxygenase 2 (IDO2). IDO2 has been recently discovered and not 
much is known about its function or distribution, however, TDO and IDO1 are found in 
different tissues and also have different roles, structure, substrate specificity and cofactor 
requirements (Le Floc'h et al., 2011).  
1.3.2.1 Protein synthesis 
In human beings, the main role of tryptophan is its use in protein synthesis. Since 
tryptophan is an essential amino acid, the percentage of this amino acid used in cellular 
metabolism is lost for protein synthesis. The average proportion of essential amino acids 
in the body is relatively high, for instance, lysine, leucine, and threonine contribute to 7.6, 
7.1 and 4.0 g per 100g of protein, respectively (Mahan and Shields, 1998). However, 
tryptophan only corresponds to 1.2g/ 100 g which is much lower than the other essential 
amino acids (Mahan and Shields, 1998). Several studies have tried to estimate the 
proportion of tryptophan incorporated into a protein, but the results vary considerably. 
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This variation has been attributed to methodology, development stage versus adulthood 
and physiological status. There was a study conducted by Sawadogo et al. (1997) which 
showed that, in growing pigs, 54% of tryptophan was incorporated into a protein, when 
tryptophan was supplied under the normal tryptophan requirement. However, when 
tryptophan was administrated above the requirement, the percentage of tryptophan 
retained in body protein decreased, being attributed to an increase in tryptophan 
metabolism (Sawadogo et al., 1997). In adults, it is still debatable how much dietary 
tryptophan is used for protein synthesis. Taking a few statistics from different studies, an 
adult human degrades and synthesises about 300 g of protein /day (Garlick et al., 1980) 
and as mention above, tryptophan corresponds to 1- 1.2 % of the total protein (Mahan 
and Shields, 1998), this way an adult would require 3 – 3.6 g of tryptophan every day. It 
is recommended that an adult should obtain 350 – 400 mg of tryptophan per day through 
diet (Lazaris-Brunner et al., 1998), which is much lower than the tryptophan necessary 
to resynthesize proteins, suggesting that dietary tryptophan only allows replacement of 
tryptophan that was metabolised.  
Tryptophan is the amino acid found in the lowest concentrations being relatively 
less available and for that reason it is thought to play an important role in protein 
synthesis as a rate-limiting amino acid (Cortamira et al., 1991; Wurtman et al., 1980). 
1.3.2.2 Kynurenine pathway  
The degradation of L-tryptophan by the kynurenine pathway was first described 
in 1947 (Beadle et al., 1947) and is responsible for about 90% of the catabolism of this 
amino acid in humans (Richard et al., 2009). This pathway is a complex chain of 
reactions that depend on a series of enzymes to catalyse all the steps as represented in 
Figure 7. It can be initiated by 3 distinct enzymes: indoleamine 2,3-dioxygenase 1 (IDO1; 
(Thomas and Stocker, 1999)), indoleamine 2,3-dioxygenase 2 (IDO2; (Ball et al., 2009)) 
and tryptophan 2,3-dioxygenase (TDO; (Ren and Correia, 2000)). These 3 molecules 
cleavage the 2,3-double bond of the indole ring in the L-tryptophan resulting in N-formyl-
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kynurenine. N-formyl kynurenine is converted to kynurenine, one of the key metabolites 
in this pathway, by formyl kynurenine formamidase.  
At this point, the kynurenine pathway can then be split into two branches. 
Kynurenine can be irreversible transaminated by kynurenine aminotransferases (KATs) 
originating kynurenic acid (KYNA). Another branch, which competes with KATs, 
transforms kynurenine into 3-hydroxykynurenine (3-HK) and anthranilic acid, by 
kynurenine 3-monooxygenase (KMO) and kynureninase, respectively (Chiarugi et al., 
1995). Cellular localisation, intracellular compartmentalization, and enzyme kinetics will 
determine the fate of kynurenine (Dang et al., 2000; Schwarcz and Pellicciari, 2002).  
Kynureninase and KATs can further catalyse 3-HK into 3-hydroxyanthranilic acid (3-
HANA) and xanthurenic acid, respectively (Kawai et al., 1988). Anthranilic acid can also 
be degraded into 3-HANA by non-specific oxidases (Baran and Schwarcz, 1990). 3-
HANA can be oxidised into cinnabarinic acid or it can be transformed into 2-amino-3-
carboxymuconic-6-semialdehyde by 3-hydroxyanthranilic acid 3,4-dioxygenase (3-HAO; 
(Foster et al., 1986). The kynurenine pathway divides into two arms again, 2-amino-3-
carboxymuconic-6-semialdehyde can spontaneously rearrange into quinolinic acid 
(QUIN), which has a short half-life, about 20 minutes. The production of QUIN can be 
regulated by a change in the concentration of Fe2+ that modulates the activity of 3-HAO 
(Stachowski and Schwarcz, 2012) or by changing pH and temperature to influence the 
non-enzymatic reaction. The second branch of this pathway is possible via the activity of 
2-amino-3-carboxymuconic-6-semialdehyde decarboxylase producing picolinic acid 
from 2-amino-3-carboxymuconic-6-semialdehyde (Pucci et al., 2007). QUIN can be 
further degraded by quinolinate phosphoribosyl transferase to end up synthesising 
NAD+; this pathway has been shown crucial under infection diseases to prevent energy 
failure and apoptosis (Bellac et al., 2010; Braidy et al., 2011).  
The kynurenine pathway is extensively studied. Many research projects have 
shown the importance of kynurenine pathway in physiological processes, such as to 
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degrade excess of tryptophan under normal conditions (Le Floc'h et al., 2011), and in 
disease settings, such as its role in modulating immunity and inflammation (Kwidzinski 
and Bechmann, 2007). 
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Figure 7: The kynurenine pathway (Schwarcz et al., 2012).
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Tryptophan-catabolizing enzymes 
Three dioxygenases are known to catalyse tryptophan into N-formyl-kynurenine 
and initiate the kynurenine pathway: Tryptophan 2,3-dioxygenase (TDO), Indoleamine 
2,3-dioxygenase 1 (IDO1) and Indoleamine 2,3-dioxygenase 2 (IDO2). Although these 
enzymes have the same enzyme activity, they differ in many aspects, including function, 
substrate specificity, structure, cofactors requirements and tissue distribution, as 
summarised in the Table 2.  
1.3.2.2.1 Tryptophan 2,3-dioxygenase (TDO) 
In 1936, Kotake and Masayama discovered TDO in the liver of rats. Human TDO, 
which comprises 406 amino acids, is encoded by the TDO2 gene in the chromosome 4. 
The TDO2 gene comprises 12 exons and 11 introns and is composed of 65,669 bps 
(Comings et al., 1995). This gene has intron and exon variants that results in 
polymorphisms, linked to mental disorders (Miller et al., 2009b; Vasiliev et al., 1999). 
TDO has only one substrate, L-tryptophan in the tetrameric form. The crystal structure 
of TDO has been reported in human, Ralstonia metallidurans and Xanthomonas 
campestris, its haeme-binding site has only been investigated in Ralstonia metallidurans 
(Zhang et al., 2007).  TDO has an open and closed configuration, the open configuration 
exposes the heme-binding site to the substrate.  
1.3.2.2.2 Indoleamine 2,3-dioxygenase (IDO1) 
IDO1 was isolated for the first time in 1967 from the rabbit intestine (Yammotto 
and Hayaishi, 1967). IDO1 is an intracellular haem enzyme which converts L-tryptophan 
into N-Formylkynurenine. IDO1 is a monomeric protein that comprised 403 amino acids 
with a molecular mass of about 42- 54 kDa (Arefayene et al., 2009; De Luca et al., 2013; 
Tardito et al., 2013). This protein is encoded by the IDO1 gene located on chromosome 
8 with 10 exons (Burkin et al., 1993; Grohmann and Bronte, 2010; Tone et al., 1994). 
Several studies have identified genetic variations of IDO1 gene leading to differential 
expression and activity of IDO1 (Burkin et al., 1993; Grohmann and Bronte, 2010; Tone 
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et al., 1994). IDO1 genetic variants have been associated with the severity and outcome 
of some human diseases. For instance, an IDO1 variant has been correlated with a 
reduced risk of vulvovaginal candidiasis recurrence (De Luca et al., 2013). Also an IDO1 
single nucleotide polymorphism (SNP) has been associated with autoimmune systemic 
sclerosis (Arefayene et al., 2009). Another type of IDO1 regulation at transcriptional level 
is involved in histone deacetylation by histone deacetylase (HDAC).  
Interferon-gamma (IFNγ) is the most powerful stimulus of IDO1 gene expression, 
both in vivo and in vitro (Gough et al., 2008; Jeong et al., 2009).  IFNγ activates both 
Janus kinase (JAK)/STAT and protein kinase Cδ (PKCδ) molecular pathways. JAK, 
STAT1 and IRF1 are crucial for optimal IDO1 expression (Chon et al., 1995; Jeong et 
al., 2009; Konan and Taylor, 1996; Robinson et al., 2003). Other molecules can be 
important to IDO1 expression depending on the cell type. For instance, in human cord-
blood-derived mesenchymal stem cells phosphoinositide 3-kinase (PI3K) modulates 
STAT1 phosphorylation level, thus influencing IDO1 expression (Mounayar et al., 2015), 
also IFNγ- mediating IDO1 expression in murine splenic CD8α+ DCs depends on IRF8 
transcription factor (Orabona et al., 2006). The promoter region of IDO1 comprises three 
IFNγ-activated sites (GASs), which contains binding sites to STAT1, and 2 IFNγ-
stimulated response elements (ISREs), which have binding sites to IFN regulatory factor 
1 (IRF1) (Robinson et al., 2006).  
Tumour necrosis factor α (TNFα) cannot induce IDO1 expression on its own, but 
it can synergistically stimulate IDO1 with other cytokines, such as IFNγ or other stimuli. 
TNFα activates the nuclear factor κB (NF- κB) pathway stimulating IRF1 transcription 
and STAT1 phosphorylation which leads to an upregulation of the expression of IFNγ 
receptors (Babcock and Carlin, 2000; Braun et al., 2005; Robinson et al., 2006; Robinson 
et al., 2003). IDO1 expression can also be trigged or modulated by type I IFNs (IFNα and 
IFNβ), Toll-like receptor (TLR) 3, 4, 7, 8 and ligands, interleukin 1 (IL-1), IL-6, oestrogen, 
thymosin α, prostaglandin E2 (PGE2), muramyl tripeptide, glucocorticoids, α-
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galactosylceramide and haemoglobin (Adams et al., 2004; Babcock and Carlin, 2000; 
Braun et al., 2005; Furset et al., 2008; Hissong et al., 1995; Hissong and Carlin, 1997; 
Jung et al., 2010; Jung et al., 2007; Robinson et al., 2005; Suh et al., 2007; Zhu et al., 
2007). Bacteria and virus can also stimulate IDO1 expression (Fujigaki et al., 2006; Liu 
et al., 2014). 
IDO1 is constitutively or upon stimulation expressed in a broad range of cell types 
and tissues. Under normal physiological conditions, IDO1 protein is constitutively 
expressed mostly in subpopulations of immune cells and mucosal tissues. In rodents, 
IDO1 protein expression has been identified as constitutively in the caput of the 
epididymis, adipose tissue, the prostate, the placenta during pregnancy, in lymphoid 
organs, certain lymph nodes, spleen, gastrointestinal track, central nervous system, 
lung, pancreas, kidney and in certain areas of the eye (Dai and Zhu, 2010). Interestingly, 
in adult mice, IDO1 expression in the large intestine is constitutively but it dependents 
on its normal flora and IFNγ which is thought to have an important homeostatic role by 
preventing an immune response towards the intestinal microorganisms (Harrington et 
al., 2008; Takikawa et al., 1999).  Studies have shown that IDO1 is constitutively 
expressed in the eye, pancreas and placenta (Ryu and Kim, 2007; Sarkar et al., 2007; 
Sedlmayr et al., 2002), eosinophils (Odemuyiwa et al., 2004). IDO1 is mainly detected in 
the cytosol of the cell and also in the perinuclear region. Interestingly, functional IDO1 
has been detected in microvesicles which were derived from human amniotic fluid stem 
cells (Romani et al., 2015). 
IDO1 enzyme houses a haem prosthetic group within its active site and Sugimoto 
et al. published in 2006 the first crystal structure of human IDO1, Figure 8 A (Sugimoto 
et al., 2006). The crystal structure showed two large and two small α-helical domains 
revealing that the first ones formed a pocket for the haem group and the small domains 
covered the cavity, Figure 8 B (Sugimoto et al., 2006).  
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Figure 8: Crystal structure of IDO1 protein. A- Molecular module of the surface of 
the IDO1 protein. B- Representation of the overall IDO1 structure, small domains are 
represented in blue and large domains represented in green. The ball-and-stick model 
represent the haem molecule in both images. (Adapted from Sugimoto et al., 2006). 
 
If IDO1 enzymatic uncontrolled activity could cause harm to the host, thus IDO1 
is highly controlled through several mechanisms ahead transcriptional control.  Some 
cell populations, which constitutively express IDO1, have been found to express low 
IDO1 enzymatic activity (Fallarino et al., 2002; Munn et al., 2004; Munn et al., 2002). For 
example, CD123+ DCs constitutively express IDO1, but requires IFNγ to activate its 
enzymatic activity (Munn et al., 2002). Interestingly, both mouse splenic CD8α+ DCs and 
CD8α- DCs express similar levels of IDO1 upon IFNγ stimulation, but only the first one 
degrades L-tryptophan (Fallarino et al., 2002). The mechanisms behind this 
phenomenon have not yet been uncovered, but DAP12, a transmembrane signalling 
adapts as a co-activator of immunoreceptor tyrosine-based activation motifs (ITAMs) 
was found to be determinant in this process (Orabona et al., 2006).  
The IDO1 enzymatic activity switch has been extensively studied in the past years 
and a complex net of mechanisms have been identified, including: availability of the 
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haem group and reducing factors, redox reactions, protein-protein interactions, tyrosine 
phosphorylation and proteasome degradation.  
IDO1 protein is only enzymatically active when the haem group is incorporated 
into its structure. The enzymatic IDO1 activity in monocytes is regulated by the proportion 
of haem-free IDO1 and haem-containing IDO1 (Thomas et al., 2001). Biosynthesis and 
degradation of haem is responsible for the cellular availability of haem. Haem 
biosynthesis is driven by δ-ALAS which initiates haem synthesis and works as a rate-
limiting enzyme, while haem oxygenase 1 controls haem degradation. IFNγ-induced-
Inhibition of haem synthesis in human macrophages prevented haem incorporation into 
IDO1 and blocked its enzymatic activity. In contrast, incorporation of a haem precursor 
enhanced IDO1 activity (Hill et al., 2005; Thomas et al., 2001). IDO1 activity can also be 
modulated by other proteins that compete for intracellular haem. For example, IDO2 has 
been identified as a negative regulator of IDO1 by competing for haem (Lee et al., 2014).  
In order to have an active IDO1, the haem group has to undergo an electron reduction 
from FeIII to FeII, which allows O2 and L-tryptophan to form a ternary complex with the 
reduced haem group (Sono et al., 1980).  Thus, IDO1 cofactors could involve 
physiological reductants. Three IDO1 cofactors have been identified such as flavin 
mononucleotide (FMN), tetrahydrobiopterin and O2− (Hayaishi et al., 1977; Hirata and 
Hayaishi, 1975; Hirata et al., 1977; Ozaki et al., 1987; Ozaki et al., 1986). However, only 
O2 has been validated in further studies as a reducing cofactor and substrate for IDO1 
(Hayaishi et al., 1977). 
IDO1 can also be phosphorylated in two conserved tyrosine residues (tyr115, 
try253), which can trigger a signalling pathway independent from the IDO1 enzymatic 
activity (Pallotta et al., 2011) or can work as a signal for IDO1 protein proteasome 
degradation (Orabona et al., 2008) depending on the microenvironment. These two 
distinct signalling pathways involve interaction of IDO1 with other signalling proteins. In 
murine pDCs, IDO1 is phosphorylated upon TGFβ stimulation in a Fyn-dependent 
manner, a member of the Src family kinase (Pallotta et al., 2011). In this situation, IDO1 
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induces IFNs expression through activating the non-canonical NF-kB pathway by the 
recruitment and binding of SHP-1 and SHP-2 to IDO1. This pathway as an 
immunosuppressive regulatory role (Pallotta et al., 2011). IDO1 proteasomal 
degradation also requires phosphorylation, which in CD8α+ DCs can be stimulated by 
IL-6 and is dependent on the binding of suppressor of cytokine signalling 3 (SOCS3) to 
the IDO1 phosphorylated tyrosines that recruits the elogin/cullin/SOCS (ECS) E3 ligases 
that drives the proteasomal degradation of the IDO1-SOCS3 complex by ubiquitination 
(Pallotta et al., 2011).  
IDO1 is an enzyme that has been mainly studied as a key regulator of immune 
and infection response through the degradation of L-tryptophan lowering its availability 
and producing kynurenine pathway metabolites.  
Munn and collaborators described, for the first time in 1998, that IDO1 could 
modulate the immune response (Munn et al., 1998). This study used female mice that 
mated with syngeneic (same strain) or allogeneic (different strain) males. In theory, the 
second group of females would generate an immune response against the faetus, but it 
is not the case. The study showed that IDO1 was expressed in the placenta of both group 
of females. However, when females were treated with 1-methyl-tryptophan (1-MT), an 
IDO1 inhibitor, the development of the syngeneic embryos was not altered, none of the 
allogeneic embryos survived. Since then, the role of IDO1 in regulating the immune 
response has been extensively studied in order to uncover its mechanism of action. 
Studies have focused on the role of antigen-presenting cells (APCs), such as 
macrophages and dendritic cells, on mediating T-cell suppression through IDO1 
expression. Interestingly, APCs can express IDO1 depending on their microenvironment 
and maturation status (Carlin et al., 1989a; Fallarino et al., 2002; Guillemin et al., 2005; 
Munn et al., 1999; Munn et al., 2004; Munn et al., 2002; Nouël et al., 2015). Other innate 
immune cells can also express IDO1, such as eosinophils, neutrophils and natural killer 
cells (De Ravin et al., 2010; Kai et al., 2003; Odemuyiwa et al., 2004).  
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Depending on the cell type, the IDO1 mechanism of action is different, such as 
on T-cells it induces Treg maturation, faulty activation of T-cell receptor or apoptosis of 
T-cell subpopulations, while it controls the production of cytokines by macrophages or 
its phenotype.  
In vivo studies showed that DCs and macrophages express IDO1 and induce cell 
cycle arrest of T-cells, which is dependent on the IDO1 enzymatic activity (Munn et al., 
1999; Munn et al., 2004; Munn et al., 2002). Interestingly, T-cell inhibition by IDO1-
expressing DCs and macrophages does not necessary involve defective TCR activation. 
Several studies demonstrated that IDO1 or tryptophan starvation induces cell cycle 
arrest of T-cells via Fas signal, apoptosis and can also inhibits a T-cell response (Lee et 
al., 2002; Mellor et al., 2004; Mellor and Munn, 2003; Munn et al., 2004). Romani and 
collaborators showed that vesicles from human amniotic fluid stem cells, which were 
stimulated by IFNγ, contained active IDO1 and they were capable of inhibiting a T-cell 
response (Romani et al., 2015).  
In vivo studies that the T-cell activity was restored by adding more L-tryptophan 
suggested that the immune regulation by IDO1 was due to a substantial decrease in 
tryptophan rather than any metabolite produced by the tryptophan degradation. Thus, in 
response to a lack of tryptophan, the levels of unchanged tRNA increase in T-cells 
activates the general control nonderepressible 2 (GCN2) kinase pathway, which stops 
most protein synthesis, but increases the synthesis of a few ones. GCN2 also inhibits 
the mTOR and PKCθ signalling pathway leading to T-cell anergy and autophagy (Metz 
et al., 2012; Munn et al., 2005; Sharma et al., 2007). In summary, the lack of L-tryptophan 
induced by IDO1 is responsible for some of the IDO1 immune effects on T-cells.  
An intriguing question is how IDO1- expressing cells or surrounding cells survive 
and remain functional to the lack of L-tryptophan but not T-cells. Tryptophanyl-tRNA 
synthetase (TTS) is an enzyme that is constitutively expressed and catalyses the 
association between tRNA and tryptophan so this amino acid can be incorporated into 
proteins and it has been shown that TTS is primarily responsible for the survival of cells 
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to the lack of tryptophan (Boasso et al., 2005). This way, the level of TTS expression 
dictates the level of tolerance that the cells can support to an environment which lacks 
tryptophan preventing a cellular stress response (Boasso et al., 2005).  
IDO1 plays a critical role as immune regulator in a wide range of physiological 
settings and diseases. IDO1 have an essential role in pregnancy (Baban et al., 2004; 
Mellor et al., 2001; Munn et al., 1998). Although, IDO1 gene-knockout mice do not lead 
to an autoimmune disorder, IDO1 knockout or inhibition has led to an unregulated and 
excessive immune response from the host when in contact with new or foreign antigens. 
IDO1 has been found to be overexpressed in autoimmune diseases, such as 
inflammatory bowel disease, arthritis and diabetes. The inhibition of its activity enhanced 
the severity of some of these diseases, suggesting that IDO1 activation might control the 
excessive immune response against self-antigens (Choi et al., 2006; Ciorba et al., 2010; 
Coquerelle et al., 2009; Grohmann et al., 2003; Gurtner et al., 2003; Ravishankar et al., 
2012; Schröcksnadel et al., 2006; Szántó et al., 2007; Takamatsu et al., 2013).  
IDO1 is also known to be part of the immune response against organisms such 
as bacteria, virus, parasites and fungi (Carlin et al., 1989b; Taylor and Feng, 1991). Even 
though some of these organisms can synthesise L-tryptophan, the L-tryptophan 
synthesis is not efficient and these organisms evolved to be tryptophan- dependent from 
the host (Mellor and Munn, 2004; Zegarra-Moran et al., 2004). Thus, they are sensitive 
to the lack of tryptophan.   
Recent studies have identified IDO1 as an important molecule in different 
settings, such as vascular tone and blood pressure (Wang et al., 2010; Xiao et al., 2013), 
bone remodelling (Bozec et al., 2014; Vidal et al., 2015), and neurological disorders, 
such as depression and Parkinson’s disease (Myint, 2012; Myint et al., 2012) and age-
related cataracts (Mailankot et al., 2009).   
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1.3.2.2.3 IDO1 in cancer 
The immune system is design to identify and eliminate cancer cells, but these 
cells can evolve and acquire mechanisms to be immune tolerant and escape the effects 
of T-cells and other immune cells. Once cancer cells reach the estate of immune 
resistance, tumour cells survive, including in new metastatic sites, allowing tumour 
progression (Prendergast et al., 2010).  
Interestingly, the first in vitro studies suggested that IDO1 had an anti-tumour 
effect, through IFNγ in several cancer cell lines and this effect was dependent on the 
lack of L-tryptophan (Aune and Pogue, 1989; Ozaki et al., 1988). Also, an increase of 
IDO1 in stroma cells, such as human mesenchymal stem cells, which supports the 
growth of follicular lymphoma B-cells, leads to cell cycle arrest and apoptosis of the 
cancer cells (Maby-El Hajjami et al., 2009).  
Despite the fact that the initial in vitro research suggests that IDO1 has an anti-
tumour role, a substantial and growing human and animal data shows that IDO1 is a key 
molecule in the tumour cell immune escape. High expression and activity of IDO1 is a 
feature of a wide range of tumours, such as prostatic, breast, pancreatic and colorectal 
carcinomas. IDO1 is expressed by cancer cells, as well as by tumour-recruited 
leucocytes (e.g. macrophages and DCs) and tumour-draining lymph nodes (Munn et al., 
2004; Munn et al., 2002; Uyttenhove et al., 2003). IDO1 enzymatic activity, indicated by 
Kynurenine and L-tryptophan levels in serum, correlates with poor prognostic in many 
human malignancies including ovarian, breast and lung (Astigiano et al., 2005; 
Brandacher et al., 2006; Chen et al., 2014; Inaba et al., 2010; Inaba et al., 2009; Ino et 
al., 2006; Jia et al., 2015; Okamoto et al., 2005; Pan et al., 2008; Suzuki et al., 2010; 
Urakawa et al., 2009; Wainwright et al., 2012; Witkiewicz et al., 2008; Yu et al., 2013; Yu 
et al., 2011) and in lymphomas such as myeloma (Bonanno et al., 2012; Choe et al., 
2014; Lin et al., 2013; Masaki et al., 2015; Ninomiya et al., 2011; Yoshikawa et al., 2010). 
Also, increase IDO1 expression correlates with an increase in the number of Treg in the 
tumour microenvironment or in circulation (Choe et al., 2014; Curti et al., 2007b; Lin et 
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al., 2013; Moretti et al., 2014; Nakamura et al., 2007; Speeckaert et al., 2012; Spranger 
et al., 2013; Yu et al., 2013; Yu et al., 2011). In vitro and in vivo studies showed that 
leukaemia cells expressing IDO1 increase the number of Tregs which was prevented by 
1-MT (Curti et al., 2007a; Curti et al., 2007b; Curti et al., 2010). When focused on the 
link between IDO1 and clinical outcome, it has been demonstrated that IDO1 
overexpression correlated with poor prognosis in breast, ovarian, leukemic, colorectal, 
endometrial and lung cancer (Astigiano et al., 2005; Brandacher et al., 2006; Chamuleau 
et al., 2008; Ino et al., 2006; Okamoto et al., 2005; Suzuki et al., 2010; Takao et al., 
2007). 
Although these studies suggest that IDO1 expression or its enzymatic activity 
might indicate an adverse clinical prognosis, controversies exist in that. Some research 
groups have shown a complete opposite connection. For example, IDO1 expression has 
been shown to be correlated with a better prognosis in breast, hepatocellular and renal 
cell carcinoma (Ishio et al., 2004; Jacquemier et al., 2012; Riesenberg et al., 2007) or 
with no correlation between IDO1 expression and prognosis in melanoma and cervical 
cancer (Lee et al., 2003; Nakamura et al., 2007). Possible reasons for such controversy 
are likely to be multiple factors, including different types and subtypes of cancer, different 
therapeutic approaches, testing time (namely prior or post chemotherapy), the nature of 
test samples and test methods. Further studies clearly are needed to further clarify this 
important link and to better understand the precise role played by IDO1 in cancer. 
Although the importance of IDO1 as a prognostic marker has still to be elucidated, 
animal studies have shown that IDO1-expressing tumours are more aggressive than 
those negative of IDO1 (Muller et al., 2005; Pilotte et al., 2012; Uyttenhove et al., 2003). 
The pro-inflammatory microenvironment, which is a feature of many tumour types, 
seems to be the driven factor for IDO1 expression by stroma cells and/or antigen-
resenting cells (APCs) (Belladonna et al., 2006) resulting in a local lack of tryptophan.   
Many in vivo animal data confirm the concept of tryptophan metabolism by IDO1 
as an important factor in tumour immune tolerance. IDO1 expressing cancer cells 
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develop tumours when injected into syngeneic mice, these tumours are characterised by 
a lack of infiltrating T-cell, which could be reversed by 1-MT resulting in a decrease of 
the tumour volume (Friberg et al., 2002; Uyttenhove et al., 2003). Muller et al. showed 
that in a breast cancer animal model, 1-MT in conjugation with paclitaxel resulted in a 
decrease in 30% of the tumour volume, further suggesting that IDO1 inhibition could be 
an effective adjuvant therapy (Muller et al., 2005). The same group also demonstrated 
that the IDO1 immune effect is dependent on T cells (Muller et al., 2005).  
1.3.2.2.4 Indoleamine 2,3-dioxygenase (IDO2) 
Murray (2007) discovered the ido2 gene, an ido1 homologous gene. Meantime, 
three different groups independently identified that an enzyme encoded by the ido2 gene 
was able to degrade tryptophan into kynurenine (Ball et al., 2007; Metz et al., 2007; 
Yuasa et al., 2007). This enzyme has been referred to as indoleamine 2,3-dioxygenase-
like protein, indoleamine 2,3-dioxygenase-2 (IDO-2 or IDO2) and proto-indoleamine 2,3-
dioxygenase (proto-IDO). Ball and collaborators showed that IDO2 degrades tryptophan 
in Human Embryonic Kidney 293 cells with a lower enzymatic activity (about 45% less 
than IDO1) (Ball et al., 2007). A different study showed similar results regarding IDO2 in 
T-rex cells (Metz et al., 2007).  
The human genes that encode IDO1 and IDO2 proteins are adjacent to each 
other on chromosome 8. The IDO2 protein comprises 420 amino acids and shares 43% 
of its sequence with IDO1 but not with TDO. This evidence suggests that these two genes 
originated from gene duplication (Ball et al., 2007; Yuasa et al., 2007). 
The expression patterns of IDO2 mRNA and protein have suggested some 
functional overlap with IDO1 but also revealed some unique aspect in its functions. IDO2 
mRNA is predominantly found in the liver, kidney and cerebral cortex, while IDO1 is 
mostly expressed in colon and epididymis. Interestingly, mice genetically modified to 
have a deficiency in IDO1 expression, showed an upregulation of IDO2 in the epididymis 
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(Fukunaga et al., 2012), suggesting a functional redundancy of IDO2. Both IDO1 and 
IDO2 are expressed in antigen-presenting cells but IDO2 seems to be constitutively 
expressed whereas IDO1 requires inflammatory mediators (Trabanelli et al., 2014), 
suggesting that IDO2 might be involved in the homeostasis of these cells. IDO2 promoter 
has a binding site for IRF-7, a key transcription factor involved in the maturation of 
dendritic cells (Trabanelli et al., 2014). Intriguingly, the same study showed that IDO2 
has a similar basal level of expression as IDO1 does. Like IDO1, IDO2 responds to pro-
inflammatory stimuli, such as prostaglandin E2, lipopolysaccharide, IFN-γ and IL-10, with 
less robust (Lo et al., 2011; Metz et al., 2007; Simones and Shepherd, 2011; Sun et al., 
2010; Trabanelli et al., 2014). Intriguingly, in a malaria animal model, a disease 
characterised by its high levels of IFN-γ, whereas levels of IDO2 mRNA and protein 
remain were unchanged (Ball et al., 2007).  
IDO2, like IDO1, has been reported as being overexpressed in number of cancer 
types, such as pancreatic cancer, renal cancer and colorectal cancer (Löb et al., 2009). 
Interestingly, cancer cell lines only expressed IDO1 and IDO2 when stimulated by IFN-γ 
(Löb et al., 2009). The same study also showed that HeLa cells expressed IDO1 and 
IDO2 upon IFN-γ stimulation but only IDO1 was responsible for tryptophan degradation 
(Löb et al., 2009), suggesting that IDO2 might not have a role in the kynurenine pathway 
in cancer cells. IDO2 was also found to be overexpressed in basal cell carcinomas (BCC) 
of skin, and CXCL11 seems to be involved in the IDO2 regulation (Lo et al., 2011).  
Several studies have shown that IDO2 is not a typical tryptophan enzyme (Austin et al., 
2010; Meininger et al., 2011) when compared to IDO1. Pantouris and collaborators 
assessed the IDO1 and IDO2 kinetic properties in response to L-tryptophan, D-
tryptophan and analogues (Pantouris et al., 2014). Kinetic analysis measures the 
behaviour of enzymes using simple chemical principles, such as Km and Kcat. Km is the 
substrate concentration at which the reaction is half of the maximum velocity, while Kcat 
is the limiting rate of any enzyme-catalysed reaction at saturation (Pantouris et al., 2014).   
52 
 
Among the substrates used, L-tryptophan was the second best substrate for both 
IDO1 and IDO2 in terms of the catalytic rate (Kcat), but L-tryptophan was second for 
IDO1 and fourth for IDO2 best substrate in terms of Kcat/Km.  Km is defined as the 
concentration of substrate that the enzyme needs to reach half of the maximal velocity. 
The different Kcat/Km for L-tryptophan between IDO1 and IDO2 was due to a higher km 
for IDO2 (Pantouris et al., 2014).  DO1 and IDO2 might have a different active site and 
substrate binding structures (Pantouris et al., 2014). Mouse recombinant IDO1 and IDO2 
proteins exhibit their optimal activity occurs at pH 6.0 – 6.5 and 7.4 – 7.5, respectively 
(Austin et al., 2010). IDO1 and IDO2 have distinct thermal denaturation. The former was 
predominately denatured at 60° C, while the latter was denatured at 48° C (Austin et al., 
2010). Interestingly, sperm tails express IDO2 (Ball et al., 2007). Sperm is produced at 
a lower temperature than the core body. Also, the seminiferous fluid has a pH of 7.2 – 
8.0 (Harraway et al., 2000), which fits into the optimal IDO2 pH. As mentioned above, 
IDO1 and IDO2 have also been found to be overexpressed in many cancers, and 
tumours microenvironment is characterised as an acidic environment due to inadequate 
perfusion and high metabolic rates (Zhang et al., 2010). Temperature has also been 
reported as being increased in tumours(Chanmugam et al., 2012), suggesting that these 
tumour features might benefit IDO1 enzymatic activity.  
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Table 2: Summary of TDO, IDO1 and IDO2 characteristics 
 Tryptophan 2,3-dioxygenase 
(TDO) 
Indoleamine 2,3-dioxygenase 1 
(IDO1) 
Indoleamine 2,3-dioxygenase 2 
(IDO2) 
Substrate 
L-tryptophan L-Tryptophan, 
D-Tryptophan, serotonin, 5-
hydroxytryptophan 
and tryptamine 
L-Tryptophan, 
D-Tryptophan  
Substrate 
specificity 
Low High Low 
Form Tetrameric Monomeric Monomeric 
Tissue distribution Liver (skin and cortex) Ubiquitous  Liver, kidney, cerebral cortex 
Functions Tryptophan homeostasis Immune regulation Not known 
Regulation 
(Main stimulators) 
Tryptophan, glucocorticoids and 
glucagon 
IFN-γ, LPS, virus, bacteria  IFN-γ, IL-10, , LPS, prostaglandin E2 
(less responsive than IDO1) and 
possible IRF-7 
Non-enzymatic 
activity 
Not known Yes  Not known 
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1.3.2.2.5 Kynurenine pathway metabolites 
The activation of the kynurenine pathway results in the decrease of the availability 
of L-tryptophan but also in the formation of metabolites from that metabolism, which has 
considerable biological effects. 
T-cell proliferation can be inhibited in vitro by IDO1 and this phenomenon has 
been mainly attributed to a decrease in L-tryptophan at concentrations lower than 0.5-1 
µM (Munn et al., 1999). However, the levels of tryptophan in plasma are between 40 and 
100 µM and it would be very difficult to achieve such low tryptophan concentrations in 
vivo.  Additional in vitro studies have shown that the treatment of activated T-cells, B-
cells and NK cells with high levels of kynurenine pathway metabolites, such as 
kynurenine, 3-HAA, 3-HK, QA and picolinic acid can inhibit their function (Frumento et 
al., 2002; Lee et al., 2010a; Terness et al., 2002). Surprisingly, lower levels of these 
metabolites, which are closer to physiological conditions, can have the same inhibitory 
effects on T-cells when these cells are treated with diverse combination of these 
metabolites or when added to low L-tryptophan or free tryptophan medium (Fallarino et 
al., 2006; Frumento et al., 2002; Terness et al., 2002). 
Kynurenine has been identified as a ligand of the aryl hydrocarbon receptor (AhR) 
transcription factor, which is involved in several physiological pathways, such as immune 
regulation, reproduction and vascular development (Stockinger et al., 2014). CD4+ T-
cells differentiate into pro-inflammatory Th7 cells when stimulated with TGFβ, but 
Mezrich and collaborators reported that kynurenine modulates the differentiation of naïve 
CD4+ T cells when stimulated with TGFβ into FoxP3+ Treg in vitro, in an AhR dependent 
manner (Mezrich et al., 2010). It has also been shown that kynurenine induce the 
expression of IDO1 through AhR activation in DCs (Nguyen et al., 2010; Vogel et al., 
2008). Other metabolites of the kynurenine pathway have been shown to activate AhR 
signalling, for examples, kynurenic acid induces the expression of IL-6 in MCF7 cells 
through AhR activation and interestingly, it synergistically stimulates IL-6 when IL-1β is 
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present in the medium (DiNatale et al., 2010). Also, 3-HAA plays an important role in 
suppressing the immunoresponse by depleting glutathione (Lee et al., 2010a) and 
activating NF-kB through inhibition of TCR pathway (Hayashi et al., 2007) which results 
in T-cell function impaired. 
The studies described above show that IDO1 induce tryptophan degradation 
through the kynurenine pathway leading to L-tryptophan deprivation but also to the 
production of kynurenine pathway metabolites which have significant biological meaning 
that can help to explain the immune modulation role of IDO1.   
1.5 Hypothesis and aims 
Disseminated breast cancer cells have been detected near microvessels in a 
TSP1 rich microenvironment. Thus it has been speculated that the TSP1 might be one 
of the molecules modulating tumour dormancy. TSP1 has a higher content of L-
tryptophan than the average protein. L-tryptophan is the rarest essential amino acid in 
mammalians and a rate limiting-step on protein synthesis. IDO1 enzyme activity controls 
the local availability of L-tryptophan. IDO1 is overexpressed by breast tumours.  
Here, it was hypothesised that endothelial cells may reduce TSP1 protein levels 
in the extracellular matrix of microvessels, due to an increase of IDO1 stimulated by 
cancer cells. Reduction in TSP1 may be permissive to the proliferation of cancer cells 
and induce angiogenesis leading to development of metastasis.  
 
Aims of this project: 
✓ Assess TSP1 and IDO1 staining in invasive breast carcinoma, lymph node 
metastasis and adjacent normal tissue by immunohistochemistry. In order to 
evaluate their expression in each tissue and also their expression in terms of 
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cancer progression and survival. A correlation between vascular IDO1 and 
stromal TSP1 was also estimated.  
✓ Evaluate in a series of in vitro assays whether endothelial cells and human 
recombinant TSP1 induce breast cancer dormancy. The role of TSP1 as a 
protective molecule against anti-tumour drugs was also investigated.  
✓ Understand whether breast cancer cells are capable of inducing vascular IDO1 
and whether tryptophan limits TSP1 synthesis and secretion by endothelial cells. 
✓ Investigate the potential role of IFNγ as a soluble factor secreted by cancer cells 
to induce IDO1 in endothelial cells.  
 
 
 
 
Chapter II: General Material and Methods 
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2.1 Materials 
2.1.1 Cell lines 
In this study five microvascular endothelial cell lines, one epithelial lung cell line (Table 
3), one non-tumorigenic breast cell line and two breast cancer cell lines were used 
(Table 4). HMVECaD was obtained from Gibco (Paisley, UK). BEAS-2B, MDA-MB-231, 
MCF7 and MCF10A were obtained from American Type Culture Collection (ATCC, 
Rockville, Maryland, USA). HECV cells were kindly provided by Dr G. Di Domenico 
(Istituto Nazionale per la Ricerca sul Cancro, Italy). Ty09 and TY10 were kindly 
provided by Professor Takashi Kanda (Yamaguchi University Graduate School of 
Medicine, Ube, Yamaguchi, Japan) and hCMEC/D3 was kindly provided by Professor 
Pierre-Olivier Couraud (Institut Cochin, Université René Descartes, Paris, France). 
Details of the cell lines are presented in the Tables 3 and 4 including culture conditions.
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Table 3: Cell lines information, part 1. 
Type Cell line Morphology Sources and features Growth conditions 
E
n
d
o
th
e
li
a
l 
c
e
ll
 l
in
e
s
 
Human Microvascular 
Endothelial Cells, adult 
dermis (HMVECad, Lonza) 
Endothelial Primary human 
microvascular 
endothelial cells 
isolated from adult 
dermis 
 
Pre-coated flasks with Attachment Factor (AF, 
Lonza) in EGM™-2MV BulletKit™ (hEGF, 
hydrocortisone, gentamicin, amphotericin-B, 
5% FBS, VEGF, hFGF-B, R3-IGF-1 and 
ascorbic acid; Lonza) and antibodies. Cells 
cultured at 37oC and 5% CO2. 
Human endothelial vascular 
(HECV, provided by Dr G. 
Di Domenico, Centro 
Biotecnologie Avanzate, 
Italy) 
Endothelial Primary endothelial 
cells from umbilical 
cord 
Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% FBS and antibodies. 
Cells cultured at 37oC and 5% CO2. 
TY09 (provided by 
Professor Yasuteru Sano, 
Yamaguchi University, 
Japan) 
Endothelial Endothelial cells 
derived from the brain 
and immortalised with 
nTERT and SV40 large 
T antigen. 
Pre-coated flasks with AF in EBM2 
supplemented with SingleQuots™ Kit (hEGF, 
VEGF, IGF1, Ascorbic acid, Hydrocortisone, 
hFGF-b, Hepanin and 20% FBS; Lonza) and 
antibodies. Cells cultured at 34oC and 5% CO2. 
TY10 (provided by 
Professor Yasuteru Sano, 
Yamaguchi University, 
Japan) 
Endothelial Endothelial cells 
derived from the brain 
and immortalised with 
nTERT and SV40 large 
T antigen. 
Pre-coated flasks with AF in EBM2 containing 
SingleQuots™ Kit (hEGF, VEGF, IGF1, 
Ascorbic acid, Hydrocortisone, hFGF-b, 
Hepanin and 20% FBS, Lonza) and antibodies. 
Cells cultured at 34oC and 5% CO2.  
Blood-Brain Barrier 
hCMEC/D3 (provided by 
Institut Cochin, France) 
Endothelial Derived from human 
temporal lobe 
microvessels and 
immortalised with 
nTERT and SV40 large 
T antigen. 
Pre-coated flasks with AF in EBM2 
supplemented with 5% FBS, 1% Penicillin-
Streptomycin, Hydrocortisol (1.4 µM), ascorbic 
acid (5 µg/mL), 1% chemically defined lipid 
concentrated 1/100, HEPES (10 mM), bFGF 
(1ng/mL) and antibodies. (all supplements from 
Lonza). Cells cultured at 34oC and 5% CO2. 
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Table 4: Cell lines information, part 2. 
Type Cell line Morphology 
Sources and 
features 
Growth conditions 
L
u
n
g
 c
e
ll
 l
in
e
 BEAS-2B (Sigma-
Aldrich) 
Epithelial Derived from normal 
human bronchial 
epithelium and 
immortalised by 
adenovirus 12-SV40 
virus hybrid 
(Ad12SV40) and 
cloned 
Pre-coated flasks with AF in Bronchial Epithelial 
Cell Growth Medium (BEGM, Lonza), BEGM Bullet 
Kit (Hydrocortisone solution, GA-1000, retinoic 
acid, BPE high protein, recombinant human insulin 
0.5%, transferrin, triiodothyronine, epinephrine, 
hEGF) and antibiotics. Cells cultured at 37oC and 
5% CO2. 
N
o
n
- 
c
a
rc
in
o
g
e
n
ic
 
b
re
a
s
t 
c
e
ll
 l
in
e
 MCF10A (ATCC) Epithelial  Mammary Epithelial Basal Medium (MEBM; Lonza, 
Walkersville, MD, USA), supplemented with 
SingleQuots™ Kit (BPE, hydrocortisone, hEGF, 
insulin; Lonza), 0.1% Cholera toxin (Sigma-Aldrich) 
and antibiotics. Cells cultured at 37oC and 5% CO2. 
B
re
a
s
t 
c
a
n
c
e
r 
c
e
ll
 
li
n
e
 
MCF7 (ATCC) Epithelial Derived from 
metastatic site: pleural 
effusion 
DMEM (Sigma-Aldrich), 10% FBS and antibiotics. 
Cells cultured at 37oC and 5% CO2. 
MDA-MB-231 
(ATCC) 
Epithelial Derived from 
metastatic site: pleural 
effusion 
DMEM (Sigma-Aldrich), 10% FBS and antibiotics. 
Cells cultured at 37oC and 5% CO2. 
 
Note: all cell lines cultured under standard tissue culture conditions (37oC and 5% CO2) unless otherwise specified. 
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2.1.2 Human tissue microarrays 
Two different tissue microarrays were used in this study which comprised 
sections from paraffin embedded tissue. One of the tissue arrays was purchased from 
US BIOLAB Corporation (Gaithersburg, MD, USA) containing 52 samples of breast 
invasive ductal carcinoma (patient’s information in Appendix I). The second tissue array 
was purchased from US Biomax (Rockville, MD, USA) which contained 46 cases of 
invasive ductal carcinoma, 1 neuroendocrine carcinoma, 3 medullary carcinoma, 40 
metastatic carcinoma and 10 adjacent normal tissues (patient’s information in Appendix 
II). Both arrays provided information about the carcinoma: grade, AJCC clinical stage 
and TNM classification, and also the age of the patient. Tissue was stored at 4
o
C until 
use. Antibody optimisations and IgG controls were conducted using mammary tissues 
from the institute tissue bank at Cardiff University School of Medicine. The collection of 
the mammary tissue was under local ethics approval and under the Home Office Tissue 
Act licence. 
2.1.3 Primers 
Primers used in this study for quantitative PCR were designed on the primer 
designing tool on the Nacional Center for Biotechnology Information (NCBI, Bethesda 
MD, USA) website and were synthetized by Sigma (Poole, Dorset, UK). Primers were 
designed to have an annealing temperature of 60oC. Full details of the primers are 
presented in Table 5 and Table 6.  
2.1.4 Antibodies  
Full details of primary and secondary antibodies are exhibit in Table 7. 
62 
 
Table 5: Primer sequences for qPCR, part 1. 
Gene Type Primer sequence (5’-3’) 
IFNγ Forward  TGTCGCCAGCAGCTAAAACA 
Reverse ACTGAACCTGACCGTACATGCAGGCAGGACAACCATTA 
IDO1 Forward  AAAAGGATCCTAATAAGCCCC 
Reverse ACTGAACCTGACCGTACACAGTCTCCATCACGAAATGA 
TSP1 Forward  ACCAACCGCATTCCAGAGTC 
Reverse ACTGAACCTGACCGTACATACATCAGGTTGGCATCCTCGAT 
IDO2 Forward  GAGCTGCGGAGCTATCACAT 
Reverse ACTGAACCTGACCGTACACCACGTGGGTGAAGGATTGA 
TDO Forward  CCAGGTGCCTTTTCAGTTGC 
Reverse ACTGAACCTGACCGTACACTTCGGTATCCAGTGTCGGG 
ABCB1 Forward  CCAGAAACAACGCATTGCCA 
Reverse ACTGAACCTGACCGTACAGTGCCATGCTCCTTGACTCT 
ABCC1 Forward  CCCGCTCTGGGACTGGAA 
Reverse ACTGAACCTGACCGTACAGTAGAAGGGGAAACAGGCCC 
ABCC2 Forward  TACTTTGGGAACTGGTGAGTCT 
Reverse ACTGAACCTGACCGTACAGATGACCTTTCATCCCAACCA 
ABCC4 Forward  GTGTACCAGGAGGTGAAGCC 
Reverse ACTGAACCTGACCGTACATGAGCCACCAGAAGAACACG 
CFTR/ 
MRP7 
Forward  GGCACCCAGAGTAGTAGGTC 
Reverse ACTGAACCTGACCGTACAAGGCGCTGTCTGTATCCTTT 
 
ACTGAACCTGACCGTACA represents the Z sequence 
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Table 6: Primer sequences for qPCR, part 2. 
Gene Type Primer sequence (5’-3’) 
ABCG2 Forward  AGGCAGATGCCTTCTTCGTT 
Reverse ACTGAACCTGACCGTACAACCAACAGACCATCATAAACACA 
ABCC3 Forward  GGGCTCATTGGACTCTACCC 
Reverse ACTGAACCTGACCGTACACGTACACGTACACCCAGAGG 
ABCC5 Forward  CTTGTTTTGCTGCAGGGCTC 
Reverse ACTGAACCTGACCGTACAGCTGGTTCTCTCCCTCACAC 
ABCC6 Forward  GCTGGAACCTGGTGAAGTCT 
Reverse ACTGAACCTGACCGTACATTTGCGCATGCGTGGATTTT 
ABCC10 Forward  CGGCTAGGTCTTCCAACCTC 
Reverse ACTGAACCTGACCGTACACAGGCATCCGGAACCTCAAA 
CYP3 A4 Forward CACCCCCAGTTAGCACCATT 
Reverse ACTGAACCTGACCGTACACCCCACGCCAACAGTGATTA 
CYP1B1 Forward  GCAAGGGCATGGGAATTGAC 
Reverse ACTGAACCTGACCGTACAAAGGAACTGGGACCTTTGCC 
CYP3A5 Forward  CTCCTCTATCTATATGGGACCCG 
Reverse ACTGAACCTGACCGTACAGCACAGGGAGTTGACCTTCA 
GAPDH Forward  CTGAGTACGTCGTGGAGTC 
Reverse ACTGAACCTGACCGTACACAGAGATGATGATGACCCTTTTG 
 
                              ACTGAACCTGACCGTACA represents the Z sequence 
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Table 7: Antibodies information. 
Primary antibodies  
Name Species Technique 
Molecular 
weight 
(KDa) 
Supplier 
Product 
code 
Dilutions 
Anti- IDO1 Mouse 
Western 
blotting 
and IHC 
45 Abcam Ab156787 
WB: 1:500 
IHC: 1:100 
Anti- TSP1 Rabbit IHC NA 
Thermo 
Scientific  
MA5-13377 
IHC: 1:50 
Anti- Vwf Mouse IHC NA Abcam AB6994 IHC: 1:100 
Anti- 
GAPDH 
polyclonal 
antibody 
Mouse 
Western 
blotting 
37 
Santa 
Cruz 
sc-47724 
 
WB: 1:2000 
Anti- Ki67 
Alexa Fluor 
488 
conjugate 
Rabbit 
Flow 
cytometry 
NA 
Cell 
Signaling 
11882 
FC: 1:50 
P21 
Waf1/Cip1 
Alexa Fluor 
488 
conjugate 
Rabbit 
Flow 
cytometry 
NA 
Cell 
Signaling 
5487 
FC: 1:50 
IgG Isotype 
control 
Alexa Fluor 
488 
conjugate 
Rabbit 
Flow 
cytometry 
NA 
Cell 
Signaling 
4340 
FC: 1:50 
Secondary antibodies  
Name  Species Supplier 
Product 
code 
 
Anti-mouse 
IgG 
peroxidase 
conjugate 
NA Rabbit Sigma-Aldrich A-9044 
1:1000 
Anti-rabbit 
IgG 
peroxidase 
conjugate 
NA Goat Sigma-Aldrich A-9169 
1:1000 
 
NA: not applicable; WB: western blot, IHC: immunohistochemistry; FC: flow cytometry
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2.1.5 Specialised reagents 
 
Recombinant human Interferon-γ (IFN-γ) 
IFN-γ was purchased from Sigma-Aldrich, and diluted to 100 µg/mL with sterile 
BSS containing 0.1% BSA and store at -80oC until use.   
Recombinant human Thrombospondin 1 (TSP1) 
TSP1 was purchased from Sigma-Aldrich, and diluted to 100 µg/mL with sterile 
BSS containing 0.1% BSA and stored at -80oC until use.  
L-tryptophan 
Tryptophan was purchase from Sigma-Aldrich, and diluted to 20 mM with sterile 
H2O and stored at -80oC until use. 
Tryptophan free Dulbecco's Modified Eagle's Medium (DMEM) 
DMEM without tryptophan was purchased from USBiological, Life Science 
(Salem, MA, USA), and diluted with distilled H2O, filtered and stored at 4oC until use.  
Dialyzed Fetal Bovine Serum (FBS) 
Dialyzed FBS was purchased from Thermofisher Scientific (Rockford, IL, USA), 
and stored at -20oC until use.  
Docetaxel 
Docetaxel was purchased from Sigma-Aldrich, and reconstituted with DMSO to 
a final concentration of 100 mM and stored at -80oC.  
Cell tracers 
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CellTraceTM Oregon®Green 488 Carboxylic Acid Diacetate, Succinimidyl Ester and 
CellTrackerTM Orange CMRA Dye were purchased from ThermoFisher, reconstituted in 
DMSO to a final concentration of 1µg/µL and stored at -20oC.  
 2.1.6 Standard reagents and solutions for Western blot 
 Lysis Buffer 
This was made up by dissolving NaCl150mM (8.76g), Tris 50mM (6.05g), Sodium 
azide 0.02% (200mg), Sodium deoxycholate 0.5% (5g), Triton X-100 1.5% (15ml), 
Aprotinin 1µg/ml (1mg), Na3VO45mM (919.5mg), Leupeptin 1µg/ml (1mg) in 1 L of 
distilled water. The solution was then stored at 4oC for further use. 
10% Ammonium Persulphate (APS)  
One gram of APS was dissolved in 10 ml distilled water and then stored at 4oC 
for further use. 
Tris Buffered Saline (TBS) 
10X TBS (0.5M Tris, 1.38 M NaCl, pH 7.4) stock solution was prepared by 
dissolving606g of Trisand765g of NaCl (Melford Laboratories Ltd., Suffolk, UK) in 10L 
distilled water. The pH was adjusted to 7.4 using HCl and stored at room temperature. 
10X Running Buffer (for SDS-PAGE) 
10X running buffer (0.25M Tris, 1.92M glycine, 1% SDS, pH8.3) was prepared by 
dissolving 303g of Tris, 1.44kg of Glycine (Melford Laboratories Ltd., Suffolk, UK) and 
100g SDS (Melford LaboratoriesLtd., Suffolk, UK) in 10L distilled water. It was diluted to 
1X running buffer with distilled water before use. 
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2.1.7 Standard solutions for immunohistochemistry 
Diaminobenzidine (DAB) chromagen 
2 drops (approximately 50µl) of wash buffer, 4 drops of DAB (Vector Laboratories, 
Inc., Burlingame, USA) and 2 drops of H2O2 were added to 5ml of distilled water and 
mixed well before use. 
ABC Complex 
The ABC complex is prepared by using a kit provided by Vector Laboratories Inc. 
4 drops of each reagent A and B were added to 20ml of wash buffer before being mixed 
thoroughly and left at room temperature for 30 minutes before use. 
2.2 Cell culture, maintenance and storage  
2.2.1 Medium preparation and cell maintenance 
Several growth media were used in this study. For instance, Dulbecco’s Modified 
Eagle’s medium (DMEM/ Ham’s F-12 with L-Glutamine; Sigma-Aldrich, Inc., Poole, 
Dorset, England, UK) was supplemented with 10% heat inactivated Foetal Bovine Serum 
(Sigma-Aldrich, Inc., Poole, Dorset, England, UK) and antibiotics. The other growth 
media and respective supplements can be seen in the Table 3 and Table 4. Media was 
stored at 4oC until used for no more than 1 month. Media and trypsin/EDTA were warmed 
up to 37oC before use.  
Cells were routinely cultured in T25 and T75 flasks and media changed every 2 days. 
Culture specifications of each cell line or primary cells can be found in the Table 3 and 
Table 4.  
When cells reached 80-90% confluency medium was aspirated and cells were 
washed twice with sterile PBS, in order to remove any remained medium that can inhibit 
trypsin activity. 
1 – 2 ml of Trypsin/EDTA was added to each culturing flask and incubated at 
37oC for 2-5 minutes to detach adherent cells. Cells were visualised under a light 
microscope in order to verify if cell had detached, flasks were also gently tapped to help 
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cells to detach from the surface of the flask. After cells detached the flask, 4-5 ml of 
medium was added to the cells to inhibit trypsin activity and cells were collected into a 
universal tube (Greiner Bio-One Ltd, Gloucestershire, UK). Cell suspension was 
centrifuged at 1,700 xg for 5 minutes, supernatant was aspirated and pellet re-
suspended in the appropriated medium. Cells were re-cultured by transferring 1/4 of the 
cell suspension into a fresh culturing flask or cells were counted to be used in an 
experiment or to be stored at -80oC.  
Cells were counted using a cell counter (TaliTM, Invitrogen ). A slide containing 25 
µl of the cell suspension was inserted into the cell counter, which allowed visualisation 
of the cells, in order to know if there were any cell aggregations. The cell counter 
calculated the cell concentration and the size of the cells in a graph.  
2.2.2 Storage 
Cells were stored in liquid nitrogen at low passage in order to have a stock of 
cells for the project.  
Cells were trypsinised and counted as described above. Cell suspension was 
diluted to 1 million cells/ mL and 900 µl of the cell suspension was transferred into 1 mL 
CRYO.STM (Greiner Bio-One, Germany). One hundred µl of Dimethylsulphoxide (10% 
DMSO; Fisons, UK) was added to each tube and mixed gently. Tubes were closed, 
wrapped in tissue paper and stored at -80oC overnight. Samples were then transferred 
to liquid nitrogen for long term storage.  
In order to revive the cells, tubes were removed from the liquid nitrogen and 
quickly thawed in a 37oC water bath. Cells were then transferred into a universal tube 
with 5 mL of pre-warmed medium and gently centrifuged at 1000 xg for 5 minutes. 
Supernatant was aspirated to remove the DMSO. Cells were re-suspended in medium 
and transferred into a culturing flask. Cells were then kept in an incubator.  
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2.3 Methods for RNA detection 
2.3.1 Total RNA isolation 
Total RNA was isolated from cells using the Tri Reagent kit (Sigma-Aldrich, Inc., 
Poole, Dorset, UK), protocol was carried out according to the 
manufacturer's instructions. The cell type and the conditions that cells were cultured are 
described in the specific result chapter. Culturing plate was placed on ice and cells were 
then washed twice with PBS and 1 mL of Tri Reagent was added to the cells, in order to 
induce cell lysis. Cells were further scrapped with cell scrapers to ensure that all cells 
have been lysed. The homogenate was transferred into an eppendorf and incubated on 
ice for 5 minutes. Two hundred µl of chloroform (Sigma-Aldrich) was added to each tube, 
mixed for 15 seconds and incubated on ice for 5 minutes. The solution was then 
centrifuged at 12 000 x g for 15 minutes at 4oC. Under this conditions, the solution 
separated into 3 phases: a pink organic phase was at the bottom of the tube which 
contains proteins, a white phase which contains DNA was placed in the inter segment, 
and on the top there was an aqueous phase containing RNA. The top phase was 
carefully transferred to a fresh eppendorf, 500 µl of isopropanol (Sigma-Aldrich) was 
further added and samples were incubated for 10 minutes on ice. Samples were 
centrifuged at 12 000 x g for 10 minutes at 4oC and supernatant was discarded. The 
pellet was washed twice with 75% ethanol in DEPC water. The RNA pellet was then air 
dried for 5- 10 minutes to remove any ethanol. Finally, the RNA was dissolved in DEPC 
water by vortexing. The DEPC water is used to inhibit the effects of RNAases as it 
contains histidine specific alkylating agent.  
2.3.2 RNA quantification 
After RNA isolation was completed, its concentration and purity was assessed by 
a UV1101 Biotech Photometer (WPA, Cambridge, UK). The spectrophotometer was set 
to read single strand RNA and the results were the difference of the absorbance between 
the RNA sample and the DEPC water (blank) at a wavelength of 260 nm. The purity was 
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assessed using the ratio of A260/A280 nm, RNA was considered of good quality when 
this ratio was between 1.7 and 2.0. Samples were then used for reverse transcription 
(RT) or stored at -80oC.  
2.3.3 Reverse Transcription of RNA into cDNA 
Reverse transcription is a simple technique that converts mRNA into cDNA 
allowing further examination by PCR. The procedure employed iScriptTM cDNA 
Synthesis Kit (Bio-Rad Laboratories, California, USA) to convert 0.5 µg of RNA into 
cDNA.  
Each RT reaction was set in PCR tubes (thin-walled 200 µl PCR tubes, ABgene, 
Surrey, UK) as described in Table 8.  
Table 8: Components and volumes for the RT reaction. 
Component Volume per reaction (µl) 
5x iScript Reaction Mix 4 
iScript Reverse 
Transcriptase 
1 
RNA template  X (volume to have 0.5 
µg) 
Nuclease-free water Up to 20  
Total Volume 20  
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Solution was mixed, centrifuged to ensure the solution is at the bottom of the PCR 
tube and incubated in a T-Cy Thermocycler (Creacon Technologies Ltd, The 
Netherlands) through the following temperatures:  
5 minutes at 25oC 
30 minutes at 42oC 
5 minutes at 85oC 
At the end of the reaction, cDNA was diluted 1:4 with PCR water, and used 
immediately as a template for PCR or stored at -20oC until needed.  
2.3.4 Quantitative RT-PCR (Q-PCR) 
Q-PCR is a sensitive technique which allows the detection and quantification of 
extremely small amounts of cDNA. In this method, it is used a sequence specific DNA 
based fluorescence reporter probe that recognises and binds DNA containing the probe 
sequence, allowing its quantification. Here it was used the AmplifluorTM Universal 
system (Intergen company®, New York, USA) in order to quantify the DNA copies. This 
probe contains a 3’ region that recognises the Z-sequence 
(ACTGAACCTGACCGTACA), which is present on the reverse target specific primers. 
The probe also contains a 5’ hairpin structure labelled with a fluorophore (FAM). This 
structure does not emit any fluorescence when in its hairpin conformation, once it is 
linked to an acceptor moiety (DABSYL) which quenches the fluorescence. However, 
when the probe is incorporated and it is used as a template for DNA polymerisation, the 
DNA polymerase degrades and unfolds the hairpin conformation disrupting the 
fluorophore-quencher structure which allows the emission of fluorescence. The signal 
emitted during each PCR cycle is detected and it is directly correlated to the amount of 
DNA being amplified. The technology requires 15-20 cycles to consume the reverse Z-
primer. The process described here is illustrated in Figure 9.  
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Table 9: Components and volumes for a Q-PCR reaction. 
 
 
Each Q-PCR reaction was set as described in the Table 9, loaded into a 96 well 
plate (BioRad laboratories, Hemel Hampstead, UK) and placed in an iCyclerIQ thermal 
cycle and detection software (BioRad) at the following conditions: 
Initial denaturation: 94oC for 5 minutes 
Followed of 80 cycles of:  
Denaturation 94oC for 10 seconds 
Annealing: 55oC for 35 seconds 
Extension: 72oC for 20 seconds   
Signal is quantified at the annealing stage by a camera that detects the 
fluorescence emitted. A threshold cycle (Ct) for each reaction is then determined which 
Component Volume (µl) 
Forward primer 0.3 
(10pmol/µl) 
Reverse Z 
primer 
0.3 (1pmol/µl) 
Amplifluor probe 0.3 
(10pmol/µl) 
2x iQTM 
Supermix 
5 
cDNA 4 
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is used to calculate the amount of the specific cDNA. The amount of a housekeeping 
gene (GAPDH) was also assessed in order to normalise the samples. The amount of the 
specific DNA is determined by ΔΔCt. For each sample, the Ct value of the gene being 
tested was subtracted by the GAPDH Ct value (ΔCt). Followed by the 2^ (-(ΔCt1- ΔCt2)), 
where ΔCt1 corresponds to a reference sample (such as control) and ΔCt2 corresponds 
to a tested sample (such as treated sample).  
 
 
Figure 9: Diagram illustrating the incorporation and emission of the signal of the 
fluorescence reporter probe during the DNA amplification in Q-PCR. 
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2.4 Protein detection 
2.4.1 Protein extraction and preparation of cell lysates 
Cells were washed twice with PBS and 50 µl of lysis buffer was added to the well. 
Cells were then scraped off and the cell suspension was transferred into an eppendorf. 
The eppendorf was placed on a Labinco rotating wheel (Wolf laboratories, York, UK) for 
1 hour at 4oC to allow for cell lysis. In order to pellet cell debris, the cell suspension was 
centrifuged at 13 000 xg for 15 minutes at 4oC. The supernatant was transferred into a 
fresh eppendorf and protein was quantified or stored at -20oC.  
2.4.2 Protein quantification 
For an accurate analysis of the protein by western blotting, the total protein in 
each sample has to be standardised, for that reason the protein was first quantified. The 
protein quantification followed the protocol by Bio-Rad DC Protein Assay kit (Bio-Rad 
laboratories, Hemel Hampstead, UK). The first step was to serially dilute 50 mg/mL of 
bovine serum albumin (BSA) (Sigma, Dorset, UK) to a concentration of 0.78 mg/mL in 
order to set up a standard curve of protein concentration. In a 96 well plate, 5 µl of sample 
or standard was added into a well. All samples and standards were done in duplicate. 
The next step was to add 25 µl of working reagent A, which was prepared by adding 20 
µl of reagent S/ 1 mL of reagent A, followed by 200 µl of reagent B to each well. Solution 
was mixed and then plate was left at room temperature for 20- 30 minutes avoiding direct 
light. After the period of incubation to allow the colorimetric reaction, the absorbance was 
read at 620 nm using the spectrophotometer (Bio-Tek, Wolf laboratories, York, UK). 
Using the absorbance values of the BSA dilutions, a standard curve was set and an 
equation was established. Protein concentration of each sample was calculated using 
the equation from the standard curve. Samples were then diluted in lysis buffer to a 
concentration of 1.0 µg/µl. Finally, samples were further diluted in 2x Lamelli sample 
buffer concentrated (Sigma-Aldrich, St Louis, USA), followed by a denaturation step 
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which was reached by boiling samples at 100oC for 10 minutes. Samples were then 
loaded onto a SDS-PAGE gel or stored at -20oC.  
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The system employed here was the OmniPAGE VS10 vertical electrophoresis 
system. Ten percentage resolving gels were prepared, as described in the Table 10, to 
assess IDO1 and GAPDH protein.  
Table 10: Ingredients for a 10% resolving gel (enough for 2 gels) 
Component Volume 
(mL) 
Distilled water 5.9 
30% acrylamide mix (Sigma-
Aldrich) 
5.0 
1.5M Tris (pH 8.0) 3.8 
10% SDS 0.15 
10% Ammonium persulphate 0.15 
TEMED (Sigma-Aldrich) 0.006 
 
Once the resolving mixture was done, it was poured in between of two glass 
plates that were on the loading cassette. The level of the resolving gel was until about 
1.5 cm below the top of the edge of the plate. A thin layer of isopropanol (Sigma -Aldrich) 
was added to the top of the resolving gel to prevent oxidation. Gels were left at room 
temperature for 30 minutes to allow polymerisation. Isopropanol was removed and 
stacking gel was added on the top of the resolving gel. Stacking gel was prepared as 
described in the Table 11.  
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Table 11: Ingredients for the stacking gel 
Component Volume 
(mL) 
Distilled water 3.4 
30% acrylamide mix (Sigma-
Aldrich) 
0.83 
1.5M Tris (pH 6.8) 0.63 
10% SDS 0.05 
10% Ammonium persulphate 0.05 
TEMED (Sigma-Aldrich) 0.005 
 
A well forming Teflon comb was inserted at the top of the plate. Once the stacking 
gel was set, the loading cassette was placed into an electrophoresis tank and covered 
with 1x running buffer. The comb was carefully removed, 5 µl of BLUeye Prestained 
Protein Ladder (Geneflow, Lichfield, UK) was added to the first well and 30 µl of each 
sample was added to the followed wells. In the empty wells, it was added 30 µl of 1x 
Lamelli sample buffer. The gels were then run at 110V, 50mA and 50W for 1.5- 2 hours.  
2.4.3 Western blotting: transferring protein from gel to nitrocellulose 
membrane 
Once the SDS-PAGE was complete, protein was transferred onto a nitrocellulose 
membrane by western blotting. The electrophoresis cassette was disassembled and 
stacking gel was discarded. Two pieces of transfer buffer pre-soaked sponges were 
placed on a transfer cassette, a piece of transfer buffer pre-soaked filter paper (Whatman 
International Ltd., Maidstone, UK) was placed on the top and the resolving gel was 
placed on the filter paper. On the top of the gel, it was placed a sheet of Hybond 
nitrocellulose membrane (Amersham Biosciences UK Ltd., Bucks, UK). An additional 
piece of pre-soaked filter paper and 2 pieces of pre-soaked sponges were added to the 
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top of the membrane, and the transfer cassette was closed and placed into a transfer 
tank with 1x transfer buffer. Electroblotting was carried out at 100V, 500mA and 8W for 
1 hour. Once the transference was finished, the membranes were blocked at room 
temperature for 1 hour in 10% skimmed dry milk solution (10% milk powder and 0,1% of 
Tween (Sigma-Aldrich) in TBS).  
After the blocking step, membranes were incubated with the primary antibody in 
the blocking solution for 1 hour. Membranes were then washed 3 times with 0.1% Tween- 
TBS (TBS-T), 5 minutes each, followed by incubation with secondary antibody for 1 hour. 
Membranes were washed again 3 times with TBS-T.  
Protein was visualised by chemiluminescence detection. Membrane was 
incubated with Luminata (Millipore, Billerica, MA, USA) for 5 minutes, which consists of 
a chemiluminescent substrate that detects the horseradish peroxidise (HRP) in the 
secondary antibody. The excess solution was drained over a piece of tissue paper. The 
chemiluminescent signal was detected using a G:BOX Chemi XRQ imager (Syngene, 
Cambridge, UK).  
The housekeeping gene GAPDH was used to normalise the experiments. The 
intensity of the bands shown by the chemiluminescent reaction was quantified by ImageJ 
(National Institute of Health, USA).  
2.4.4 Immunohistochemistry of tissue microarray  
In order to analyse IDO1 and TSP1 protein in breast cancer samples, 
immunohistochemistry was carried out in a tissue microarray in sequential slides. IDO1 
and Von Willebrand factor (vwf) were also assessed in a second breast cancer tissue 
microarray, also in sequential slides. The protocol followed here is a modified protocol 
described previously by Jo and collaborators (Jo et al., 2011). Prior to staining, the slides 
were dewaxed in xylene and hydrated through alcohol gradient (100%, 95%, 70%, 50% 
and 30% ethanol, 5 minutes in each). For antigen retrieval, slides were immersed in 
citrate buffer (pH 8.0) and heated in a microwave (≥700W) for 20 minutes. Slides were 
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left to cool down at room temperature. Endogenous peroxidase activity was blocked with 
3% H2O2 for 5 minutes and washed 3 times with TBS. Non-specific binding was blocked 
by incubating slides for 1 hour at 4oC with blocking buffer (1% BSA, 1% Marvel and 5% 
goat serum in TBS). Samples were incubated with primary antibody (antibody 
specifications in Table 7) at 4oC overnight. Mouse and rabbit IgG control antibodies were 
used as negative controls. On the following day, slides were washed 3 times with TBS 
for 5 minutes each time and incubated with secondary antibody (antibody specifications 
in Table 7) for 30 minutes at room temperature. The slides were then washed 3 times in 
TBS for 5 minutes each time and incubated with the ABC complex for 30 minutes (Vector 
Laboratories, Peterborough, UK). The colour reaction was developed with 3,3’-
diaminobenzidine (DAB) and the sections were then counterstained with haematoxylin 
(Vector Laboratories, Peterborough, UK). Finally, sections were washed in tap water, 
dehydrated through a series of graded ethanol (30%, 50%, 70%, 95% and 100%), 
cleared in xylene, and mounted in DPX, followed by observation and imaging under an 
optical microscope. At ×200 magnification, the staining intensity was assessed in 
different cell types as 0 (negative), 1 (weak), 2 (intermediate) and 3 (strong) by two 
independent observers (FR, LJ).  
2.4.4.1 Histomorphometric analysis of tissue microarray 
The area fraction of staining occupied by the tumour cells, stroma and vascular 
ECs was evaluated. An eyepiece systemic point-sampling grid with 100 points and 50 
lines was placed on the top of the section pictures at 400x magnification, as ellustrated 
in the Appendix III, and it was counted the number of points overlying positively-stained 
cells, as previously described (Ruan et al. 2011). Measurements were averaged over 
five microscopic fields to obtain an indexed percentage. Comparisons were performed 
in 20% of the staining by the two observers (LJ, JC), the coefficient of variation for the 
inter-observer error regarding cell count was <5%.  
79 
 
2.4.5 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of TSP1, VEGF and L-kynurenine was assessed in the 
conditioned medium of cells by ELISA. To perform this assay, it was used 3 different kits: 
TSP1 ELISA kit (R&D systems, Abingdon, UK), VEGF ELISA kit (Thermo 
Fisher Scientific, Runcorn, Cheshire, UK) and L-kynurenine ELISA kit (ImmuSmol, 
Bordeaux, France). The protocol was carried out according to the specific kit 
manufacturer's instructions. The generic protocol is described above. 
The generation of the samples is described in the method section of each result 
chapter. Conditioned medium was collected and centrifuged at 17000 x g to pellet any 
debris and dead cells. Samples used to assess L-kynurenine had to go through an 
acylation step, where 20 µl of sample or standard were mixed with 500 µl of acylation 
buffer and 50 µl of acylation reagent and it was incubated at 37 oC for 90 minutes. 
In the meanwhile, plates were washed 3 times with wash buffer and 300 µl of 
blocking buffer was added to each well. In the case of the TSP1, plate was coated with 
capture antibody the day before (100 µl/ well). One hour after incubation with blocking 
buffer, wells were washed 3 times with wash buffer and 100 µl of each sample or 
standard was added to the respective well. After 2 hours of incubation at room 
temperature, wells were washed again and 100 µl of detection antibody was added to 
each well. Two hours after, wells were washed and 100 µl of streptavidin-HRP was 
added to each well. Plate was incubated at room temperature for 20 minutes and direct 
light was avoided. Wells were once again washed and 100 µl of substrate solution was 
added to each well. After 10-20 minutes, 50 µl of stop solution was added to each well 
and mixed gently. The optical density was measured in a spectrophotometer at 450 nm. 
A standard curve was built using the absorbance values of the standard solutions and 
an equation that represents that curve was found. The concentration of TSP1, VEGF or 
L-Kynurenine was calculated using that equation.  
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2.5 Knocking down IDO1 gene expression using siRNA 
In order to knockdown endothelial IDO1 expression, endothelial cells were 
transfected with small interference RNA (siRNA) which specifically targets IDO1 mRNA. 
Ratcliff et al. discovered the RNA interference (RNAi) mechanism in plants 
(Ratcliff et al., 1997) and only a year later, Fire et al. demonstrated that double-stranded 
RNA (dsRNA), when microinjected into Caenorhabditis elegans, led to a transitory 
decrease of gene expression (Fire et al., 1998). In 2001, Elbashir et al. demonstrated 
that this mechanism could be applied to mammalian cells showing that siRNA could 
specifically knockdown a gene in several mammalian cell lines (Elbashir et al., 2001).  
The siRNAs used here were purchased from Dharmacon (GE Healthcare, 
Lafayette, USA). Cells were transfected with a SMARTpool siRNA which contains 4 
different siRNA sequences to increase the knockdown effect. As a negative control, cells 
were transfected with a non-targeting negative control. All information on the siRNA used 
here are presented in the Table 12.  
Since HMVECad cells do not constitutively express IDO1, to the cells were 
stimulated by IFNγ or breast cancer conditioned medium. Cell number and protocol to 
stimulate IDO1 expression is described in the respective result chapters.  
All knockdown experiments were conducted in 24 well plates and cells were 
transfected with Lipofectamine 3000 (Invitrogen, Paisley, UK) as described by the 
manufacturer’s instructions and described below. Cells were cultured in antibiotics free 
medium prior to transfection and cells were at the confluency of 60 – 80% at the time of 
transfection.  
First, the transfection solution was prepared (volumes correspond to one 
reaction). One hundred µl of DMEM (no FCS or antibiotics) was transferred to an 
eppendorf, followed by 5 µl of siRNA (20 µM) and solution was carefully mixed. In a 
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different eppendorf, 100 µl of DMEM (no FCS or antibiotics) and 5 µl of Lipofectamine 
were mixed. The content of the second eppendorf was then mixed to the first one and 
left to incubate at room temperature for 30 minutes. An extra 800 µl of DMEM (no FCS 
or antibiotics) was added to the eppendorf. Cells were washed twice with PBS and the 
transfection mixture was added to the well and plate was placed in a standard incubator 
at 37oC. After 6- 8 hours, 1 mL of full endothelial medium was added to the cells, and 24 
hours after transfection, medium was aspirated, cells washed with PBS and fresh 
medium was added to the cells. Knockdown confirmation was done 48 and 72 hours 
after transfection.  
Table 12: siRNA information (Dharmacon, GE Healthcare, Lafayette, USA). 
 siRNA code number siRNA sequence 
ID
O
1
 p
o
o
l 
J-010337-09 UCACCAAAUCCACGAUCAU 
J-010337-10 UUUCAGUGUUCUUCGCAUA 
J-010337-11 GUAUGAAGGGUUCUGGGAA 
J-010337-12 GAACGGGACACUUUGCUAA 
N
o
n
-t
a
rg
e
ti
n
g
 
p
o
o
l 
D-001810-10-05 
UGGUUUACAUGUCGACUAA 
UGGUUUACAUGUUGUGUGA 
UGGUUUACAUGUUUUCUGA 
UGGUUUACAUGUUUUCCUA 
 
2.6 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) assay 
The MTT assay is a common method to assess proliferation, viability and 
cytotoxicity of health cells in response to a stimulus. MTT can be cleavage by 
dehydrogenase enzymes in the cell into an insoluble purple substrate. The insoluble 
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formation can be dissolved in proper solvents and measured spectrophotometrically and 
the proliferation/viability/toxicity can be quantified.  
After a set amount of time of treatment or culture, 10% of the culture volume of 
MTT (5 mg/mL in PBS) was added to the cells, plate was shaken for 5 minutes and then 
cells were incubated at 37oC for 4 hours. Medium was discard and 100 µl of isopropanol 
was added to each well. Plate was then shaken for 30 minutes to ensure that all 
precipitate is dissolved by the isopropanol. The absorbance of the converted dye was 
measured at 540 nm in a spectrophotometer.  
2.7 Flow cytometry  
This technique was used to analyse the expression of Ki67 and p21 in cells under 
different conditions. Cells were washed with PBS and harvested at 17000 x g for 5 
minutes. Supernatant was discarded and cell pellets were re-suspended in 100 µl of 4% 
formaldehyde for 10 minutes on ice for 1 minute. Nine-hundred µl of ice-cold ethanol was 
added to the cell suspension, vortexed and left on ice for 30 minutes. Following 
incubation, cells were then counted and aliquoted 1 x 106 cells/ tube. Cells were washed 
twice with incubator buffer (0.5% BSA in PBS) by centrifugation. Cells were incubated 
for 1 hour with relevant antibodies diluted in incubator buffer.  Then, cells were washed 
twice with incubator buffer. At the end of the second wash, cells were re-suspended in 
PBS. Samples were analysed using the flow cytometer (BD FACSCANTO II, Beckman 
Coulter (UK) Ltd., High Wycombe, UK) and the FCS Express 4 Flow Research Edition 
software (DeNovo, Glendale, CA, USA), measuring any fluorescence emission at 530 
nm and 575 nm. A range of controls were used to assure the quality of the results, 
including non-stained cells and cells incubated with the respective IgG control.  
2.8 Apoptosis analysis by flow cytometry  
Annexins are a family of calcium-dependent phospholipid-binding proteins, which 
bind to phosphatidylserine (PS) indicating apoptotic cells. In healthy cells, PS is 
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predominantly located along the cytosolic side of the plasma membrane. Upon initiation 
of apoptosis, PS loses its asymmetric distribution in the phospholipid bilayer and 
translocates to the extracellular membrane, which is detectable with fluorescently 
labelled Annexin V. In early stages of apoptosis, the plasma membrane excludes viability 
dyes such as propidium iodide (PI) and 7-AAD, therefore cells which display only 
Annexin V staining (PI/7-AAD negative) are in early stages of apoptosis. During late-
stage apoptosis, loss of cell membrane integrity allows Annexin V binding to cytosolic 
PS, as well as cell uptake of PI and 7-AAD. Annexin V staining, paired with 7-AAD or PI 
is widely used to identify apoptotic stages by flow cytometry. 
For this technique, it was used an Annexin V apoptosis kit (eBioscience, San 
Diego, US). The protocol was carried out according to the manufacturer's instructions as 
follows. Both adherent cells and cells floating in the medium were harvested, centrifuged 
and washed once in PBS. Cells were re-suspended in 1 X binding buffer at a 
concentration of 1 x 106 cells/mL. 200 µl of the cell suspension was transferred into a 
new eppendorf. Five µl of Annexin V- FITC was added to each eppendorf and mixed well   
for 10 minutes. Cells were then centrifuged, washed in binding buffer and re-suspended 
in 190 µl of the same buffer. Ten µl of Propidium iodide (20 µg/mL) was added to the cell 
suspension. Stained cells were analysed immediately or kept on ice and in the dark until 
required, but no more than 4 hours. Apoptosis analysis was procedure using the BD 
FACSCANTO II flow cytometer (Beckman Coulter (UK) Ltd., High Wycombe, UK) and 
FCS Express 4 Flow Research Edition software (DeNovo, Glendale, CA, USA). 
Fluorescence was read at 530 nm and 575 nm. In order to have a positive control for 
apoptosis, cells were treated with staurosporine (Sigma, 1 µg/mL) for 1.5 hours before 
harvesting. Negative and single staining was also carried out using apoptotic cells in 
order to calculate compensation settings and define gates.  
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2.9 Cell sorting 
This technique was used to separate two different cell lines that were co-cultured 
for a period of time. One of the cell lines was pre-labelled with a red dye (CellTrackerTM 
Orange CMRA Dye) by incubating the cells with the dye (1 µg/mL) diluted in FCS free 
DMEM for 20 minutes.  
At the end of the co-culture time, cells were washed twice with PBS and 
harvested. Cells were re-suspended in ice cold PBS at the density of 1x106 cells/100 µl. 
The two different cell lines were separated on the basis of the size and labelled 
fluorescent dye (emission at 575 nm) in the MoFlo™ XDP (Beckman Coulter (UK) Ltd., 
High Wycombe, UK). A range of controls were used to define proper gates for the sorting, 
including non-labelled cells and only labelled cells. 
2.10 statistical analysis  
Statistical analysis was performed using GraphPad Prism (GraphPad Software 
Inc, San Diego, CA). Data were represented as mean± S.E.M. Student’s t- test was used 
to evaluate the statistical difference of two groups, while One-Way ANOVA was 
employed to calculate the difference between more than 2 groups. Linear regression was 
also used in this study to find a correlation between two dependent variables. The sample 
size of each experiment was at least 3. The legend of each figure clearly informs of the 
statistical test used and the sample size of each experiment. P value < 0.05 was 
considered statistical significant.  
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Chapter III: IDO1 and TSP1 expression in breast cancer 
tissue 
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3.1 Introduction 
Indoleamine-2,3- dioxygenase (IDO1) is an intracellular enzyme that degrades L-
tryptophan in mammalians (Austin and Rendina, 2015). IDO1 is overexpressed in many 
types of tumour, which has been shown to confer immune tolerance to cancer cells 
(Munn et al., 2004; Munn et al., 2002; Uyttenhove et al., 2003). Although the IDO1 
mechanism of action is not fully understood, research suggests that IDO1 leads to a 
depletion of tryptophan in the tumour microenvironment, which induces apoptosis of T-
cells (Friberg et al., 2002; Uyttenhove et al., 2003). IDO1 is expressed in tumours by 
many cell types, including cancer cells, macrophages, dendritic cells and endothelial 
cells (Vigneron et al., 2015). IDO1 expression has been correlated with a poor prognosis 
in several tumours, including breast cancer (Astigiano et al., 2005; Brandacher et al., 
2006; Chen et al., 2014; Inaba et al., 2010; Inaba et al., 2009; Ino et al., 2006; Jia et al., 
2015; Okamoto et al., 2005; Pan et al., 2008; Speeckaert et al., 2012; Suzuki et al., 2010; 
Urakawa et al., 2009; Wainwright et al., 2012; Witkiewicz et al., 2008; Yu et al., 2013; Yu 
et al., 2011), however more studies are needed to clarify this assumption.  
Thrombospondin 1 (TSP1) is an extracellular matrix protein that belongs to the 
thrombospondin family (Adams and Lawler, 2004, 2011). TSP1 was the first protein to 
be identified as an endogenous anti-angiogenic molecule (Good et al., 1990). In tumours, 
decreased level of TSP1 has been linked with tumour growth and angiogenesis 
(Kawakami et al., 2001). Interestingly, TSP1 has also been shown to promote of 
metastasis (Incardona et al., 1995; Yee et al., 2009). In the tumour microenvironment 
TSP1 is secreted by stromal fibroblasts, endothelial cells and immune cells (Lawler, 
2002).  
This chapter aimed to evaluate the expression of IDO1 and TSP1 in human 
invasive breast cancer, lymph node metastasis and adjacent normal tissue. It also aimed 
to assess whether stromal TSP1 and vascular IDO1 correlate with the TNM stage or with 
the grade of the primary tumours. As this thesis hypothesises that the enzymatic activity 
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of vascular IDO1 limits the synthesis of TSP1, it was also logic to determine if there was 
a correlation between these two molecules.  
3.2 Material and methods 
3.2.1 Tissue microarrays  
Two human tissue microarrays were used in this study. One of the tissue arrays 
(USBIOLAB, Maryland, US) contained 52 sections of tissue (breast cancer) while the 
second one (Biomax, Inc. Rockville, MD, USA) had 101 sections of tissue (tissue from 
50 primary tumours, 40 lymph node metastasis, 10 adjacent tissues and an adrenal 
gland section). For each tissue array, there were 2 sequential slides. The 52 samples 
tissue array was used to stain for IDO1 and vwf. The other tissue array was used to 
assess the expression of IDO1 and TSP1.  
3.2.2 Immunohistochemistry 
IDO1, TSP1 and vwf expression was assayed in the tissue arrays by 
immunohistochemistry. Description of the full protocol and antibody details can be found 
in the sections 2.4.4 and 2.1.4. Observation and imaging of the staining were done under 
an optical microscope. At ×200 magnification, the staining intensity was assessed as 0 
(negative), 1 (weak), 2 (intermediate) and 3 (strong). The area fraction of staining 
occupied by the tumour cells, stroma and vascular cells was evaluated using an eyepiece 
systemic point-sampling grid as described in the section 2.4.4.1, a representative image 
with the grid system can be seen in the Appendix III. The area of the staining of IDO1 
and TSP1 was also evaluated according to the same method. 
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3.3 Results 
3.3.1 Differential expression of TSP1 and IDO1 in breast cancer tissue 
The tissue microarray used here contained samples from patients with invasive 
breast carcinoma. The primary tumour samples comprised forty-six cases of invasive 
duct carcinoma, one neuroendocrine carcinoma and three medullary carcinomas. The 
microarray also contained forty metastatic lymph node, ten adjacent normal tissues and 
a pheochromocytoma (male) which could be used as a control. IDO1 and TSP1 
expression was assessed by immunohistochemistry in sequential sections of the tissue 
in 50 primary breast cancer samples, 40 lymph node metastasis and 10 adjacent normal 
tissues.  
IDO1 and TSP1 expression were assessed by immunohistochemistry and the 
intensity of the signal was scored from 0-3 (weak to strong). The TSP1 staining was very 
week in the invasive breast carcinoma tissue, while stronger in adjacent normal tissue, 
as shown in the representative images in Figure 10 (All pictures shown in Appendix IV). 
TSP1 staining was also weak in the lymph node metastasis (Figure 10 and Appendix 
IV). TSP1 was observed as typical fine fibrillary stromal staining as well as in the 
basement membrane of the ductal space (Figure 10). As represented in Table 13, the 
average intensity of the TSP1 signal in the invasive breast carcinoma was significantly 
weaker when compared to the adjacent normal tissue (p= 0.021). The intensity of the 
TSP1 staining was also found to be statistically weaker in the lymph node metastasis 
(p= 0.035). On the other side, there was no statistical differences between adjacent 
normal tissue and invasive breast carcinoma or lymph node metastasis in terms of IDO1 
signal (Table 13).  
To further evaluate the signal of TSP1 and IDO1 in the primary tumour, a 
histomorphometry analysis was adopted. This method allowed estimating the area of the 
TSP1 and IDO1 signal by cancer cells, stromal cells and vascular cells in the primary 
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tumour. In this analysis, the distinction between the different cell types was done taking 
into consideration the morphology of the cells. The TSP1 signal was strong in the 
adjacent normal tissue but it was weak in the primary tumour and lymph node metastasis 
(Figure 11 and Table 14). In the primary tumour the TSP1 signal was mostly observed 
in the stromal tissue. In average, 6.576% of the signal was observed in the stromal cells, 
while positive tumour cells corresponded to 2.12% and vascular cells to 0.016% (Table 
14).  
IDO1 signal was detected in the tissues of the primary tumour but also in the 
lymph node metastasis and adjacent normal tissue (Figure 11). In the primary tumour, 
IDO1 positive tumour cells accounted for 43.068% of the total IDO1 staining, while 
stroma accounted for 44.012 % and vasculature for 1.112% (Table 14).  
Although TSP1 is a protein that is secreted by many cell types, it is constitutively 
synthesised by endothelial cells under physiological conditions (Ghajar et al., 2013). 
Since the main hypothesis of this work is that endothelial IDO1 limits the synthesis of 
TSP1, it is important to determine whether IDO1 is expressed in the tumour vasculature. 
As mention above, IDO1 staining showed that the vasculature does expresse IDO1. The 
microvasculature of the tumour was first identified only by its morphology. A vascular 
marker, vwf, were also used to determine the tumour vasculature. In a second tissue 
microarray, the IDO1 and vwf signal was detected by immunohistochemistry in 
sequential sections of primary breast cancer, allowing clearly identification of 
microvessels and assessment of endothelial/vessel staining of IDO1. In 23 breast cancer 
tissue sections it was possible to detect vessels, of which 21 were positive for IDO1 
(Figure 12), corresponding to 91.3% of samples with vessels that exhibited vascular 
IDO1.   
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Table 13: Summary of the IHC intensity results in the adjacent normal tissue, 
invasive carcinoma and lymph node metastasis. Statistical significance of each 
group to the adjacent normal tissue was determined by One-way ANOVA.*p<0.05 
 
 
 Staining intensity 
(SI) 
Average ±SEM 
 0 1 2 3 
Adjacent normal (n=10) TSP1 0 9 1 0 1.100±0.100 
 IDO1 1 5 4 0 1.3000±0.2134 
Invasive carcinoma (n=50) TSP1 26 23 0 1 0.5200±0.08685* 
 IDO1 1 22 23 4 1.560±0.09545 
Lymph node metastasis (n=40) TSP1 17 18 3 2 0.7500±0.1279* 
 IDO1 0 26 13 1 1.375±0.08539 
 
 
Table 14: Summary of the IHC morphometric results in the primary tumour. The 
units “% of points” indicate the number of points overlying the structure of interest 
divide by total number of points overlying the tissues. 
   Mean minimum maximum 
Tumour Cells 
(%) 
TSP1 2.12 0.00 16.50 
IDO1 43.068 5.00 98.60 
Stromal (%) TSP1 6.576 0.00 42.20 
IDO1 44.012 0.00 76.60 
Vasculature (%) TSP1 0.016 0.00 0.08 
IDO1 1.112 0.00 4.60 
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Figure 10: Representative immunohistochemistry images of TSP1 and IDO1 in tissue sections from breast cancer patients 
which englobes lymph node metastasis, invasive carcinoma and normal adjacent tissue. 
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Figure 11: A- Percentage of TSP1 and IDO1 immunostaining area, in lymph node metastasis, invasive carcinoma and adjacent 
normal tissue, by tumour cells, vasculature and stromal cells. B- Two representative images of tumour sections stained by IDO1 
where it is possible to see tumour cells (red arrow), stromal cells (blue arrow) and vessels (black arrow).  
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Figure 12: Detection of vascular IDO1 in invasive carcinoma by 
immunohistochemistry. A- Representative images of vwf and IDO1 immunostaining 
of sequential sections of invasive breast carcinoma. Representative image of their IgG 
control staining. B- Quantification of the total number of samples with detectable 
vessels and the number of samples with IDO1 expressing endothelial cells.  
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3.3.2 Stromal TSP1 and vascular IDO1 in invasive breast cancer 
As disseminated breast cancer cells have been found dormant near microvessels 
(Ghajar et al., 2013), it has been speculated that the perivascular niche is responsible 
for inducing and maintaining the dormancy of those cells. The same study identified 
TSP1, an extracellular matrix protein that is secreted by endothelial cells, as a possible 
protein involved in this process. Thus, in the present study only stromal TSP1 has been 
analysed. The present study also hypothesised that TSP1 synthesis can be limited by 
vascular IDO1, therefore only vascular IDO1 has been considered in this section.  
Breast cancer can be classified according to the TNM stage system, which 
evaluates the tumour on the basis of the primary tumour (T), lymph node (N) and 
metastasis (M). For the analysis of the TSP1 and IDO1 signal, it was only taken into 
account the primary tumour classification (T) of the TNM stage system because the 
tissue array did not have enough samples for some of the groups in the lymph node and 
metastasis classification. The T1 group (n=6) represents patients with a tumour not 
bigger than 2 cm (mean stromal TSP1: 9.90% of total TSP1), the T2 (n=27) contains 
patients with a tumour between 2 and 5 cm of dimension (mean stromal TSP1: 12.31% 
of total TSP1), the T3 patients (n=9) had tumours bigger than 5 cm (mean stromal TSP1: 
2.089% of total TSP1), whereas T4 group (n=10) contains tumours of any size with direct 
extension to the chest wall or skin increasing the probability of metastasis (mean stromal 
TSP1: 1.900% of total TSP1). Although the stromal TSP1 staining is higher in the T2 
stage, compared to T1, it was found an inverse correlation between the level of stromal 
TSP1 staining and the TNM grading (Figure 13 A; p=0.0207).  
Breast cancer can also be classified according to the degree of differentiation of 
the tissue and cells. It can be graded 1- well differentiated, 2- moderately differentiated 
and 3- poorly differentiated. In terms of aggressiveness, grade 3 is the most aggressive 
phenotype. Stromal TSP1 staining was also negatively correlated to the grading of breast 
cancer (Figure 13 B; p=0.0375). The difference in the stromal TSP1 staining between 
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the grade groups was even more apparent when compared to the TNM classification, 
grade 1 tumours presented 17.43% of TSP1 positive- stromal cells (n=6), grade 2 
tumours corresponded to 5.738% (n=32), and grade 3 tumours had 4.333% (n=6).  
As mention above, IDO1 staining was strong in the primary tumour and only one 
sample was negative for this enzyme (Table 13). In terms of primary tumours, vascular 
IDO1 occurred in most cases (49/50). Although there was a trend towards a decrease in 
the vascular IDO1 with high T staging (1.300% for T1, 1.278% for T2, 0.320% for T3 and 
0.640% for T4), it did not reach statistically significant (Figure 13 C; p=0.7481). On the 
other hand, vascular IDO1 expression was significantly decreased in the group of high 
grade tumours (Figure 13 D; p= 0.0247). The immunohistochemistry results showed that 
vascular IDO1 corresponded to 2.633% of the total IDO1 in grade 1 tumours, which is 
reduced to 0.9438% in grade 2 and it was very low in grade 3.  
As TSP1 is secreted by endothelial cells, the vascular IDO1 might work as a 
negative regulator of the tumour stromal TSP1. Interestingly, a significant negative 
correlation between stromal TSP1 and vascular IDO1 (r2=0.1125, p=0.000456) was 
found in the primary tumour tissues (Figure 13 E).  
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Figure 13: Stromal TSP1 and vascular IDO1 in invasive carcinoma. 
Histomorphometric scores of stromal TSP1 in invasive carcinoma by A- the TNM stage 
system and by B- the grading system. Histomorphometric scores of vascular IDO1 in 
invasive carcinoma by C- the TNM stage system and by D- the grading system. E- 
Linear regression between the histomorphometric scores of stromal TSP1 and vascular 
IDO1 in invasive carcinoma. A-D, One-Way ANOVA was used to detect any 
differences between the groups. 
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3.3.3 Both stromal TSP1-medium/high and vascular IDO1-low groups 
exhibit a trend towards survival superiority of patients with breast cancer 
Although both stromal TSP1 and vascular IDO1 in primary breast cancer 
correlated negatively with the progression of the tumour, it was found that these two 
molecules were negatively correlated between themselves. To further evaluate a 
possible role of these two molecules in the aggressiveness of the tumour, their signal 
was correlated with the overall survival of the patients. There was no statistical difference 
between the TSP1-low and TSP1-medium/high groups (p=0.3587), but a trend in overall 
survival was observed where survival was higher in the group of patients with low stromal 
TSP1 (Figure 14). On the other hand, overall survival of patients did not show a statistical 
difference between vascular IDO1-low and vascular IDO1-medium/high groups (Figure 
14). However, the total survival curve also exhibited a trend of superiority for the vascular 
IDO1-low group compared to the vascular IDO1-medium/high group (Figure 14). These 
two trends observed here might reach significance if the sample size is increased.  
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Figure 14: Stromal TSP1 and vascular IDO1 might be potential breast cancer survival markers. Kaplan-Meier invasive breast 
carcinoma patient’s survival curves stratified by two groups of histomorphometric scores of stromal TSP1 or by two groups of 
histomorphometric scores of vascular IDO1. N (stromal TSP1 low) = 38, N (stromal TSP1 medium/high) = 12, N (vascular IDO1 low) = 37, 
N (stromal IDO1 medium/high) =13.  
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3.4 Discussion 
Angiogenesis is essential for tumour growth and progression, once tumours 
cannot grow beyond 2-3 mm in diameter without the formation of new blood vessels 
(Vasudev and Reynolds, 2014). Angiogenesis is controlled by the ratio of anti- and pro-
angiogenic factors in the microenvironment of the tumour. These angiogenic factors are 
secreted by the cells within the tumour microenvironment, such as cancer cells, 
macrophages, fibroblasts and endothelial cells (Lopes-Bastos et al., 2016). TSP1 was 
the first endogenous anti-angiogenic molecule to be identified (Good et al., 1990). In 
tumours, TSP1 has been correlated to tumour growth and vascularisation (Kawakami et 
al., 2001), and TSP1 inhibits angiogenesis and limits the growth of the primary tumour 
(Yee et al., 2009). Controversially, TSP1 has also been shown to promote metastasis 
(Incardona et al., 1995; Yee et al., 2009), probably due to the ability of TSP1 in promoting 
cell migration and invasion (Albo et al., 1997; Albo et al., 2000). However, there is a study 
showing that TSP1 expression in the primary tumour was inversely correlated with lymph 
node metastasis (Ioachim et al., 2012). 
Here, 26 out of 50 invasive breast carcinoma cases showed the absence of TSP1 
expression. The intensity of the TSP1 immunohistochemistry signal was significantly 
decreased in the primary tumour and the lymph node metastasis when compared to the 
adjacent normal tissue, suggesting a role of this extracellular matrix protein in the primary 
tumour but also at the metastatic site. Interestingly, TSP1 signal was mainly observed in 
the stroma of the primary tumour, and was inversely correlated with the size of the 
primary tumour, assessed by the tumour (T) stage. This finding confirmed the findings 
from the others that TSP1 limits tumour growth (Kawakami et al., 2001). Stromal TSP1 
was also inversely correlated with tumour grade of the primary tumour, classified based 
on the degree of differentiation of cancer cells and poor differentiated cells indicate a 
more aggressive phenotype. There was a trend in the survival of the patients and the 
stromal TSP1, which suggested a protective role of stromal TSP1 in the primary tumour. 
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Taking together, these results indicated that stromal TSP1 might be a good marker for 
tumour progression and a good tool to assess the patient’s survival. However, a larger 
cohort of samples is required to clarify whether TSP1 can be used as a predictive tool in 
breast cancer.  
IDO1 is an intracellular enzyme that degrades tryptophan causing a local 
deprivation of that amino acid (Richard et al., 2009). IDO1 has been identified as an 
immune protective enzyme in physiological and pathological settings (Munn et al., 1998) 
once T cells are sensitive to the lack of tryptophan and initiate apoptosis (Carlin et al., 
1989a; Fallarino et al., 2002; Guillemin et al., 2005; Munn et al., 1999; Munn et al., 2004; 
Munn et al., 2002; Nouël et al., 2015).  During the metastatic process, cancer cells have 
to overcome the immune system in order to colonise a new organ (Aguirre-Ghiso, 2007). 
IDO1 has been increasingly recognised as one of the mechanisms employed by cancer 
cells to evade the immune system (Lee et al., 2002; Munn et al., 1999). A wide range of 
solid tumours express IDO1 and the level of IDO1 activity has been correlated with a 
poor prognosis (Astigiano et al., 2005; Brandacher et al., 2006; Chen et al., 2014; Inaba 
et al., 2010; Inaba et al., 2009; Ino et al., 2006; Jia et al., 2015; Okamoto et al., 2005; 
Pan et al., 2008; Speeckaert et al., 2012; Suzuki et al., 2010; Urakawa et al., 2009; 
Wainwright et al., 2012; Witkiewicz et al., 2008; Yu et al., 2013; Yu et al., 2011). 
Immunohistochemistry analysis of IDO1 protein I showed that the overall IDO1 protein 
is present at the same level in the invasive carcinoma and lymph node. Interestingly, the 
adjacent normal tissue also expressed the same level of IDO1. One of the plausible 
explanations for this observation is the fact that IDO1 expression is stimulated by 
cytokines, such as IFNγ (Gough et al., 2008; Jeong et al., 2009), resulting in easily 
diffusion of IDO1 to the adjacent tumour tissue. The tumour cells adapted the strategy to 
immunise the surroundings of the tumour. In the primary tumour, the IDO1 protein was 
expressed across the tissue and cancer cells, stromal cells and endothelial cells.    
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Disseminated breast cancer cells have been localised in the perivascular niche 
of several organs, including bone marrow, lung and brain (Ghajar et al., 2013). These 
cells were in a dormant state and one of the molecules present in the perivascular niche 
was TSP1, suggesting that TSP1 might be involved in inducing and/or maintaining the 
dormancy of single breast cancer cells (Ghajar et al., 2013).  
This project hypothesised that vascular IDO1 might regulate the TSP1 synthesis 
and therefore cancer dormancy. Thus, this research focused on the vascular IDO1. 
Interestingly, the vascular IDO1 levels did not correlate with the tumour staging, 
but it inversely correlated with the grading of the primary tumour. The vascular IDO1 
might be more important in the early development of the tumour. Others group reported 
that IDO1 was only expressed in newly formed microvessels (Riesenberg et al., 2007). 
Although an inverse correlation between vascular IDO1 and the tumour grading, patients 
with low vascular IDO1 signal in the primary tumour showed a weak trend towards an 
improved survival rate. Lastly, an inverse correlation between vascular IDO1 and stromal 
TSP1 was found supporting the idea that vascular IDO1 might limit TSP1 synthesis.  
Taking together, these results support the hypothesis that vascular IDO1 might 
regulate TSP1 synthesis in endothelial cells. Thus, the dormant cancer cells, near 
microvessels, may induce IDO1 expression in nearby endothelial cells in order to escape 
dormancy by reducing TSP1 synthesis.   
Although the results above are encouraging, they have to be validated in a bigger 
cohort and in an in vivo dormancy model.  
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Chapter IV: Endothelial cells slow down MDA-MB-231 
proliferation via TSP1 
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4.1 Introduction 
Most tumour-related deaths are due to metastasis that grows in the host 
organs/tissues. Metastasis leads to the development of cachexia and subsequently 
weakens the functions of vital organs (Pantel and Brakenhoff, 2004). Disseminated 
tumour cells are cells that colonise distant tissues and organs and, upon successful 
survival in the new host environment, are the source of metastatic lesions. These cells 
often experience a period of dormancy (Schmidt-Kittler et al., 2003). About 20- 45% of 
breast and prostate cancer patients suffer relapses years or even decades after therapy 
(Karrison et al., 1999; Pfitzenmaier et al., 2006; Weckermann et al., 2001). A study 
detected disseminated tumour cells in 17% and 27% of breast cancer patients, 
depending on the cancer type, after treatment (Hall et al., 2010). It has been difficult and 
even impossible in most cases to determine whether and when metastases will occur 
(Aguirre-Ghiso, 2007). Although the recently proposed concept of metastatic niche can 
be used to explain the earlier relapses, the late relapsing population of cancer cells has 
yet to be studied and understood.  
In vivo studies and the analysis of human tumour sample have unveiled that 
single and small cluster of tumour cells can remain dormant for a long period of time 
(Goss and Chambers, 2010; Naumov et al., 2002; Pantel et al., 1993; Suzuki et al., 
2006). Because it is very challenging to identify disseminated tumour cells, it is not known 
much about them and key questions, such as the location that these cells reside and the 
inducing and awakening factors for their dormancy state, are still under investigation. 
Tumour dormancy can be divided into two major groups (Osisami and Keller, 2013): 1- 
tumour mass dormancy, in which cancer cells still divide but the lesion does not grow 
due to the lack of blood vessels or the action of the immune system, 2- cellular dormancy, 
in which cancer cells are in a quiescence state.  
Ghajar and collaborators have demonstrated in a mouse model that disseminated 
breast cancer cells are found near microvessels in a brain, bone marrow and lung 
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(Ghajar et al., 2013). The extracellular matrix, in particularly the basement membrane, 
has shown to provide a microenvironment that allows survival, quiescence and 
resistance to cytotoxic molecules of mammary epithelial cells, key features common to 
dormant cancer cells (Bissell et al., 1982; Boudreau et al., 1995; Petersen et al., 1992; 
Spencer et al., 2011; Weaver et al., 2002; Weaver et al., 1997). Endothelial cells have 
been shown to induce and sustain the quiescent state of breast cancer cells and pre-
treated lung carcinoma cells with endothelial cell conditioned medium resulted in a less 
metastatic phenotype (Franses et al., 2011; Ghajar et al., 2013). TSP1 was   present in 
stable microvascular niches at high concentrations, which resulted in cellular 
quiescence. TSP1 was absent in the microenvironment of sprouting vessels, which did 
not stop cellular division, suggesting that TSP1 might be involved in inducing and 
maintaining cellular quiescence in cancer (Ghajar et al., 2013).  
In this chapter, it was aimed to confirm that endothelial cells and TSP1 induce 
breast cancer dormancy. It was also aimed to evaluate whether TSP1 confers any 
resistance to breast cancer chemotherapy.  
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4.2 Material and Methods 
4.2.1 Cell lines 
Breast cancer cell lines MCF7 and MDA-MB-231, non- tumorigenic breast cell 
line MCF10A and primary endothelial cells HMVECad were used in this chapter. MDA-
MB-231 and MCF7 cells were continuously maintained in DMEM with 10% FBS and 
antibiotics. MCF10a were continuously cultured in MEBM supplemented with MEGM kit 
and cholera toxin (100 ng/mL). HMVECad were continuously cultured in pre-coated 
flasks with attachment factor in EGM with endothelial supplements and antibiotics.  
4.2.2 Fluorescence microscopy 
HMVECad cells were seeded in pre-coated 6 well plates with attachment factor 
at the density of 500,000 cells/well. On the following day, MDA-MB-231, MCF7 and 
MCF10A cells, which are at 70- 80% confluency, were washed twice with PBS and 
incubated with serum free DMEM containing a red dye (1μg/mL; CellTrackerTM Orange 
CMRA, life technologies) for 20 minutes. Cells were then trypsinized and 500,000 MDA-
MB-231, MCF7 or MCF10A cells were seeded on the top of the endothelial monolayer. 
Forty- eight hours after co-culture, cells were visualised under a fluorescence 
microscope with a 40x objective. Cells were imaged using bright field and under FITC 
filter.   
4.2.3 Flow cytometry  
Flow cytometry was used to analyse several aspects: percentage of each cell line 
after a period of co-culture, percentage of MDA-MB-231 cells expressing ki67 and p21-
waf1-cip1 after co-culture with endothelial cells, treatment with endothelial conditioned 
medium or TSP1 treatment.  
For the co-culture in vitro model, HMVECad cells were incubated with serum free 
DMEM containing a red dye (1μg/mL; CellTrackerTM Orange CMRA, life technologies) 
for 20 minutes. Cells were then trypsinized and seeded in pre-coated 6 well plates with 
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attachment factor at the density of 500,000 cells/well. On the following day, 500,000 
MDA-MB-231, MCF7 or MCF10A cells were seeded on the top of the endothelial 
monolayer. Twenty-four or 48 hours after the initiation of the co-culture, cells were 
trypsinized and re-suspended in ice-cold PBS at the confluency of 1x106 cells/100 μl. 
Cells were then run on a flow cytometer and the percentage of each cell lines, or the 
percentage of ki67 or p21-waf1-cip1 positive MDA-MB-231 cells were evaluated. Full 
protocol for ki67 and p21-waf1-cip1 staining is described in section 2.7. In order to 
analyse the MDA-MB-231 cell cycle by PI staining after co-culture with endothelial cells, 
the endothelial cells were traced with a green dye (1μg/mL; CellTraceTM Oregon®Green 
488 Carboxylic Acid Diacetate, ThermoFisher). PI staining protocol is described in 
section 2.9.  
For the endothelial conditioned medium experiment, HMVECad were seeded in 
6 well plates pre-coated with attachment factor at the density of 500,000 cells/well. On 
the following day, the medium was changed and conditioned medium after 48 hours 
culture was collected and centrifuged at 1,700 xg for 5 minutes to pellet any dead cells 
and debris. MDA-MB-231 cells were seed in 6 well plates at the density of 200,000 
cell/mL. On the following day medium was aspirated, MDA-MB-231 cells were washed 
twice with PBS and 250 μl of DMEM and 750 µl of the endothelial conditioned medium 
was added into each well. As a control, 1 mL of DMEM was added to the cells. The 
percentage of Ki67 positive cells was evaluated by flow cytometry.  
In order to evaluate the effect of TSP1 on the proliferation of MDA-MB-231 cells, 
MDA-MB-231 cells were seeded in 6 well plates at the confluency of 200,000 cells/mL. 
On the following day medium was aspirated, cells washed twice with PBS and 1 mL of 
medium with TSP1 (100ng/mL) or PBS (control) was added to the cells. Twenty-four 
hours after treatment, the percentage of Ki67 positive cells or the percentage of live, 
early apoptosis or late apoptosis was evaluated by flow cytometry. Apoptosis was 
evaluated by annexin V/propidium iodide apoptosis assay, full protocol in section 2.8.  
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4.2.3 ELISA 
TSP1 concentration was assessed in the medium of several endothelial cell lines 
by ELISA. HMVECad, HECV, CMEC, TY09 and TY10 were seeded in 24 well plates at 
the density of 200,000 cells/mL. Media from each well was collected and centrifuged at 
1,700 xg for 5 minutes before being used in the assay. The ELISA protocol for TSP1 is 
fully described in the section 2.4.5. 
4.2.4 Proliferation /cell survival 
MDA-MB-231 cell proliferation and cell survival was assessed by MTT.  
MDA-MB-231 cells were seeded in 96 well plates at the density of 5,000 cells/mL. 
On the following day, the medium were aspirated, cells washed twice with PBS and 135 
μl of medium containing 0, 10, 50 or 100 ng/mL of TSP1 was added to each well and left 
for 48 hours.  
The second experiment aims to evaluate the effect of TSP1 on cell survival to a 
breast cancer drug, Docetaxel. First the percentage of cell survival of MDA-MB-231 cells 
to a range of concentrations of docetaxel was evaluated. MDA-MB-231 cells were 
seeded in 96 well plates at the density of 5,000 cells/mL. On the following day, the 
medium was aspirated, cells washed twice with PBS and 135 μl of medium containing 
docetaxel was added to the wells for 24 hours. The mitochondria activity was measured 
with MTT solution and read at 540 nm in a plate reader. The full MTT protocol is 
described in section 2.6. The next step of the experiment was to seed MDA-MB-231 cells 
as described above and treated them with 0, 10, 50 or 100 ng/mL of TSP1 for 48 hours. 
The medium was aspirated, and medium containing 100 μM of docetaxel was added to 
each well and left for 24 hours. The mitochondria activity was also measured with MTT 
at 540 nm in a plate reader.  
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4.2.5 RNA isolation, cDNA synthesis and qPCR  
The expression of 13 genes (SLCO1B3, CYP3A4, CYP1B1, CYP3A5, ABCB1, 
ABCC1, ABCC2, ABCC4, CFTR, ABCG2, ABCC5, ABCC6 and ABCC10) was analysed 
by qPCR in the MDA-MB-231 cells. MDA-MB-231 cells were seeded in 6 well plates at 
the density of 200,000 cells/mL. In the first experiment, MDA-MB-231 cells were treated 
with TSP1 (100 ng/mL) or BSA (control) for 48 hours. In the second experiment, MDA-
MB-231 cells were treated with TSP1 for 48 hours followed by 24 hours of docetaxel 
treatment (100 μM) or DMSO (control). RNA was isolated using the TRI reagent kit; the 
detailed protocol is described in the section 2.3.1, followed by the generation of cDNA 
by reverse transcription PCR, as described in the section 2.3.3. Quantitative PCR was 
then performed as described in the section 2.3.4 and data was normalised to GAPDH. 
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4.3 Results 
4.3.1 Endothelial cells induce MDA-MB-231 cell cycle arrest 
In order to study the influence of the endothelial extracellular matrix on breast 
cancer cells, a two-dimension in vitro model was developed. Stable microvessels are 
composed of non-proliferating endothelial cells (Ghajar et al., 2013), for this reason, a 
large number of endothelial cells were seeded to reach high confluency to mimic a stable 
endothelium niche (Ghajar et al., 2013).  
To determine whether endothelial cells are able to induce breast cancer 
dormancy, cells from two different breast cancer cell lines, a non-aggressive cell line 
(MCF7) and an aggressive cell line (MDA-MB-231) and a non-tumorigenic breast cell 
line (MCF10A) were co-cultured on the top of an endothelial monolayer. Co-culture 
models can be challenging and medium and medium supplements may influence the 
results. To overcome this limitation, cells were cultured with half endothelial medium with 
its supplements and half breast cell medium and respective supplements. Breast cells 
were stained with a red dye before co-culture. The breast cells could be visualised by 
fluorescence microscopy and they also could be separated by flow cytometry. 
Fluorescence microscopy showed that both breast cancer cell lines, MDA-MB-231 and 
MCF7 cells, were well spread along the endothelial monolayer but they were still not 
confluent after 48 hours after seeding (Figure 15 A). Interestingly, MCF10A cells, a non-
tumorigenic breast cell line, appeared to be much more confluent than MCF7 and MDA-
MB-231 cells as they do in a single culture (Figure 15 A). However, to have a better 
understanding of the influence of the endothelial cells on the confluency and growth 
patterns of the breast cells used in this experiment, it should have been added proper 
controls. These controls would be each breast cell line cultured individually in the same 
culturing conditions. In order to have a more analytical evaluation of the proliferation of 
each cell line, the percentage of each breast cell line in co-cultured cell mixture with the 
endothelial monolayer was assessed by flow cytometry. Results show that MCF7 cell 
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line was the one that was in a smaller percentage in comparison to the endothelial cells 
(Figure 15 B), about 13.1 %. MDA-MB-231 cells were about 30.6 % of the cells after 48 
hours of co-culture with endothelial cells (Figure 15 B). Surprisingly, MCF10A cells were 
almost 80% of the cells after 48 hours of co-culture (Figure 15 B). Results show that 
there is a significant difference in the percentage of MDA-MB-231 and MCF7 in 
comparison to MCF10A. MCF7 cells are also in a smaller percentage than MDA-MB-231 
cells. The proliferation marker Ki67 was also evaluated on MDA-MB-231 cells of co-
culture with endothelial cells, revealing that a decreased proportion of MDA-MB-231 cells 
express this molecule (Figure 16 B and C, p=0.0021). The senescence marker p21-waf1-
cip1 was also assessed, showing that the percentage of MDA-MB-231 cells expressing 
this marker significantly decreased after co-culture with endothelial cells (Figure 16 D 
and E, p=0.0025). Cell cycle analysis by propidium iodide showed that there is a 
significant accumulation of MDA-MB-231 cells in the G0/G1 phase (Figure 17 A, 
p<0.0001) and a decrease in the percentage of MDA-MB-231 cells in the S phase after 
24 hours of co-culture with endothelial cells.  
 
111 
 
    
Figure 15: Endothelial cells reduce breast cancer proliferation but not normal 
breast cell proliferation. A) Representative images of the co-culture of MDA-MB-231, 
MCF7 or MCF10A cells with endothelial cells (ECs, in red). B) Percentage of 
endothelial cells and breast cells 48 hours after co-culture was initiated, 1 million of 
each cell type were seeded in each well. N=3. One-way ANOVA was used to analyse 
any statistical differences between the groups. ****p< 0.0001. 
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Figure 16: MDA-MB-231 cells reduce Ki67 and p21 expression when in co-culture with endothelial cells for 24 hours. A-
Representative gates used to select live cells, single cells and MDA-MB-231 cells, respectively. B, C- percentage of Ki67 positive MDA-
MB-231 cells. D, E- percentage of p21-waf1-Clp1 positive MDA-MB-231 cells. N=3, bars are mean±S.E.M.  Student t-test was used to 
identify any statistical differences between the groups. **p<0.01.
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Figure 17: The proportion of MDA-MB-231 cells in G0/G1 increases, and S 
decreases, when in co-culture with endothelial cells for 24 hours. A, B- 
percentage of cells in each cell cycle phase in a bar graph and a representative flow 
cytometry histogram, respectively. N=3, bars are mean±S.E.M. One-way ANOVA was 
used to detect any statistical differences between the groups. ****p<0.0001.  
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4.3.2 TSP1 reduces MDA-MB-231 proliferation 
To determine whether endothelial cells regulate breast cancer cell proliferation through 
soluble factors, MDA-MB-231 cells were cultured with the endothelial conditioned 
medium. This study intended to investigate the influence of endothelial cells and TSP1 
on breast cancer cells that later will eventually form a tumour. Once MCF-7 is a non-
aggressive cell line and doesn’t form tumours when injected into mice, only MDA-MB-
231 cells were used in these experiments. Flow cytometric analysis of Ki67 expression 
showed that conditioned medium induced a significant reduction in MDA-MB-231 cell 
proliferation (Figure 18, p=0.0425). The TSP1 concentration of several EC conditioned 
medium was evaluated by ELISA including those from microvascular endothelial cells 
(HMVECad), endothelial cells from the umbilical cord (HECV) and microvascular 
endothelial cells from the brain (TY09 and TY10).  All the endothelial cells in this 
experiment secreted TSP1 and its concentration ranged from 100 to 50 ng/mL (Figure 
19 A).  
Culturing MDA-MB-231 cells with different TSP1 concentrations (0, 10, 50 and 
100 ng/mL) showed that TSP1 inhibited MDA-MB-231 cell proliferation with a significant 
decrease at 100 ng/mL (Figure 19 B, p=0.0325). Flow cytometry also showed a 
significant decrease in the percentage of MDA-MB-231 cells expressing Ki67 when 
cultured with TSP1 (100 ng/mL, Figure 19 D, p=0.0269).  Since TSP1 induced a 
decrease in MDA-MB-231 proliferation of just over 10%, it was logic to determine 
whether TSP1 also triggers   apoptosis in breast cancer cells. To assess apoptosis, the 
presence of annexin Vin the outer side of the cellular membrane, a marker of apoptosis, 
and the infiltration of propidium iodide into the cells, a marker of necrosis, was evaluated. 
Flow cytometric analysis of annexin V revealed that comparing MDA-MB-231 cells 
cultured with and without TSP1 (100 ng/mL), TSP1 did not change the percentage of 
live, apoptotic or necrotic cells (Figure 20 B).  
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Figure 18: MDA-MB-231 cells decrease Ki67 expression when cultured with 
endothelial cell conditioned medium for 24 hours. A, B- Representative flow 
cytometry histogram and bar graph, respectively. N=3, bars are mean±S.E.M. Student 
t-test was used to detect any statistical differences between the groups. *p<0.05.
IgG control Control Conditioned medium
FITC-A
C
o
u
n
t
-10
1
10
2
10
3
10
4
10
5
0
16
33
49
65
Data 1
%
 K
i6
7
 p
o
s
it
iv
e
M
D
A
-M
B
-2
3
1
 c
e
ll
s
Control Conditioned
 medium
0
20
40
60
80
100 *
116 
 
 
Figure 19: A: TSP1 expression in different endothelial cells and the effect of 
TSP1 on MDA-MB-231 proliferation. A- TSP1 concentration in the medium of several 
endothelial cell types. B- MDA-MB-231 cell proliferation when cultured with TSP1 
normalised to the control group (BSA). C,D: Percentage of Ki67 positive MDA-MB-231 
cells when cultured with TSP1 normalised to the control group (BSA). N=4, bars are 
mean±S.E.M.  One-way ANOVA and Student t-test were used to detect any statistical 
differences between the groups. *p<0.05.
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Figure 20: The percentage of live, apoptotic and necrotic MDA-MB-231 cells were 
analysed 24 hours after TSP1 or BSA treatment by flow cytometer. Segment Q1 of 
the quadrants refers to non-specific PI staining which are alive cells; Q2 indicates late 
apoptotic and necrotic cells which are stained with both annexin V and PI; Q3 includes 
healthy and alive cells with low staining of both PI and annexin V; and Q4 to early 
apoptotic cells with high annexin V but low PI staining. N=3, bars are mean±S.E.M. 
One-way ANOVA was used to detect any statistical differences between the groups. 
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4.3.3 TSP1 increases MDA-MB-231 resistance to docetaxel  
An essential characteristic of disseminated dormant cancer cells is their ability to 
resist cytotoxic drugs (Hall et al., 2010). For that reason, it was assessed whether TSP1 
confers MDA-MB-231 cells any cytotoxic resistance to a breast cancer drug, docetaxel.  
First, a range of docetaxel concentrations was tested on MDA-MB-231 cell 
viability, measured by MTT assay, following a 24 hour drug treatment. Figure 21 A shows 
that the docetaxel EC50 is 83 µM. It was decided to treat MDA-MB-231 with 100 µM 
docetaxel, once it is an easier concentration to prepare, to evaluate the effect of TSP1 
pre-treatment. MDA-MB-231 cells were pre-treated with 0, 10, 50 or 100 µM of TSP1 for 
48 hours, followed by docetaxel treatment for 24 hours. There is a positive trend between 
TSP1 concentration and cell survival (Figure 21 B). Pre-treatment with 100 µM of TSP1 
increased significantly cell survival to docetaxel (p=0.0423) from 43% to 58%. In this 
experiment, it should have been added a control group where MDA-MB-231 cells were 
cultured only with TSP1 (no docetaxel) to have an idea of the influence of this protein on 
the viability of the MDA-MB-231 cells.  
Docetaxel is a taxane drug that prevents cell division by stabilising microtubules 
which leads to cell death (Huizing et al., 1995; Jordan and Wilson, 2004). It is thought 
that slowly proliferating or non-proliferating cancer cells are resistant to therapy, mainly 
due to that fact that cancer drugs act on cell division. For that reason, qPCR was used 
to evaluate whether TSP1 increases gene expression of any of the genes that have been 
involved in the uptake (SLCO1B3), metabolism (CYP3A4, CYP1B1 and CYP3A5) or 
withdrawal (ABC transporters) of docetaxel. As shown in Figure 21 C, CYP3A5, an 
enzyme that is involved in the metabolism of docetaxel, is upregulated in MDA-MB-231 
cell treated with TSP1 (100 ng/mL, p=0.062) for 48 hours. Gene expression analysis was 
conducted to evaluate the same group gene after TSP1 pre-treatment for 48 hours 
followed by docetaxel treatment for 24 hours. In order to determine whether the drug 
itself could induce the expression of those genes and TSP1 could have a synergetic role. 
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In Figure 21 D it is shown that CYP3A5 is again the only gene that is significantly up-
regulated when MDA-MB-231 cells are pre-treated with TSP1 (p=0.0023).  
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Figure 21: TSP1 pre-treatment for 48 hours, significantly improved cell survival 
against docetaxel. A- Dose-dependent curve for docetaxel in MDA-MB-231 cells. B- 
MDA-MB-231 cell survival to 24-hour docetaxel treatment when pre-cultured with or 
without TSP1 for 48 hours. C, D- mRNA quantification of genes involved in docetaxel 
metabolism in MDA-MB-231 cells C- before and D- after docetaxel treatment when 
cells were pre-cultured with TSP1 or BSA (control). N=3, bars are mean±S.E.M. One-
way ANOVA was used to detect any statistical differences between the groups. 
*p<0.05, **p<0.01. 
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4.4 Discussion 
Disseminated breast cancer cells have been found near microvessels in lung, 
brain and bone marrow in cell cycle arrest (Ghajar et al., 2013). The extracellular matrix 
has already been shown to induce quiescence and provide cytotoxic resistance to 
mammary epithelial cells (Bissell et al., 1982; Boudreau et al., 1995; Petersen et al., 
1992; Spencer et al., 2011; Weaver et al., 2002; Weaver et al., 1997). Ghajar and 
collaborators demonstrated in a series of in vivo and in vitro assays that a stable 
endothelium induces cell cycle arrest of breast cancer cells, identifying TSP1 as a 
possible contributor (Ghajar et al., 2013). Using a two- dimensional co- culture model 
and endothelial conditioned medium, the study of this chapter demonstrated that 
endothelial cells induce a quiescence state in breast cancer cells TSP1, an extracellular 
matrix protein secreted by endothelial cells, reduces breast cancer cell proliferation and 
increases cell survival to a breast cancer drug. TSP1 has been described as a central 
ECM protein in cancer progression and metastasis initiation (Cinatl et al., 1999; Harada 
et al., 2003; Kawakami et al., 2001; Yee et al., 2009), but its anti-tumour role has been 
mainly attributed to its anti-angiogenesis effect. The results of this chapter provided 
further evidence to support the previous findings by Ghajar and collaborators (Ghajar et 
al., 2013) that TSP1 role in metastasis initiation has been studied, not just as a protein 
that modulates angiogenesis, but also as having a direct effect on the cancer cells.  
Vascular endothelial cells can directly modulate the phenotype of other cells in 
the perivascular niche of non-tumorigenic tissues (reviewed in (Butler et al., 2010). 
Stable endothelium inhibits proliferation of smooth muscle cells (Dodge et al., 1993), 
maintains neural, haematopoietic and mesenchymal stem cell pluripotency (Butler et al., 
2010; Crisan et al., 2008; Ding et al., 2012; Kobayashi et al., 2010; Shen et al., 2004) 
and induces differentiation of pancreatic cells (Lammert et al., 2001). However, lung 
alveoli regeneration and liver growth and morphogenesis are stimulated by endothelial 
cells, which possess a neovascular tip cell phenotype (Matsumoto et al., 2001). In 
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cancer, stablished endothelium inhibits proliferation of breast cancer cells, whereas the 
sprouting endothelium stimulates tumour growth (Ghajar et al., 2013).  
Using an in vitro stablished endothelium model developed in this project, which 
is characterized by low levels of cell proliferation, suggests that endothelial cells can 
modulate breast cancer dormancy. Endothelial cells reduced MDA-MB-231 cell 
proliferation, but this effect was stronger in the proliferation of MCF7 cells. Previous in 
vivo studies have demonstrated that MDA-MB-231 cells have a high metastatic potential 
while MCF7 have no metastatic potential (Adams et al., 2011; Ziegler et al., 2014). 
Disseminated breast cancer cells have been found near microvessels (Ghajar et al., 
2013), suggesting that endothelial cells might have a role in inducing and maintaining 
breast cancer cells in a quiescence status (Ghajar et al., 2013). Surprisingly, endothelial 
cells did not show to have any inhibitory effect on the proliferation and growth pattern of 
MCF10A cells, a non-tumorigenic breast cell line with no metastatic potential (Sanchez-
Garcia et al., 2014).  
Taking together, these results suggest that endothelial cells modulate breast 
cancer cell proliferation. Additionally, endothelial cells decreased the expression of Ki67 
in MDA-MB-231 cells, a proliferation marker, and increased the percentage of MDA-MB-
231 cells in the G0/G1 phase indicating that MDA-MB-231 cells are proliferating slower 
or they are in cell cycle arrest. Ki-67 is expressed in all cell cycle phases apart from the 
G0 phase (Scholzen and Gerdes, 2000). These group of cells can be in quiescence or 
senescence. Quiescent cells are in cell cycle arrest but can enter G1 phase and initiate 
proliferation, while senescence cells are not able to proliferate again (Blagosklonny, 
2011). Dormant cancer cells are characterised by cell cycle arrest, but they can 
proliferate after a period of dormancy. For that reason, it is important to evaluate whether 
endothelial cells induce senescence or quiescence of breast cancer cells. Interestingly, 
endothelial cells reduced the percentage of MDA-MB-231 cells expressing the senescent 
marker, p21-waf1-cip1 (Romanov et al., 2010), suggesting that MDA-MB-231 cells are 
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not in a senescence status. The endothelial conditioned medium also reduced Ki67 
expression in MDA-MB-231 demonstrating that the inhibitory effect of endothelial cells 
on breast cancer cell proliferation is due to an extracellular molecule.  
TSP1 was one of the proteins present at high concentration in the perivascular 
niches of lung, bone marrow and brain, where disseminated breast cancer cells where 
found (Ghajar et al., 2013). Endothelial cells secrete TSP1. In several endothelial cell 
lines, the TPS1 concentrations in the conditioned medium were between 50 and 100 
ng/mL. However, it is important to bear in mind that TSP1 bind to structural extracellular 
proteins, resulting in deposition and retention of TSP1 in the matrix (Sottile and Hocking, 
2002). Taking this into consideration, it is likely more closely to the endothelial cells, 
much higher of TSP1 concentration. TSP1 can bind to fibronectin and other structural 
proteins. For this reason, the subsequent experiments used the highest concentration of 
TSP1 (100 ng/mL) measured in the conditioned medium of endothelial cells, a much 
lower concentration showed to affect tubule formation in vitro (1 µg/mL; (Qin et al., 2014).  
Recombinant TSP1 showed to reduce ki67 expression in MDA-MB-231 cells as 
a proliferative marker, but not increase apoptotic markers, suggesting that the endothelial 
cells secreting TSP1 might involve in the dormancy process of breast cancer. Even 
though TSP1 can exert some degree of proliferative effects on cells under physiological 
conditions, pathological TSP1 concentration is much higher with different post-
translational modifications and a stronger anti-proliferative effect. An in vivo study 
showed that RenCa renal carcinoma cells formed less metastasis in the liver which 
overexpressed TSP1, but not in the lung (Lee et al., 2010b). Also, a lack of TSP1 has 
been associated with an increase in spontaneous tumours, which was attributed to an 
inhibition of angiogenesis, but it could also be explained in part by the inhibitory effect of 
TSP1 on the proliferation of tumour cells (Gutierrez et al., 2003; Lawler, 2002; Rodriguez-
Manzaneque et al., 2001).    
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Another important characteristic of dormant cancer cells is their resistance to 
therapy, which may lead to the disseminated tumour cells forming metastasis many 
years or even decades after cancer therapy and patient declared disease-free (Hall et 
al., 2010). Dormant cancer cells are at cellular arrest. Non-proliferating cells or slow 
proliferative cells have been found to be more resistant to therapy (Addla et al., 2008; 
Dembinski and Krauss, 2009; Hadnagy et al., 2006; Ho et al., 2007; Nishimura et al., 
2002; Roesch et al., 2010; Scharenberg et al., 2002). TSP1 treatment increased 15% 
survival of MDA-MB-231 cells upon to docetaxel. Docetaxel is a common cancer drug 
that blocks cell division leading to cell death (Huizing et al., 1995; Jordan and Wilson, 
2004). Many tumours acquire resistance to this drug, and for that reason, the mechanism 
behind it has been extensively studied. There is a set of proteins involved in the uptake, 
metabolism and efflux of docetaxel in cancer cells. Gene analysis revealed that TSP1 
up-regulates the expression of CYP3A5 in MDA-MB-231. CYP3A5 is an enzyme 
involved in the metabolism of docetaxel. Docetaxel treatment further enhanced CYP3A5 
expression in the TSP1 pre-treated MDA-MB-231 cells. Knockdown CYP3A5 has been 
applied to validate the TSP1- CYP3A5 pathway in docetaxel resistance. Two 
independent studies, one in gastric cancer (Bi et al., 2014) and another one in prostate 
cancer (Lih et al., 2006) showed that a decrease in TSP1 increased resistance to 
oxaliplatin and taxane, respectively. The results here suggest a protective role of TSP1 
in breast cancer cells to docetaxel, by increasing CYP3A5, but a knockdown of this gene 
is essential to clarify this assumption. 
The results in this chapter support notion that the stable endothelium induces 
breast cancer dormancy via TSP1 modulating breast cancer cell proliferation. 
Interestingly, this study suggested that TSP1 might have a protective role in breast 
cancer against docetaxel. TSP1 up-regulated CYP3A5 expression in MDA-MB-231 cells, 
which is an enzyme that metabolises docetaxel, but further study is required to assess 
the importance of this novel pathway.  
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Chapter V: Breast cancer cells induce endothelial 
tryptophan degradation via IDO1 causing a possible 
decrease in TSP1 secretion by endothelial cells 
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5.1 Introduction 
Tryptophan is an essential amino acid and therefore has to be obtained from the 
diet. This amino acid is also one of the lowest concentrations in mammalians, and for 
that reason is relatively less available than other essential amino acids and it is thought 
to be a rate-limiting amino acid for protein synthesis (Cortamira et al., 1991; Wurtman et 
al., 1980). Although most tryptophan is used to synthesise protein, it can also be used 
for serotonin and tryptamine synthesis or enter the kynurenine pathway (Figure 7) 
(Richard et al., 2009). The kynurenine pathway is responsible for about 90% of the 
tryptophan metabolism (Richard et al., 2009), and it can be initiated by three enzymes, 
TDO (Ren and Correia, 2000), IDO1 (Thomas and Stocker, 1999) and IDO2 (Ball et al., 
2009). An important consideration is that the tryptophan used in cellular metabolism is 
lost for protein synthesis. The first step of the kynurenine pathway is dependent on the 
concentration and activity of these three enzymes (Austin and Rendina, 2015). IDO1 has 
been reported as being overexpressed in some diseases, including several types of 
cancer (Munn et al., 2004; Munn et al., 2002; Uyttenhove et al., 2003). IDO1 
overexpression and increased tryptophan degradation have been linked to more 
aggressive tumours in some studies (Chen et al., 2014; Inaba et al., 2010; Inaba et al., 
2009; Okamoto et al., 2005; Yu et al., 2013; Yu et al., 2011).  
The lack of tryptophan in the microenvironment of IDO1 expressing tumours has 
been shown to be a strategy to confer immune protection to cancer cells against T-cells, 
which are very sensitive to a low concentration of tryptophan trigging T-cell anergy and 
autophagy (Munn et al., 2005; Munn et al., 2004; Szántó et al., 2007; Wang et al., 2010). 
While cancer cells and other stromal cells seem not to be affected by the lack of 
tryptophan, this situation has been attributed to a higher expression of TTS in those cells 
than in T-cells preventing them from activating autophagy (Boasso et al., 2005). IDO1 
overexpression which leads to a decrease in tryptophan concentration in the cancer 
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microenvironment has been extensively studied in an immune protective perspective, 
but other effects, such as on protein synthesis, has not been assessed.  
TSP1 is a well-known anti-angiogenic ECM protein that has been shown to play 
an important role in cancer progression. TSP1 protein levels were found to be lower in 
malignant tumours than in adenomas in gliomas, human adrenocortical carcinomas, 
thyroid carcinomas and non-small lung carcinomas (Bunone et al., 1999; de Fraipont et 
al., 2000; Hsu et al., 1996; Kazuno et al., 1999; Oshika et al., 1998; Tenan et al., 2000). 
In the thyroid, colon and bladder carcinomas, TSP1 expression was also reported to 
correlate inversely with the survival rate and with the grade of the tumour (Bunone et al., 
1999; Grossfeld et al., 1997; Tokunaga et al., 1999). In animal models of melanoma, 
lung and breast carcinomas, cancer cells that expressed an increased level of TSP1 
were correlated with a reduced metastatic potential (Zabrenetzky et al., 1994). 
Endothelial TSP1 has also been involved in contributing for breast cancer dormancy 
(Ghajar et al., 2013). Additionally, the current study as presented in the previous chapter 
has shown that TSP1 slows down MDA-MB-231 cell proliferation.  
The amino acid sequence of TSP1 showed that this protein is composed of 1170 
amino acids of which 22 are tryptophan, as represented in Figure 22, revealing that TSP1 
contains a higher percentage of tryptophan (1.88% of tryptophan) than the average 
protein – 1.2% (Mahan and Shields, 1998).  
In the previous two result chapters it was shown that endothelial cells exert an 
inhibitory effect on the proliferation of breast cancer cells, and TSP1, which is secreted 
by endothelial cells, seems to have a similar effect. It was also shown that IDO1 is 
expressed in the tumour vasculature and an inverse correlation between vascular IDO1 
and stromal TSP1 was found in the breast cancer tissue. Therefore, this chapter aims to 
evaluate whether cancer cells are able to induce enzymatically active endothelial IDO1 
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and whether tryptophan can limit TSP1 synthesis. We also aim to evaluate the effect of 
low tryptophan on VEGF secretion by MDA-MB-231 cells.  
 
Figure 22: TSP1 amino acid sequence, tryptophan highlighted in yellow 
(NP_003237.2, National Center for Biotechnology Information, 
https://www.ncbi.nlm.nih.gov/). 
 
 
 
        1 mglawglgvl flmhvcgtnr ipesggdnsv fdifeltgaa rkgsgrrlvk gpdpsspafr 
       61 iedanlippv pddkfqdlvd avraekgfll laslrqmkkt rgtllalerk dhsgqvfsvv 
      121 sngkagtldl sltvqgkqhv vsveeallat gqwksitlfv qedraqlyid cekmenaeld 
      181 vpiqsvftrd lasiarlria kggvndnfqg vlqnvrfvfg ttpedilrnk gcssstsvll 
      241 tldnnvvngs spairtnyig hktkdlqaic giscdelssm vlelrglrti vttlqdsirk 
      301 vteenkelan elrrpplcyh ngvqyrnnee wtvdsctech cqnsvtickk vscpimpcsn 
      361 atvpdgeccp rcwpsdsadd gwspwsewts cstscgngiq qrgrscdsln nrcegssvqt 
      421 rtchiqecdk rfkqdggwsh wspwsscsvt cgdgvitrir lcnspspqmn gkpcegeare 
      481 tkackkdacp inggwgpwsp wdicsvtcgg gvqkrsrlcn nptpqfggkd cvgdvtenqi 
      541 cnkqdcpidg clsnpcfagv kctsypdgsw kcgacppgys gngiqctdvd eckevpdacf 
      601 nhngehrcen tdpgynclpc pprftgsqpf gqgvehatan kqvckprnpc tdgthdcnkn 
      661 akcnylghys dpmyrceckp gyagngiicg edtdldgwpn enlvcvanat yhckkdncpn 
      721 lpnsgqedyd kdgigdacdd dddndkipdd rdncpfhynp aqydydrddv gdrcdncpyn 
      781 hnpdqadtdn ngegdacaad idgdgilner dncqyvynvd qrdtdmdgvg dqcdncpleh 
      841 npdqldsdsd rigdtcdnnq didedghqnn ldncpyvpna nqadhdkdgk gdacdhdddn 
      901 dgipddkdnc rlvpnpdqkd sdgdgrgdac kddfdhdsvp diddicpenv disetdfrrf 
      961 qmipldpkgt sqndpnwvvr hqgkelvqtv ncdpglavgy defnavdfsg tffinterdd 
     1021 dyagfvfgyq sssrfyvvmw kqvtqsywdt nptraqgysg lsvkvvnstt gpgehlrnal 
     1081 whtgntpgqv rtlwhdprhi gwkdftayrw rlshrpktgf irvvmyegkk imadsgpiyd 
     1141 ktyaggrlgl fvfsqemvff sdlkyecrdp 
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5.2 Material and methods 
5.2.1 Cell lines 
MDA-MB-231 breast cancer cells and HMVECad, primary endothelial cells, were 
used in this chapter. MDA-MB-231 cells were continuously maintained in DMEM media 
with 10% FBS and antibiotics. HMVECad were continuously cultured in pre-coated flasks 
with attachment factor in EGM with endothelial supplements and antibiotics.  
5.2.2 Two-dimensional co-culture and cell sorting  
HMVECad cells were seeded in pre-coated T75 flasks with attachment factor and 
left to proliferate to 70- 80% confluency. Endothelial cells were then washed with PBS 
twice and incubated with serum free DMEM containing a red dye (1μg/mL; CellTrackerTM 
Orange CMRA, life technologies) for 20 minutes. Cells were then trypsinized and seeded 
in pre-coated 6 well plates with attachment factor at the density of 500,000 cells/well. On 
the following day, 500,000 MDA-MB-231 cells were seeded on the top of the endothelial 
monolayer and left for 48 hours (co-culture). Wells with just endothelial cells or MDA-
MB-231 cells were also left for 48 hours (single culture). After 48 hours, cells were 
trypsinized and re-suspended in cold PBS at the confluency of 1x106 cells/100 μl. Then, 
both cell lines were sorted and collected using the BD FACSAriaTM III (BD Biosciences, 
US). This was achieved by plotting the data onto a dot plot SSC-A vs PE (575 nm) that 
allowed gating each cell line according to the presence of absence of the red dye 
followed by its sorting.  
5.2.3 Generation of conditioned medium  
Two types of conditioned media, namely that with low and that with high glucose, 
were generated from MDA-MB-231 cells. MDA-MB-231 cells were seeded in 6-well 
plates at the density of 200,000 cells/well. The day after seeding, the medium was 
aspirated, cells washed twice with PBS and 1 mL of standard DMEM, which contains 
about 5.5 mM of glucose, or 1 mL of low glucose DMEM (1 mM glucose) was added to 
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each well. After 48 hours, conditioned media were collected and centrifuged at 1,700 ×g 
for 5 minutes to pellet any dead cells and debris. The supernatant was used to treat 
endothelial cells.  
4.2.4 Conditioned media treatment 
Endothelial cells (HMVECad) were seeded in pre-coated 24-well plates with 
attachment factor at the density of 200,000 cells/well. On the next day, the medium was 
aspirated, cells were washed twice with PBS, and 250 µl of the standard endothelial 
medium was added to each well. To each well an additional 750 µl of standard 
endothelial medium (control group), standard DMEM (DMEM control), MDA-MB-231 
conditioned medium generated with standard DMEM, low glucose DMEM (low glucose 
DMEM control) or MDA-MB-231 conditioned medium generated with low glucose 
medium was added. Cells were cultured in these conditions for 24 hours. 
5.2.5 Generation of IDO1 Knockdown 
HMVECad cells were seeded in pre-coated 6-well plates with attachment factor 
at the density of 200,000 cells/well. On the following day medium was removed, cells 
were washed twice with PBS and 1 mL of the siRNA/ Lipofectamine mix containing the 
IDO1 targeting siRNA or the non-targeting siRNA (control), was added to the respective 
well (full protocol described in the section 2.5). An additional 1 mL of endothelial medium 
was added to each well 6 hours later.  24 hours after transfection cells were trypsinized 
and seeded onto pre-coated 24-well plates at the density of 200,000 cells/ well. On the 
next day, 750 µl of MDA-MB-231 conditioned medium generated under low glucose 
conditions and 250 µl of the standard endothelial medium was added to each well. Cells 
were cultured for 24 hours.  
5.2.6 RNA isolation, cDNA synthesis and qPCR 
The expression of TDO, IDO1 and/or IDO2 was analysed by qPCR in the 
endothelial samples generated as described in the sections 5.2.3, 5.2.4 and 5.2.5. RNA 
131 
 
was isolated using the TRI reagent kit, the detailed protocol is described in the section 
2.3.1, followed by the generation of cDNA by reverse transcription PCR, as described in 
the section 2.3.3. Quantitative PCR was then performed as described in the section 2.3.4 
and data was normalised to GAPDH. 
5.2.7 Differential tryptophan culturing conditions 
DMEM with different tryptophan concentrations was used in this experiment to 
culture HMVECad and MDA-MB-231 cells. The different tryptophan concentration media 
was generated using tryptophan-free DMEM (supplemented with Dialyzed FBS) and 
tryptophan was added to it from a stock solution of 50 mM in order to reach the intended 
concentration. 
HMVECad were seeded onto pre-coated 24-well plates at the density of 200,000 
cells/well in the standard endothelial medium. On the next day, the medium was 
removed, cells washed twice with PBS and 1 mL of the different tryptophan concentration 
DMEM was added to the respective well. Media were collected at 24, 48 or 72 hours.  
MDA-MB-231 cells were seeded in 24-well plates at the density of 200,000 cells/ 
well. On the next day, the medium was removed, cells washed twice with PBS and 1 mL 
of the different tryptophan concentration DMEM was added to the respective well. Media 
were collected after 48 hours of culturing.  
In both experiments, cells were trypsinised and the number of cells/ well was 
assessed by an automatic cell counter, full protocol in section 2.2.  
5.2.8 ELISA 
TSP1, kynurenine and VEGF concentrations were assessed in the medium of 
endothelial cells or MDA-MB-231 cells which were generated as described in the 
sections 5.2.4, 5.2.5 and 5.2.7. The media from those experiments were collected and 
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centrifuged at 1,700 × g for 5 minutes before being used in the assay. The ELISA protocol 
for TSP1, kynurenine and VEGF is fully described in the sections 2.4.5. 
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5.3 Results 
5.3.1 MDA-MB-231 cells induce endothelial tryptophan degradation via 
IDO1 
In chapter III, it was shown that the vasculature of breast cancer could express 
IDO1, in this subchapter, it was aimed to evaluate whether cancer cells can directly 
induce IDO1 expression in endothelial cells without the recruitment of immune cells 
known to secrete cytokines, such as IFNγ. To assess this question, MDA-MB-231 cells 
were co-cultured on the top of an endothelial monolayer for 48 hours, before separating 
by way of cell sorting. IDO1 mRNA was significantly increased (p=0.0484), about 20-fold 
increase, in endothelial cells when co-cultured with MDA-MB-231 cells compared to 
endothelial single culture control (Figure 23, A). While MDA-MB-231 cells did not change 
IDO1 mRNA level.  
IDO1 expression can be trigged by several soluble molecules, such as IL-6 and 
IFNγ (Adams et al., 2004; Braun et al., 2005; Fallarino et al., 2006). To determine 
whether breast cancer cells can induce endothelial IDO1 expression via soluble factors, 
an endothelial monolayer was cultured with MDA-MB-231 conditioned medium and 
endothelial IDO1 was assessed by qPCR and western blot. IDO1 enzymatic activity was 
also evaluated by quantifying kynurenine concentration, the first product of tryptophan 
degradation by IDO1, in the medium by ELISA. The expression of TDO and IDO2, the 
other two enzymes able to catabolise tryptophan, was also evaluated. In the context of 
tumour dormancy, as described in the previous chapter, the results suggest that the 
vascular microenvironment down regulates breast cancer cell proliferation. Thus, when 
the micrometastasis reaches the point that requires new vessels to support growth, 
cancer cells are in an equilibrium of proliferating and apoptotic cells due to the lack of 
oxygen and nutrients (Bergers and Benjamin, 2003). For this reason, endothelial cells 
were treated with MDA-MB-231 conditioned medium generated under standard 
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conditions, but also under low glucose conditions to mimic the context of the cancer cells 
in the centre of the micrometastasis.  
The MDA-MB-231 conditioned medium, generated under normal conditions (~5.5 
mM glucose), significantly increased IDO1 (p=0.02116) but not TDO (p=0.4521) nor 
IDO2 (p=0.1147) gene expression in endothelial cells in comparison to the control group 
(Figure 23 B-D). Interestingly, MDA-MB-231 conditioned medium, which was generated 
under low glucose conditions (1mM), further increased IDO1 expression in endothelial 
cells (p=0.0001) in comparison to standard conditioned medium (Figure 23 B). TDO and 
IDO2 mRNA expression did not significantly change (Figure 23, C and D). Endothelial 
IDO1 protein was also evaluated by western blot which did not detect IDO1 under any of 
the above conditions after 48 hours of culture (data not shown). Even though IDO1 
protein was not detected, kynurenine concentration, which indicates tryptophan 
degradation and it is used as a way to assess IDO1 enzymatic activity, showed that the 
standard MDA-MB-231 conditioned medium induced a significant increase in tryptophan 
degradation (p=0.0005, Figure 23 E) but not the control treatment with normal DMEM 
(p=0.1416) in which the conditioned medium was generated. Although an increase in 
endothelial IDO1 mRNA was observed when endothelial cells were cultured with the low 
glucose MDA-MB-231 conditioned medium it was not detected an increase in tryptophan 
degradation, compared to standard MDA-MB-231 conditioned medium.  
In order to evaluate whether MDA-MB-231 conditioned medium induced an 
increase in kynurenine through IDO1, endothelial cells were transfected with IDO1 siRNA 
before culturing these cells with MDA-MB-231 conditioned medium generated under low 
glucose conditions. This way, IDO1 mRNA was knockdown as shown in Figure 24 A (p< 
0.0001), which led to a significant decrease in kynurenine concentration (Figure 24 B, 
p=0.0002). TDO and IDO2 gene expression was also evaluated showing that neither of 
these genes significantly changed their expression upon IDO1 knockdown as 
represented in Figure 24 C and D (p= 0.0626, p= 0.2664, respectively). 
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Figure 23: MDA-MB-231 cells induce an increase in tryptophan degradation by stimulating endothelial IDO1 expression. A- MDA-
MB-231 cells were cultured for 48 hours on the top of an endothelial monolayer, which was previously labelled with a red dye. Each cell 
type was separated by cell sorting and RNA was extracted. The relative IDO1 mRNA was assessed by qPCR. (B, C and D) Conditioned 
media were generated by culturing MDA-MB-231 cells in normal medium (NM) or low glucose medium (LGM) for 48 hours. Endothelial 
cells were cultured with standard endothelial medium (CNT), DMEM (NM CNT), MDA-MB-231 conditioned medium [CM (NM)], low 
glucose medium (LGM CNT) or MDA-MB-231 conditioned medium generated with low glucose medium [CM (LGM)] for 24 hours. The 
relative mRNA expression of IDO1 (B), TDO (C) and IDO2 (D) in endothelial cells was assessed by qPCR. Kynurenine concentration was 
also measured by ELISA in the conditioned medium (E). Data are represented as mean ± S.E.M. (n=3), One-way ANOVA was used to 
analyse any statistical differences between the different groups. n.s., non-significant, **P˂0.01, ***P˂0.001 compared to control cells 
(CNT) unless represented otherwise. 
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Figure 24: MDA-MB-231 conditioned medium induces endothelial tryptophan 
degradation via IDO1. Endothelial cells were transfected with IDO1 siRNA (IDO1 KD) 
or with nonsense siRNA sequence (control) and then cultured, for 24 hours, with MDA-
MB-231 conditioned medium which was under low glucose conditions. The relative 
mRNA expression of IDO1 (A), TDO (C) and IDO2 (D) was assessed in these samples 
by qPCR. Kynurenine (B) concentration was also evaluated in the medium by ELISA. 
Data are represented as mean ± S.E.M. (n=3), student-t test was used to analyse any 
statistical differences between the groups. n.s., non-significant, ***P˂0.001, 
****P˂0.0001. 
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5.3.2 Low tryptophan limits TSP1 secretion 
In vivo studies have shown that the levels of tryptophan can influence protein and 
serotonin synthesis (Cortamira et al., 1991; Wurtman et al., 1980). In this chapter, it 
was aimed to assess whether tryptophan concentration can determine TSP1 synthesis 
and therefore its concentration in the ECM. In an in vivo ovarian cancer mouse model, 
it was shown that tryptophan concentration could vary in xenografts tumours from just 
below 50 µM by day 14 in IDO1 negative tumours and 20 µM after a 7 day IFNγ 
treatment to induce IDO1 expression (Burke et al., 1995). For that reason, endothelial 
cells were cultured with 8 tryptophan serial dilutions of 1:2, with the highest being 100 
µM. TSP1 concentration in the medium was measured at 24, 48 and 72 hours by 
ELISA.  
Different tryptophan concentrations did not significantly affect endothelial TSP1 
secretion at 24 hours and 48 hours, Figure 25 A and C, respectively. However, there 
appears to be a trend that low tryptophan concentrations limited TSP1 secretion. At 72 
hours, there was a significant decrease in TSP1 secreted by endothelial cells at the 
lowest tryptophan conditions (3.125, 1.5625 and 0.78125 µM) as shown in Figure 25 E, 
(p=0.0327, p=0.0051, p=0.0253, respectively) when compared to 100 µM of 
tryptophan. The number of cells in each day was also assessed showing no significant 
difference between any of the tryptophan concentration when compared to the highest 
tryptophan concentration group, in any of the days, as represented in Figure 25 B, D 
and F. 
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Figure 25: Tryptophan concentration affects TSP1 secretion by endothelial cells. 
Endothelial cells were cultures with different tryptophan concentrations for 24 hours (A, 
B), 48 hours (C, D) and 72 hours (E, F). TSP1 concentration in the medium was 
assessed by ELISA (A, C, D) and the number of cells was also determined by an 
automatic cell counter (B, D, F). Data are represented as mean ± S.E.M. (n=3), One-
way ANOVA was used to analyse any statistical differences between the groups. 
*P˂0.05, **P˂0.01 compared to the highest tryptophan concentration group. 
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5.3.3 Low tryptophan induces VEGF secretion by MDA-MB-231 cells 
The present study so far has shown that human breast tumours overexpress IDO1 in 
both cancer cells and stromal cells, including endothelial cells. It has also shown that 
cancer cells can induce IDO1 expression in endothelial cells and therefore tryptophan 
degradation. Thus, cancer cells have to survive and somehow overcome the lack of 
tryptophan. One way that cancer cells could overcome this situation would be to induce 
angiogenesis, such as by increasing VEGF secretion. 
For this reason, the effect of low tryptophan concentration on the secretion of VEGF by 
MDA-MB-231 cells was evaluated. The experiment showed, the levels of VEGF 
secretion by MDA-MB-231 cells did not differ, when treated with 10 µM and 20 µM of 
tryptophan (Figure 26 A). Strikingly, when MDA-MB-231 cells were cultured with lower 
tryptophan concentration, 1 µM, it significantly increased the level of VEGF secretion, 
when compared with the cells treated with high concentrations (p=0.0174, Figure 26 
A). The number of cells at the end of the experiment significantly increased (Figure 26 
B, p=0.0039) when the concentration of tryptophan decreased from 20 to 10 µM, but 
the number of cells significantly decreased when cells were cultured with 1 µM (Figure 
26 B, p˂0.0001).  Even though the lowest tryptophan concentration decreased the 
number of MDA-MB-231 cells, a 2.6- fold increase of VEGF secretion/ 1000 cells was 
observed at 1 µM of tryptophan when compared to 20 µM of tryptophan.  
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Figure 26: VEGF secretion by MDA-MB-231 cells is enhanced under low 
tryptophan conditions. MDA-MB-231 cells were cultured with 3 different tryptophan 
concentrations (20, 10 and 1 µM) for 48 hours and VEGF was measured in the medium 
by ELISA (A) and the number of cells was assessed at the end of the experiment (B). 
Data are represented as mean ± S.E.M. (n=3), One-way ANOVA was used to analyse 
any statistical differences between the groups. ***P˂0.001, ****P˂0.0001.  
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5.4 Discussion 
TSP1 is an extracellular matrix protein that inhibits endothelial cell motility and 
growth and therefore stabilises the microvascular endothelium and inhibits angiogenesis 
(Roberts, 1996). Endothelial secreted TSP1 has also been suggested as a possible key 
molecule in inducing sustained breast cancer cell dormancy (Ghajar et al., 2013). In the 
previous chapter, my findings support this claim that the endothelium and human TSP1 
recombinant protein reduce breast cancer cell proliferation. In a two- dimensional co-
culture model and a conditioned medium model, breast cancer cells induce an increase 
in tryptophan degradation in endothelial cells via IDO1. My study also showed that a lack 
of tryptophan limits TSP1 synthesis by endothelial cells and enhances VEGF secretion 
by breast cancer cells. Studies on tumours have focused on the role of IDO1 as an 
immune modulator, but my study has suggested a possible new function of this 
tryptophan-catabolizing enzyme. Taken together with data by others, my data suggest 
that IDO1 might be involved in the outgrowth of dormant breast cancer cells and 
angiogenesis. 
Several tumour types overexpress IDO1, including prostatic, breast, pancreatic 
and colorectal, and most studies indicate that IDO1 overexpression is correlated with a 
poor prognosis (Astigiano et al., 2005; Bonanno et al., 2012; Brandacher et al., 2006; 
Chamuleau et al., 2008; Ino et al., 2006; Okamoto et al., 2005; Suzuki et al., 2010; Takao 
et al., 2007). IDO1 expression in tumours have been attributed mainly to cancer cells 
and infiltrating leukocytes (Ishio et al., 2004; Uyttenhove et al., 2003). In cervical 
carcinoma, T-cells and tumour cells- expressing IDO1 are both located in the periphery 
of the tumour (Théate et al., 2015) and IDO1 expression was correlated with T-cell 
infiltration in melanoma (Spranger et al., 2013), suggesting that the IDO1 driven factor in 
tumours is the generic inflammation process. However, some tumours expressed IDO1 
in the absence of any inflammatory response (Théate et al., 2015; Uyttenhove et al., 
2003), which leads to speculation that there might be additional mechanisms that 
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upregulates IDO1 expression in tumours. My study (shown in Chapter III) and the results 
from other groups suggested that the tumour vasculature can also express IDO1 
(Riesenberg et al., 2007).  
The origin of factors that regulate endothelial IDO1 is not entirely clear nor its 
biological role. Endothelial IDO1 could be driven by inflammatory mediators, such as 
IFNγ secreted by T-cells. In vivo studies have shown that the immune system is able to 
target and induce cytolysis of most tumour cells (Sosa et al., 2014), but some cancer 
cells scape this process and remain clinically dormant under the immune system 
pressure (Sosa et al., 2014). Thus, the inflammatory process might induce endothelial 
IDO1 expression during cancer dormancy. As dormant breast cancer cells have been 
found in close association with the microvasculature of lung, bone marrow and brain 
(Ghajar et al., 2013), it was hypothesised that breast cancer cells are able to directly 
induce endothelial IDO1. In my study, co-culture and conditioned medium experiments 
demonstrated that breast cancer cells could directly induce endothelial IDO1 via soluble 
factors and increase tryptophan degradation. It has been demonstrated that IDO1 
present in microvesicles can degrade tryptophan (Romani et al., 2015). The data of the 
endothelial IDO1 knockdown experiments provided evidence that breast cancer- 
mediated tryptophan degradation in endothelial cells occurs via IDO1 and not through 
other tryptophan-catabolizing enzyme nor via breast cancer vesicles containing IDO1 
protein in the conditioned medium. Although there is no information whether IDO1 is 
expressed within the dormant breast tumour microenvironment, blocking CTLA-4, a 
potent negative regulator of T-cell response, or blocking IDO1 in BALB/c mice implanted 
with breast cancer cells only resulted in a transient delayed tumour growth, but combined 
CTLA-4/IDO1 blockage resulted in sustained growth delay and prolonged survival 
(Holmgaard et al., 2013) demonstrating that IDO1 is a key immune regulator, not just in 
the primary tumours, but also in the early phases of metastasis.  
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Once the micrometastasis status is reached, there is an equilibrium of 
proliferating cells at the edge and apoptotic cells in the centre of the micrometastasis 
(Gelao et al., 2013). Apoptosis is occurring due to a lack of a vascular system to supply 
nutrients and oxygen to the cells and removing toxic molecules resulted from the cellular 
metabolism (Gelao et al., 2013). Conditioned medium from breast cancer cells cultured 
under low glucose, to mimic those cells in the centre of the micrometastasis, induced a 
stronger endothelial IDO1 expression than standard conditions. This suggests that 
breast cancer cells directly induce endothelial IDO1, but this effect is enhanced when 
cells are under stress. Although endothelial IDO1 activity was not increased with low 
glucose cancer cell conditioned medium treatment, in comparison to standard 
conditioned medium, it is likely to be due to the short-term conditioned medium treatment 
of 24 hours.  
As mentioned above, in order for the micrometastasis to grow, cells have to 
trigger angiogenesis. In renal cell carcinoma, IDO1 is predominantly expressed by 
endothelial cells, and mostly present in carcinoembryonic antigen-related cell adhesion 
molecule-1 (CEACAM) positive endothelial cells, suggesting that IDO1 is expressed in 
newly formed vessels (Riesenberg et al., 2007). The authors also demonstrated that 
endothelial IDO1 positive tumours had a higher microvascular density (Riesenberg et al., 
2007). Interestingly, IDO1 is expressed in the normal lung vasculature and IDO1 
knockout mice had a reduced lung vascular density (Smith et al., 2012). IDO1 also   
exhibits other effects in the vasculature, such as vasodilatation and reduced blood 
pressure (Wang et al., 2010). Despite the fact that there are a few studies indicating an 
association between IDO1 and angiogenesis, there is no report so far regarding the 
related molecular mechanism. In chapter III, I described an inverse correlation between 
endothelial IDO1 and stromal TSP1 in breast cancer tissue. The analysis of the TSP1 
amino acid sequence from the National Center for Biotechnology Information website 
revealed that TSP1 is composed of 1.88% of tryptophan, a higher percentage of 
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tryptophan than the average protein (1.2%). This fact suggests that TSP1 synthesis 
might be affected by a decrease in tryptophan than most proteins. Low tryptophan 
concentration showed to significantly decrease TSP1 secretion by endothelial cells after 
72 hours, without changing the number of cells. Interestingly, my results showed that 
TSP1 secretion did not decreased in a tryptophan dose-dependent manner, instead 
TSP1 secretion is stable between 100 and 6.25 µM and drops between 6.25 µM and 
3.125 µM suggesting that cells activate a mechanism that modulates TSP1 synthesis 
between those concentrations. To my knowledge, my result is the first time to show that 
the concentration of tryptophan can limit TSP1 synthesis and its concentration in the 
extracellular matrix. In an in vivo study, Burke and colleagues used ovarian cancer 
xenografts, which did not constitutively expressed IDO1, demonstrated that by IFNγ 
treatment induced IDO1 expression (Burke et al., 1995). They observed the total 
concentration of tryptophan in these tumours would go from 90 µM in IDO1 negative 
tumours and 20 µM in IDO1 positive tumours in only 2 days after IFNγ/BSA treatment 
(Burke et al., 1995). At day 7, tryptophan concentrations were stable at about 40 and 20 
µM in IDO1 negative and positive tumours, respectively (Burke et al., 1995).  The total 
tryptophan concentration in the IDO1 positive tumours was higher than the concentration 
required to affect TSP1 secretion, shown in this chapter. IDO1 is an intracellular enzyme, 
and therefore is likely that the uptake of tryptophan does not compensate its degradation 
leading to a much lower intracellular tryptophan concentration in IDO1 positive cells. A 
study by Kane et al. demonstrated that stimulating IDO1 expression in human cervical 
epithelial cells (ME-180) by IFNγ (1 ng/mL) led to such low levels of intracellular 
tryptophan that it was not possible to detect the intracellular tryptophan concentration 
after only 24 hours, while IDO1 negative cells demonstrated to have a stable level of 
intracellular tryptophan (Kane et al., 1999).  A study previously described a synergetic 
role of CTLA-4 and IDO1 in cancer immune protection (Holmgaard et al., 2013), in 
another study, a CTLA-4/VEGF pathway has been found to be implicated in immune 
regulation but also in angiogenesis (Ott et al., 2015). Thus, CTLA-4 is overexpressed in 
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cells that are under low tryptophan conditioned and interestingly, CTLA-4 is composed 
of only 0.57% tryptophan (NCBI website).  
Low tryptophan has been reported to induce T-cell anergy and autophagy (Metz 
et al., 2012; Munn et al., 2005; Sharma et al., 2007) but such conditions seem not to 
affect other cell types within the tumour microenvironment (Boasso et al., 2005). Newly 
formed microvessels express IDO1 in renal cell carcinoma and an inverse correlation 
between those microvessels, and Ki67-positive cancer cells were found (Riesenberg et 
al., 2007), suggesting that the lack of tryptophan induces cell cycle arrest in tumour cells. 
Indeed, my study suggested that culturing breast cancer cells under low tryptophan 
resulted in less proliferative cells, but also resulted in an increase in VEGF secretion by 
cancer cells. A molecular mechanism has been described to explain the resistance of 
some cell types to a low tryptophan microenvironment (Boasso et al., 2005), but it does 
not explain the ability of cells to synthesise proteins with a high content of tryptophan. 
VEGF is a protein that has many isoforms and most of them contain between 2.2 and 
1.3% of tryptophan in its structure, except isoform s that does not contain any tryptophan 
(Appendix V). It would be interesting to investigate whether this particular isoform is 
upregulated under low tryptophan conditions and its role in angiogenesis.   
The results presented in this chapter shed light on the origin of the regulation 
force in endothelial IDO1 in the context of cancer, demonstrating that cancer cells may 
trigger IDO1 expression and tryptophan degradation in endothelial cells without the 
recruitment of T-cells or other immune cells. My findings also showed that a lack of 
tryptophan leads to a decrease in the secretion of endothelial TSP1 at the same time 
that induces an increase in VEGF secretion by cancer cells. A lack of tryptophan seems 
to tilt the balance of anti-angiogenic/ angiogenic factors, benefiting the latter, thus 
suggesting that endothelial IDO1 might be involved in a novel angiogenic pathway.  
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Although the findings presented here could be supported by in vivo studies 
published by other authors, it is necessary to investigate this pathway in a cancer 
dormancy context to evaluate the significance of this study. It remains to be determined 
whether micrometastasis is able to induce an IDO1 signal in endothelial cells strong 
enough to decrease tryptophan concentration to such low levels that limits TSP1 
synthesis. 
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Chapter VI: MDA-MB-231 cells increase IFNγ 
expression due to nutrient deprivation, which may 
induce a local decrease in endothelial TSP1 secretion 
via IDO1 
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6.1 Introduction 
Tumours are constituted of cancer cells but also of stromal cells, such as 
fibroblasts, macrophages and endothelial cells. Stromal cells are a key component of the 
tumour and play an essential role in initiation, growth and progression of the tumour (Lin 
et al., 2013; Tang et al., 2016). Studies have attributed other functions to stromal cells, 
such as protection of cancer cells to the immune system (Harper and Sainson, 2014) 
and against chemotherapy drugs (Shree et al., 2011; Tiago et al., 2014).  
Tumour cells have to send signals to attract and modify stromal cells.  It has been 
shown that tumours are not able to grow beyond 2-3 mm in diameter without inducing 
the formation of new blood vessels. A crucial process called tumour angiogenesis is to 
build a network of microvessels capable of sustaining the growth of the tumour. Since 
cell-to-cell communication is crucial for cancer cells to induce angiogenesis, the 
disruption of cellular communication has been demonstrated to reduce both growth and 
aggressiveness of the tumour (Vasudev and Reynolds, 2014).  
Many molecules are responsible for mediating the cell-to-cell communication 
between cancer cells and endothelial cells can be through many means, including 
soluble factors, adhesion receptors, gap junctions or vesicles (Lopes-Bastos et al., 
2016).  
Soluble factors are one of the most common means of cell communication, which 
are secreted into the extracellular space and targets adjacent cells or those in a distant 
site (Lopes-Bastos et al., 2016). IFNγ is a soluble factor mainly produced by natural killer 
and natural killer T cells and mediates the immune response of the innate and adaptive 
immune system. IFNγ has a key role in protecting the host against bacteria, protozoa 
and virus infection (Carlin et al., 1989b; Taylor and Feng, 1991), but also in preventing 
the formation of tumours in mice challenged with chemical carcinogens (Kaplan et al., 
1998; Shankaran et al., 2001). In the last decade, IFNγ has emerged as a promising anti-
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tumour molecule. Several therapeutic strategies to increase the expression of this 
cytokine have been developed and proven its efficacy in in vitro experiments (Xie et al., 
2013; Zhao et al., 2007; Zuo et al., 2011), in pre-clinical in vivo and clinical trials (Dummer 
et al., 2004; Miller et al., 2009a). IFNγ is also the strongest stimulator of IDO1 expression 
in vitro and in vivo (Gough et al., 2008; Jeong et al., 2009).   
In the previous chapter, my study showed that cancer cells or cancer cell 
conditioned medium could induce IDO1 expression in endothelial cells, suggesting that 
the cancer cells may communicate with endothelial cells via soluble factors. For that 
reason, this chapter aims to evaluate whether IFNγ is a possible mediator between 
cancer cells and endothelial cells. It was also aimed to verify the impact of this cytokine 
on other tryptophan degrading enzymes and whether IFNγ is capable of modulating 
TSP1 secretion. Lastly, this chapter intended to evaluate the impact of IFNγ on other 
stromal cells and cancer cells. 
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6.2 Material and methods 
6.2.1 Cell lines 
Breast cancer cell lines MCF7 and MDA-MB-231, non- tumorigenic breast cell 
line MCF10A, primary endothelial cells HMVECad and epithelial lung cell line BEAS-3B 
were used in this chapter. BEAS-2B cells were continuously cultured in collagen pre-
coated flasks with BEBM, supplemented with BEGM kit and antibiotics. MDA-MB-231 
and MCF7 cells were continuously maintained in DMEM with 10% FBS and antibiotics. 
MCF10A were continuously cultured in MEBM supplemented with MEGM kit and cholera 
toxin (100 ng/mL). HMVECad were continuously cultured in pre-coated flasks with 
attachment factor in EGM with endothelial supplements and antibiotics.  
6.2.2 Low glucose experiment 
HMVECad and MDA-MB-231 cells were seeded in 6-well plates at the density of 
200,000 cells/well. On the next day, the medium was removed, cells washed twice with 
PBS, and 1 mL of standard MEBM medium was added to MCF10A cells, and 1 mL of 
standard DMEM supplemented with FBS or 1 mL of low glucose DMEM (1 mM glucose) 
supplemented with FBS was added to MDA-MB-231 cells. Cells were cultured under 
those conditions for 48 hours.  
6.2.3 IFNγ treatment 
HMVECad, MDA-MB-231, MCF7, MCF10A and lung cells were seeded in 6-well 
plates at the density of 500,000 cells for HMVECad and 200,000 for the other cells lines. 
On the next day, medium was removed, cells washed twice with PBS and 1 mL of fresh 
medium was added, supplemented with IFNγ (10 ng/mL) or BSA. Cells were cultured for 
24 hours and RNA or protein was extracted.  
To investigate the expression and the enzymatic activity of IDO1 in endothelial 
cells upon IFNγ, HMVECad cells were seeded in pre-coated 24-well plates with 
attachment factor at the density of 200,000 cells/ well. On the next day, the medium was 
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removed, cells washed twice with PBS and fresh medium supplemented with 0, 10, 125, 
250, 500 or 1000 ng/mL of IFNγ was added to cells. Cells were cultured for 24 hours. 
RNA and protein were extracted and medium collected for further analysis.  
6.2.4 Two-dimensional co-culture and cell sorting 
HMVECad cells were seeded in pre-coated T75 flasks with attachment factor and 
left to proliferate to 70- 80% confluency. Endothelial cells were then washed with PBS 
twice and incubated with serum free DMEM containing a red dye (1μg/mL; Cell TrackerTM 
Orange CMRA, life technologies) for 20 minutes. Cells were then trypsinised and seeded 
in pre-coated 6 well plates with attachment factor at the density of 500,000 cells/well. On 
the following day, 500,000 MDA-MB-231 cells were seeded on the top of the endothelial 
monolayer and left for 48 hours (co-culture). Wells with just endothelial cells or MDA-
MB-231 cells were also left for 48 hours (single culture). After 48 hours, cells were 
trypsinised and re-suspended in cold PBS at the confluency of 1x106 cells/100 μl. Then, 
both cell lines were sorted and collected using the BD FACSAriaTM III (BD Biosciences, 
US). This was achieved by plotting the data onto a dot plot SSC-A vs PE (575 nm) that 
allowed gating each cell line according to the presence of absence of the red dye 
followed by its sorting.  
6.2.5 Generation of IDO1 Knockdown 
HMVECad cells were seeded in pre-coated 6-well plates with attachment factor 
at the density of 200,000 cells/well. The medium used here was supplemented with IFNγ 
(10ng/mL). After 16 hours, the medium was removed, cells were washed twice with PBS 
and 1 mL of the siRNA/ Lipofectamine mix containing the IDO1 targeting siRNA or the 
non-targeting siRNA (control), was added to the respective well (full protocol described 
in the section 2.5). An additional 1 mL of endothelial medium was added to each well 6 
hours later. 24 hours after transfection cells were trypsinised and seeded onto pre-coated 
24-well plates at the density of 200,000 cells/ well. Cells were cultured for 24 hours, 
medium and RNA was extracted for subsequent analysis.  
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6.2.6 TSP1 experiments 
In order to assess whether TSP1 in the medium regulates its own expression in 
endothelial cells, 200,000 HMVECad cells were seeded in pre-coated 24-well plates with 
attachment factor. In the first experiment, the medium was removed in half of the wells, 
cells washed with PBS and fresh medium was added. RNA was extracted at 0.5, 1, 3, 6, 
12 and 24 hours after the medium was renovated (fresh medium group), RNA was also 
extracted at the same time points in wells that the medium was not renovated 
(unchanged medium group).  
In the second experiment, the medium was removed, cells washed twice with 
PBS and 1 mL of fresh medium supplemented with TSP1 (100 ng/mL) or BSA was added 
to the wells. RNA was extracted 3 hours after treatment.  
6.2.7 RNA isolation, cDNA synthesis and qPCR 
The expression of TDO, IDO1, IDO2, TSP1 and IFNγ was analysed by qPCR in 
the samples generated as described in the sections 6.2.2, 6.2.3, 6.24, 6.2.5 and 6.2.6. 
RNA was isolated using the TRI reagent kit, the detailed protocol is described in the 
section 2.3.1, followed by the generation of cDNA by reverse transcription PCR, as 
described in the section 2.3.3 Quantitative PCR was then performed as described in the 
section 2.3.4 and data was normalised to GAPDH. 
6.2.7 Protein extraction and Western blotting 
IDO1 protein levels were assessed in the samples generated in the section 6.2.3 
and 6.2.5. Protein was isolated as described in the section 2.4.1 and protein detection 
was assessed by western blotting, the full protocol described in the section 2.4.3. The 
intensity of the signal was measured by ImageJ software ((National Institutes of Health, 
USA). Data was normalised to GAPDH.  
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6.2.8 ELISA 
Kynurenine and TSP1 concentrations were assessed in the media generated in 
the sections 6.2.3. The media from those experiments were collected and centrifuged at 
1,700 ×g for 5 minutes before being used in the assay. The ELISA protocol for TSP1 and 
kynurenine is fully described in the sections 2.4.5. 
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6.3 Results 
6.3.1 Nutrient deprivation induces IFNγ expression in MDA-MB-231 cells 
potentially leading to endothelial IDO1 expression 
In chapter V it was demonstrated that breast cancer cells could directly induce 
endothelial IDO1 expression, which was further enhanced when breast cancer cells were 
under low glucose conditions. These experiments also showed that IDO1 expression in 
endothelial cells was stimulated by cancer cells via soluble factors. This subchapter aims 
to evaluate whether IFNγ plays a role in this molecular mechanism.  
To assess this question, I investigated IFNγ expression in MDA-MB-231 cells 
under standard conditions, namely with glucose at 5.5 mM and under low glucose 
conditions (glucose at 1 mM). IFNγ expression was also assessed in MCF10A cells as 
a non-aggressive mammary epithelial cell control. While there was no difference in the 
IFNγ expression between MCF10A cells and MDA-MB-231 under standard conditions, 
IFNγ was significantly increased in MDA-MB-231 cells when cultured in low glucose, as 
shown in Figure 27 A.  
IFNγ treatment induced a significant increase of IDO1 expression in endothelial 
cells, but did not change the expression of TDO and IDO2 (Figure 27 B). Endothelial 
cells also significantly increased IDO1 protein level when treated with IFNγ (Figure 27 
C).  
My data and others have shown that endothelial cells induce breast cancer 
dormancy (Ghajar et al., 2013). This lead to additional hypothesis in this study, that IFNγ 
may be involved in the molecular mechanism that breast cancer cells use to overcome 
this situation. For that reason, IFNγ mRNA was assessed in MDA-MB-231 cells after 48 
hours of co-culture with endothelial cells. Quantitative analysis of gene transcript showed 
that IFNγ expression was significantly decreased in MDA-MB-231 cells when cultured 
with endothelial cells (Figure 27 D).  
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In order to analyse whether IFNγ concentration induces a dose-dependent IDO1 
expression and IDO1 enzymatic activity, endothelial cells were treated with a range of 
IFNγ concentration for 48 hours. IFNγ treatment induced endothelial cells to synthesise 
IDO1 protein, but the level of protein induced by the different IFNγ concentrations was 
not statistically different (Figure 28 A). The same result was observed when IDO1 activity 
was evaluated by measuring kynurenine concentration in the medium (Figure 28 B).  
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Figure 27: IFNγ indices IDO1 expression in endothelial cells. A- MDA-MB-231 
significantly increased IFNγ expression when cultured in low glucose medium (LGM). 
B- Endothelial IFNγ (10 ng/mL) treatment induced an increase in IDO1 mRNA, but not 
TDO nor IDO2. C- IFNγ (10 ng/mL) treatment also induced an increase in IDO1 protein 
by endothelial cells. D- Interestingly, IFNγ expression by MDA-MB-231 cells was 
reduced when in co-culture with endothelial cells. N=3, bars are mean±S.E.M. Student 
t-test and One-way ANOVA were used to analyse any statistical differences between 
the groups. *P˂0.05, **P˂0.01, ***P˂0.001.
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Figure 28: IFNγ induces endothelial IDO1 which is enzymatically active. A- IFNγ 
stimulated IDO1 expression in endothelial cells. B- IFNγ induced an increase in 
kynurenine in the endothelial medium which was assessed by ELISA. IFNγ treatment 
was for 48 hours. N=3, bars are mean±S.E.M. One-way ANOVA was used to analyse 
any statistical differences between the groups. *P˂0.05, **P˂0.01, ***P˂0.001, 
****P˂0.0001.
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6.3.2 Endothelial IDO1 decreases TSP1 secretion  
The main part of my hypothesis is that breast cancer cells induce a decrease in 
endothelial TSP1 secretion via IDO1. My data suggested that IFNγ is a possible 
intermediate between cancer cells and endothelial cells. IFNγ is upregulated in cancer 
cells under low glucose, leading to induction of IDO1 expression and tryptophan 
degradation in endothelial cells. In the chapter V I presented that tryptophan limits 
endothelial TSP1 synthesis/secretion. It was logical for me to evaluate whether IFNγ is 
able to induce a decrease in TSP1 secretion by endothelial cells.  
When endothelial cells were cultured with IFNγ (10 ng/mL) for 48 hours, the 
amount of secreted TSP1 were reduced by about 50%, compared with that by control 
endothelial cells with IFNγ (Figure 29 A). The next step of my investigation was to 
determine whether IFNγ induced a decrease in TSP1 via IDO1. IDO1 expression 
stimulated by IFNγ was successfully knockdown by siRNA (Figure 29 B), but kynurenine 
concentration was not decreased (Figure 29 C), showing that the degradation of 
tryptophan was not inhibited. Thus, I went to assess the expression of TDO and IDO2 in 
the IDO1 knockdown endothelial cells. My data showed that TDO was significantly 
increased, but not IDO2 (Figure 29 D), suggesting that TDO might be increased to 
compensate the lack of IDO1 in endothelial cells upon IFNγ stimulation.  TDO 
compensation during IDO1 knockdown is an interesting novel finding. However, this 
finding leads to another layer of complexity for dissection of whether IFNγ induces a 
decrease in endothelial TSP1 protein levels via IDO1 enzyme activity. In order to 
circumvent this difficulty, I performed QPCR analysis of TSP1 expression in endothelial 
cells treated by IFNγ. Intriguingly, TSP1 mRNA was found to significantly increase in the 
endothelial cells after IFNγ treatment when compared to untreated counterparts (Figure 
30 A). Taking together, IFNγ induces a decrease in TSP1 protein secretion but an 
increase in the TSP1 mRNA, suggesting that the effect of IFNγ on TSP1 protein is at the 
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translational level. This hypothesis is also supported by the previous chapter that showed 
that tryptophan limits TSP1 secretion in endothelial cells.  
Further experiments investigated whether the TSP1 protein in the medium could 
regulate TSP1 expression in endothelial cells. Endothelial cells were cultured for 16 
hours, and then the medium was changed or left unchanged. The purpose of this 
experiment was to remove TSP1 from the medium and verify the absence of the 
activation of receptors by TSP1 on TSP1 expression. Endothelial TSP1 mRNA was 
significantly increased 1, 3 and 6 hours after the medium was changed, when compared 
to cells which the medium was not changed (Figure 30 B). In another experiment, TSP1 
mRNA was significantly reduced in endothelial cells that were cultured with human 
recombinant TSP1 (100 ng/mL) for 3 hours. Taking together, this set of experiments, 
suggest that extracellular TSP1 negatively regulates its own expression in endothelial 
cells. This finding explains the increase in TSP1 mRNA upon IFNγ treatment which led 
to a decrease in TSP1 protein. 
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Figure 29: IFNγ decreases endothelial TSP1 synthesis. A- IFNγ induced a decrease 
in TSP1 synthesis by endothelial cells. B- IDO1 knockdown proof by western blot. C- L-
Kynurenine level in IDO1 knockdown endothelial cells. D- IDO1, IDO2 and TDO mRNA 
quantification in endothelial cells stimulated with IFNγ (10 ng/mL) upon IDO1 
knockdown. N=3, bars are mean±S.E.M. Student t-test and One-way ANOVA were 
used to analyse any statistical differences between the groups. *P˂0.05, **P˂0.01, 
****P˂0.0001, n.s. non-significant.
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Figure 30: Endothelial cells upregulate TSP1 mRNA when treated with IFN-γ for 
48 hours. TSP1 protein inhibited TSP1 mRNA expression by endothelial cells. 
Endothelial cells were cultured for 24 hours and then in one group, medium was not 
changed and in the second group, medium was changed. TSP1 mRNA was measured 
over-time. Also TSP1 mRNA was measured 3 hours after cultured with TSP1 (100 μM) 
or BSA. N=3, bars are mean±S.E.M. Student t-test and One-way ANOVA were used to 
analyse any statistical differences between the groups. *P˂0.05, **P˂0.01, ***P˂0.001, 
****P˂0.0001.
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6.4 IFNγ also triggers IDO1 protein synthesis in a non-tumorigenic breast 
cell line and in a lung epithelial cell line  
The above experiments suggest that IFNγ might be the molecule secreted by 
breast cancer cells that induce IDO1 expression in endothelial cells. It is worth to note 
that a cytokine secreted by cancer cells might not just target endothelial cells. For that 
reason, it is important to assess the impact of IFNγ on other cells within the tumour 
microenvironment or micrometastasis niche, especially in the induction of IDO1 
expression.  
IFNγ did not increase IDO1 protein level in breast cancer cell lines, MCF7 and 
MDA-MB-231 cells (Figure 31 A). Interestingly, the IDO1 protein was significantly 
increased upon IFNγ treatment in a non-tumorigenic breast cells line, MCF10A (Figure 
31 A). IFNγ also induced an increase in the IDO1 protein level in an epithelial lung cell 
line (Figure 31 B).  
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Figure 31: The effect of IFNγ on breast cells and lung epithelial cells. A- IFNγ 
(10ng/mL) induced IDO1 expression in MCA-10A but not in MCF7 nor MDA-MB-231 
cells. B- IFN-γ also induced IDO1 expression in lung epithelial cells. IFNγ treatment 
was over 48 hours. N=3, bars are mean±S.E.M. Student t-test was used to analyse any 
statistical differences between the groups. ***P˂0.001, ****P˂0.0001. 
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6.4 Discussion 
Once cancer cells escape the quiescence state called cancer cell dormancy, it 
reaches another dormancy phase called tumour mass dormancy. This estate is 
characterised by proliferating cells and apoptotic cells that are highly dependent on 
oxygen and nutrients availability. For the micrometastasis to overcome the lack of 
nutrients and oxygen, it has to trigger angiogenesis (Aguirre-Ghiso, 2007).  
It was shown in the previous chapter that the medium generated by breast cancer 
cells under low glucose induced a higher IDO1 expression in endothelial cells, 
suggesting that a soluble factor secreted by the cancer cells might be in the origin of the 
endothelial IDO1. The promoter region of IDO1 contain 3 IFNγ-activated sites (Robinson 
et al., 2006) and this cytokine has been described to be the most powerful inductor of 
IDO1 in vitro and in vivo (Gough et al., 2008; Jeong et al., 2009). The present study has 
clearly demonstrated that expression of IFNγ is significantly increased in the breast 
cancer cells cultured under low glucose conditions. Another independent study by Voss 
and colleagues supports this finding. It showed that breast cancer cell lines, MCF7 and 
MDA-MB-435, release IFNγ under hypoxia, although at very low levels (Voss et al., 
2011). The same study showed that MDA-MB-231 secrete IL-8 and IL-6, also both stimuli 
of IDO1 expression, in much higher concentrations (Voss et al., 2011). Interestingly, IFNγ 
inhibited proliferation of MCF7 and MDA-MB-231 cells when growing in monolayer, but 
it did not affect MDA-MB-231 anchorage-independent growth in an agar growth assay 
(Gooch et al., 2000). This suggests that this cytokine is secreted by a range of breast 
cancer cell lines under hypoxia conditions, but might have an adverse effect on less 
aggressive breast cancer cell lines.  
Although IFNγ is a strong stimulus of IDO1, the IDO1 driven factor(s) in tumours 
is still debatable. IDO1 expression is thought to be due to the generalised inflammation 
that is present in many tumours (Spranger et al., 2013; Taube et al., 2012; Théate et al., 
2015; Tumeh et al., 2014), but there are a few subtypes of tumours that express IDO1 in 
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the absence of inflammation (Théate et al., 2015; Uyttenhove et al., 2003). The 
expression pattern and the expression regulation of IDO1 in endothelial cells are even 
less understood. In some tumours, such as kidney cancer, IDO1 is almost restricted to 
endothelial cells (Riesenberg et al., 2007), suggesting a tissue- specific molecular 
mechanism to induce endothelial IDO1.  
It was shown here that IFNγ could induce IDO1 expression in endothelial cells, a 
finding supported by other authors (Wang et al., 2010). Importantly, IFNγ induced a 
similar level of IDO1 protein and enzymatic activity at low (10 ng/mL) and high (1000 
ng/mL) concentration in endothelial cells. This suggests that IFNγ is a potent stimulus of 
endothelial IDO1 and very low levels of this cytokine might be enough to trigger IDO1 
expression and tryptophan degradation.  
As shown in Chapter V, tryptophan concentration limits TSP1 secretion by 
endothelial cells and it was also demonstrated that breast cancer cells can directly induce 
IDO1 expression and tryptophan degradation in endothelial cells. Furthermore, IFNγ 
induced a decrease in TSP1 secretion by endothelial cells, supporting the initial 
hypothesis that IDO1, by degrading tryptophan, restricts endothelial TSP1 synthesis and 
secretion. Although IFNγ did not change the expression of the other 2 tryptophan 
degrading enzymes, TDO and IDO2, the expression of TDO was significantly increased 
when IDO1 was knockdown, which would allow sustained the level of tryptophan 
degradation in the cells. A previous study has shown that IDO2 was upregulated in the 
epididymis of IDO1 deficient mice, a tissue that would otherwise constitutively expresses 
IDO1 (Fukunaga et al., 2012), indicating that IDO2 might have a functional redundancy 
with IDO1. It suggests that TDO might compensate for an IDO1 deficiency in IFNγ 
stimulated- endothelial cells.  
As demonstrated in Chapter IV endothelial cells induce breast cancer cell cycle 
arrest, and here it was shown a possible molecular mechanism led by IFNγ to overcome 
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that situation. Interestingly, endothelial cells induced a decrease in IFNγ expression by 
breast cancer cells, which might be another way of endothelial cells to maintain breast 
cancer cells under dormancy. 
Here, it was established that extracellular TSP1 protein modulates TSP1 
expression in endothelial cells, working as an auto-inhibitory feedback possibly to control 
the level of TSP1 in the extracellular matrix. It is worth noting that IFNγ increased 
endothelial TSP1 mRNA level, which can be explained by the TSP1 negative feedback. 
It also suggests that the IFNγ effect on TSP1 secretion is not at the transcriptional level 
corroborating the idea that TSP1 decrease is due to a lack of tryptophan followed an 
IDO1 increase.  
As IFNγ is secreted into the extracellular matrix it can target many cell types. In 
Chapter III, IDO1 was visualised in stromal cells but also in cancer cells, however, IFNγ 
did not induce a detectable amount of IDO1 protein in MCF7 and MDA-MB-231 cells. 
This result could indicate that IDO1 in breast cancer cells is stimulated by other 
cytokines, such as IL-6, or it requires a genetic mutation and Bin1 inactivation has been 
implicated in overexpression of IDO1 in a tumour (Jia et al., 2015). Surprisingly, IFNγ 
induced a strong IDO1 signal in a non-carcinogenic breast cell line (MCF10A) and a 
weak signal in an epithelial lung cell line. This could suggest an important role of IDO1 
expression in the normal tissue surrounding the cancer cells or even stablishing pre-
metastatic niches, which could lead to a decrease of tryptophan in the tumour 
microenvironment. Clearly, the importance of this interesting observation would have to 
be further evaluated in larger and more sophisticated studies. However, as it stands, this 
data has shed light on the immune resistance of cancer cells and the induction of 
angiogenesis during cancer progression.  
Taken together, this chapter shows that IFNγ is involved in the upregulation of 
endothelial IDO1 induced by breast cancer cells under low glucose. Here it was also 
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demonstrated that IFNγ is capable of decreasing TSP1 synthesis in a transcriptional 
independent manner, supporting the results from the previous chapter that showed that 
tryptophan concentration limits TSP1 secretion. In the context of cancer dormancy, IFNγ 
appears to be a central cytokine in the molecular mechanism employed by cancer cells 
to overcome dormancy.  
This study thus indicates that when breast cancer cells are under stress, they 
secrete IFNγ, which in turn induces a decrease in endothelial TSP1 via IDO1. Although 
this mechanism has to be further validated in in vivo studies, these early findings have 
an alarming implication once IFNγ is considered as a potential therapeutic tool in cancer 
treatment. Although IFNγ has been successfully used during viral infection, its application 
in cancer therapy has been lagging. This is largely due to the significant concerns raised 
in recent years that whilst IFNγ is able to induce certain anti-cancer immune response, 
it has demonstrated effect on the stimulation of cancer cells to grow, regrowth and 
metastasise (Zaidi and Merlino, 2011). The findings from the present study certainly add 
more weight to this growing concern.  
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Chapter VII: General conclusion 
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Metastasis remains the main challenge for patients and oncologists alike (Uhr 
and Pantel, 2011). For patients with breast cancer, their prognosis is a great deal better 
when the tumour is detected at an early stage, however their clinical outcome become 
poorly when either diagnosed at a later stage or with metastasis (Cardoso et al., 2009). 
Another challenge is that about 10% of breast cancer patients who did not present 
metastasis at the diagnosis stage develop metastasis years or decades after cancer 
treatment (Noh et al., 2011). This phenomenon can be explained by the fact that 
metastatic cancer cells from the primary lesion   undergo a period of dormancy before 
the manifestation of metastasis (Aguirre-Ghiso, 2007). Current cancer therapies seem 
inefficient to eliminate these cells (Goss and Chambers, 2010). 
The dissemination of cancer cells from the primary tumour to other parts of the 
body can begin at an early stage and in many cases micrometastasis and/or metastasis 
would already occur at the diagnosis stage (Klein, 2011; Klein et al., 2002). No current 
therapeutic strategy is available to prevent it from happening. Therefore, a better 
understanding of tumour dormancy and the mechanism behind it will allow scientists to 
develop better drugs to eliminate dormant cancer cells or to keep them dormant.  
This study aimed to evaluate the role of TSP1 in breast cancer dormancy and a 
potential molecular mechanism via IDO1, which might be employed by dormant cancer 
cells to trigger the outgrowth of metastasis.  
7.1 TSP1 induces breast cancer dormancy 
TSPs are extracellular matrix proteins that do not work as structural proteins, 
rather exert their functions by interacting with and modulating other proteins in the 
extracellular matrix, or activating cell surface receptors (Chen et al., 1996; Cockburn and 
Barnes, 1991; Greenaway et al., 2007; Gupta et al., 1999). TSP1 was first detected in 
platelets (Lawler et al., 1978). Sequentially, TSP1 has been found synthesised and 
secreted by non-platelet cells including endothelial cells, cancer cells, smooth muscle 
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cells, macrophages, fibroblasts and others (Naganuma et al., 2004; Wight et al., 1985). 
In early years, TSP1 was recognised as an anti-angiogenic protein controlling tumour 
growth and progression (Good et al., 1990). Moreover, the levels of TSP1 in the lung or 
bone are correlated with the metastatic potential of melanoma and prostate cells (Catena 
et al., 2013; El Rayes et al., 2015), suggesting that TSP1 might be a key molecule in 
metastasis initiation.  
Ghajar et al. showed that the dormant disseminated tumour cells were located in 
the perivascular niche of the organs (lung, bone marrow and brain) and that in vitro stable 
endothelial tubules exerted an anti-proliferation effect on breast cancer cells (Ghajar et 
al., 2013). These authors concluded that the endothelium induces dormancy of individual 
disseminated cancer cells with TSP1, found rich in tissue (including tumour tissue) 
microenvironments. In the present study, immunohistochemistry analysis of a tissue 
microarray revealed that the stromal TSP1 expression is inversely correlated with the 
increased malignance of the invasive breast carcinoma. Higher stromal TSP1 also 
suggests a possible survival benefit, but further confirmation is needed. Another study 
showed that colorectal patients that presented high levels of TSP1 in the primary tumour 
were less likely to have lymph node metastasis (Iddings et al., 2007).  
Here, in vitro experiments further demonstrated by that endothelial cells induce 
cell cycle arrest in the G0/G1 phase of breast cancer cells. The cell cycle arrest induced 
by endothelial cells was not due to senescence, suggesting that endothelial cells might 
induce a quiescent state which is a better fit for cellular dormancy. An increased 
concentration of TSP1 had also an anti-proliferative effect on cancer cells, which is 
consistent with the findings by Ghajar and colleagues that TSP1 induce breast cancer 
dormancy. The majority of chemotherapeutic drugs fails in eliminating individual dormant 
cell (Mitchison, 2012). Pre-culturing breast cancer cells with TSP1 conferred an 
advantage of survival in the presence of docetaxel, a commonly used druf in breast 
cancer treatment. Chemoresistance of the dormant cancer cells has been attributed 
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mainly to the fact that these drugs target high proliferative cells and have little or no effect 
on slow and non-proliferative cancer cells (Mitchison, 2012). Interestingly, TSP1 induced 
breast cancer cells to express CYP3A5, an enzyme involved in the metabolism of 
docetaxel. This would suggest that TSP1 has a direct protective effect against the toxicity 
of a chemotherapy drug, such as docetaxel. Weng et al. also showed that dendritic cells 
efficiently protected cancer cells against the immune system via secretion of TSP1 
(Weng et al., 2014).  
Taken together, TSP1 may be involved in all types of cancer dormancy: cellular 
dormancy, angiogenic dormancy and immune-mediated dormancy, making TSP1 a 
potential key molecule in spread and regrowth of metastatic breast cancer. Even though 
the elevation of TSP1 levels in organs such as lung, brain and bone seems to be a good 
strategy of preventing the relapse of breast cancer, the story has not been a straight 
forward one, as with many other molecules involved in cancer. In this case, it has been 
recognised that TSP1 exerts diverse effects on a wide range of cell receptors, including 
CD47 (integrin associated protein, IAP), CD36 (FAT) and Gabapentin receptor 
alpha2delta-1. For example, TSP1 has been shown to promote tumour progression 
(Incardona et al., 1995; Yee et al., 2009), Identification of molecular pathways related to 
the diversity of TSP1 cellular functions, including   cancer dormancy, drug resistance or 
the escape from the immune system are essential for targeting the TSP1 downstream 
signalling pathway to reduce unwanted adverse-effects.  
7.2 The role of IFNγ-IDO1- TSP1 pathway in the outgrowth of 
metastasis from dormant breast cancer cells 
IDO1 is an intracellular enzyme that degrades L-tryptophan and overexpressed 
in many tumour types, such as breast cancer, prostatic cancer and colorectal cancer 
(Munn et al., 2004; Munn et al., 2002; Uyttenhove et al., 2003). Within a solid tumour, 
IDO1 has been detected in cancer cells, but also in macrophages (Munn et al., 2004; 
Munn et al., 2002; Uyttenhove et al., 2003) and endothelial cells (Riesenberg et al., 
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2007). The main function of IDO1 in tumours is believed to protect cancer cells against 
the immune system by producing a lack of L-tryptophan in the tumour microenvironment 
(Prendergast et al., 2010). Thus, high IDO1 enzymatic activity correlates with poor 
prognosis in many cancer types, including breast cancer (Astigiano et al., 2005; 
Brandacher et al., 2006; Chen et al., 2014; Inaba et al., 2010; Inaba et al., 2009; Ino et 
al., 2006; Jia et al., 2015; Okamoto et al., 2005; Pan et al., 2008; Speeckaert et al., 2012; 
Suzuki et al., 2010; Urakawa et al., 2009; Wainwright et al., 2012; Yu et al., 2013; Yu et 
al., 2011).  
L-tryptophan is the rarest essential amino acid in mammalians and it is thought 
to work as a rate-limiting amino acid in protein synthesis (Cortamira et al., 1991; Wurtman 
et al., 1980). Tryptophan availability is mainly regulated by its absorbance from the blood 
and its catabolism, for instance by IDO1.  
Here, the immunohistochemistry analysis of a tumour tissue array of invasive 
breast carcinomas revealed the presence of vascular IDO1 staining in the majority of the 
samples. Interestingly, the vascular IDO1 staining was negatively correlated with the 
stage of the tumour, which might suggest that IDO1 is more important in the early 
development of the tumour. This assumption agrees with another study that shows that 
vascular IDO1 was only present in newly formed vessels in renal cell carcinoma 
(Riesenberg et al., 2007).  
The analysis of the amino acid sequence of TSP1 revealed a higher percentage 
of tryptophan than the average protein. Interestingly, in vitro co-culture experiments and 
conditioned medium experiments showed that breast cancer cells induce an increase in 
IDO1 expression in endothelial cells. The conditions obtained from low glucose culture 
of breast cancer cells enhanced endothelial IDO1 expression. These findings are 
potentially related to cancer dormancy, since disseminated breast cancer cells have 
been found near microvessels (Ghajar et al., 2013). Disseminated tumour cells might be 
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able to induce vascular IDO1 and cause a local decrease in L-tryptophan.  Low 
tryptophan limited the amount of TSP1 secreted by endothelial cells, which was further 
supported by the immunohistochemistry data that showed an inverse correlation 
between vascular IDO1 and stromal TSP1. Furthermore, low vascular IDO1 in the 
primary tumour was found to have a potential trend towards an improved overall survival. 
Interestingly, low tryptophan increased VEGF secretion by breast cancer cells. 
Taking together, these results suggest that disseminated dormant tumour cells 
near microvessels might be capable of inducing vascular IDO1, leading to a decrease in 
the extracellular concentration of TSP1 alongside with an increase in VEGF. Although 
these findings need further confirmation, the results of this thesis provide a potential 
mechanism that dormant breast cancer cells use to overcome the inhibitory effect of the 
vascular TSP1.  
IFNγ is known to be the most potent stimulus of IDO1 (Gough et al., 2008; Jeong 
et al., 2009). This connection was confirmed in the present study that IFNγ induces a 
strong IDO1 signal in endothelial cells. Although IDO1 signal was observed in the cancer 
cells of the primary tumour, in the in vitro assay in the present study, IFNγ did not 
increase IDO1 protein in breast cancer cells. This might indicate that endothelial cells 
are more responsive to IFNγ and that IDO1 observed in cancer cells in the primary 
tumour might be induced by other molecules. As described above, the low glucose-
conditioned medium from breast cancer cells induced a stronger IDO1 signal in 
endothelial cells. The analysis of gene expression in breast cancer cells showed that 
IFNγ mRNA was upregulated under low glucose condition. The results here suggest that 
IFNγ is the molecule responsible for the increase of vascular IDO1 in this situation. It 
was also shown here that IFNγ induced a weak signal in epithelial lung cells, indicating 
a possible role of IDO1 in the normal tissue during the metastatic process. Interestingly, 
IFNγ induced a strong IDO1 signal in non-tumorigenic breast cells (MCF10A), which 
agrees with the tissue array analysis that showed a strong IDO1 staining in the adjacent 
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tissue. This might suggest that the adjacent normal breast tissue might help tumour cells 
to create a lack of tryptophan in the tumour microenvironment in order to increase the 
immune protection or even to increase angiogenesis.  
7.3 Summary – the proposed mechanism 
As a whole, the work presented here provides evidences for a non-canonical role 
of the IFNγ-IDO1-TSP1 pathway for breast cancer cells to evade from tumour dormancy, 
as shown in Figure 32. First, breast cancer cells, in part via IFNγ, induce vascular IDO1 
expression leading to tryptophan degradation. Second, the reduction in tryptophan limits 
TSP1 synthesis and secretion, which gradually results in a reduction of TSP1 in the 
perivascular niche. The deprivation of TSP1 in the microenvironment permits cancer 
cells to evade cellular dormancy. Once a micrometastasis is formed, a stress conditions, 
such as lack of nutrients and oxygen, would induce cancer cells secreting more IFNγ, 
which in turn results in high vascular IDO1 expression and tryptophan degradation. A 
significant reduction in TSP1 synthesis alongside an increase in VEGF secretion by 
cancer cells may be sufficient to trigger angiogenesis. These collectively trigger the 
outgrowth of the metastasis.   
7.3 Future work 
Although the findings in this thesis are novel, there are a number of shortfalls and 
new directions that can be tested in future studies.  
1. In vivo tumour models: some of the key findings from the study would benefit from 
validation experiments using in vivo tumour models. Key questions to answer include 
whether vascular IDO1 is induced near dormant breast cancer cells, whether the 
vascular IDO1-inducedthe deprivation of L-tryptophan is sufficient, to reduce TSP1 in the 
dormant niche. Another important point is to determine whether this TSP1 regulation 
pathway occurs in the all organs vulnerable to breast cancer metastasis and is employed 
by all breast cancer subtypes. Several experimental strategies can be valuable to get 
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answers to the questions raised above, such as IFNγ knockout breast cancer cells, 
IDO1/TSP1 knockout mice or drugs that modulate the expression or activity of those 
molecules.  
2. The analysis of human samples in a larger and most focused cohort is also a useful 
approach. This would include a large number of the patients supported by a longer follow 
up and potentially primary/secondary tumour pairs. This would allow a firm conclusion 
drawn between IDO1/TSP1/IFNγ and patient’s outcome including metastasis and 
analysis of organ trophic nature of the microenvironment associated these molecules, 
namely if those tumours destined for a specific organ have a specific pattern of these 
molecule expression.  
3. The study of dormant single cancer cells is challenging and requires the development 
of new technology and techniques. The single-cell sequencing may be a powerful tool in 
investigating the importance of rare cells in tumour progression (Navin, 2015).  
Finally, the current work also showed that TSP1 increased the survival of cancer 
cells to docetaxel, which might be due to an increase in the expression of CYP3A5, an 
enzyme involved in the metabolism of docetaxel. This finding is promising but needs 
further in vitro and in vivo confirmation.  
7.4 Clinical implications 
The identification of a non-canonical IFNγ-IDO1-TSP1 pathway that drives breast 
cancer cells to evade tumour dormancy might contribute to better understand this 
phenomenon. The manipulation of the expression or activity of any of key molecules in 
this pathway might help to delay or prevent the relapse of metastasis. It might also allow 
to develop strategies to sensitise dormant cancer cells to therapy.  
IFNγ was initially identified to play a significant role in the detection and 
elimination of tumour cells as well as enhancing tumour cell immunogenicity (Pestka et 
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al., 2004). Thus, IFNγ has been tested as an anti-cancer therapy. However, this cytokine 
has also demonstrated to have pro-tumorigenic effects (Bernabei et al., 2001; Bröcker 
et al., 1988; Gorbacheva et al., 2002) and has caused some significant concerns (Zaidi 
and Merlino, 2011). Here, the results have firmly demonstrated that IFNγ induces 
vascular IDO1. Together with the concerns in the literature, this strongly argues that IFNγ 
may indeed trigger the development of metastasis from disseminated and dormant 
tumour cells. For this reason, it is strongly suggested that the efficacy and safety of IFNγ 
for cancer treatment must be carefully considered and counter measures for the 
unwanted side effect will have to be sought if IFNγ is to be used in these patients.   
Another medical challenge in oncology is to detect metastasis at the beginning of 
their development or to evaluate at diagnosis stage whether that patient will develop late 
metastasis. Currently, it is not possible to predict the risk of late recurrence or to know 
which dormant cancer cells or micrometastasis are going to generate a full scale 
metastasis. Thus, there is a medical need to find markers that help to predict metastasis 
formation. Two proteins, MYC and Ras, have shown to affect dormancy by regulating 
genes involved in angiogenesis, which make them promising dormancy markers 
(Watnick et al., 2003).  
If the molecular mechanism described in this study is further validated, it would 
open the prospect of using the levels of L-tryptophan or L-kynurenine in the blood as a 
marker for metastasis initiation or even as an early sign of cancer dormancy evasion. 
This would of course need a rather large and carefully devised clinical trial.  
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Figure 32: Proposed molecular mechanism for breast cancer dormancy evasion. A- Breast cancer cells remain near microvessels, a 
TSP1 rich microenvironment which induces cell cycle arrest of cancer cells. B- Breast cancer cells induce vascular IDO1 expression, 
which leads to a decrease in TSP1 synthesis and secretion overtime, allowing cancer cells to proliferate. C- Once cancer cells form a 
micrometastasis, the cells in the centre of the micrometastasis are under stress due to the lack of oxygen and nutrients. Those cells 
increase the secretion of IFNγ increasing even further vascular IDO1 leading to a more dramatic decrease of TSP1 in the 
microenvironment. IFNγ also induces IDO1 expression in other cell types, such as lung epithelial cells, within the tumour 
microenvironment. The lack of L-tryptophan caused by IDO1 induces also an increase in the secretion of VEGF by cancer cells. The 
decrease of TSP1 and an increase in VEGF may trigger angiogenesis allowing the outgrowth of the metastasis.  (MV environm.: 
microvessel environment; vIDO1: vascular IDO1; mTSP1: microenvironment TSP1).
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Appendix I: Breast cancer patient’s clinical data. 
Number 
of sample 
Pathology diagnosis Age TNM Grade 
1 Invasive ductal carcinoma 64 T1N0M0 G2 
2 Invasive ductal carcinoma 48 T1N0M0 G3 
3 Invasive ductal carcinoma 56 T1N0M0 G2-G3 
4 Invasive ductal carcinoma 58 T1N0M0 G2 
5 Invasive ductal carcinoma 36 T1N0M0 G3 
6 Invasive ductal carcinoma 42 T1N1M0 G3 
7 Invasive ductal carcinoma 48 T1N1M0 G3 
8 Invasive ductal carcinoma 59 T1N1M0 G2 
9 Invasive ductal carcinoma 70 T2N0M0 G3 
10 Invasive ductal carcinoma 37 T2N0M0 G2 
11 Invasive ductal carcinoma 70 T2N0M0 G2 
12 Invasive ductal carcinoma 50 T2N0M0 G2 
13 Invasive ductal carcinoma 42 T2N0M0 G2 
14 Invasive ductal carcinoma 63 T2N0M0 G2 
15 Invasive ductal carcinoma 50 T2N0M0 G2 
16 Invasive ductal carcinoma 49 T2N0M0 G3 
17 Invasive ductal carcinoma 68 T2N0M0 G2 
18 Invasive ductal carcinoma 53 T2N0M0 G2 
19 Invasive ductal carcinoma 46 T2N0M0 G3 
20 Invasive ductal carcinoma 77 T2N0M0 G3 
21 Invasive ductal carcinoma 63 T2N0M0 G3 
22 Invasive ductal carcinoma 52 T2N0M0v G3 
23 Invasive ductal carcinoma 71 T2N1M0 G1 
24 Invasive ductal carcinoma 72 T2N1M0 G2 
25 Invasive ductal carcinoma 56 T2N1M0 G2 
26 Invasive ductal carcinoma 56 T2N1M0 G2 
27 Invasive ductal carcinoma 34 T2N1M0 G3 
28 Invasive ductal carcinoma 55 T4N0M0 G3 
29 Invasive ductal carcinoma 52 T2N0M0 G2 
30 Invasive ductal carcinoma 60 T3N0M0 G3 
31 Invasive ductal carcinoma 47 T2N2M0 G3 
32 Invasive ductal carcinoma 41 T3N1M0 G3 
33 Invasive ductal carcinoma 42 T3N2M0 G3 
34 Invasive ductal carcinoma 77 T4N2M0 G2 
35 Invasive ductal carcinoma 46 T3N3M0 G2 
36 Invasive ductal carcinoma 53 T3NxM0 G2 
37 Invasive ductal carcinoma 46 - G2 
38 Invasive ductal carcinoma 42 T2NxM0 G2 
39 Invasive ductal carcinoma - - G2 
40 Invasive ductal carcinoma 52 - G2 
41 Invasive ductal carcinoma 53 - G2 
42 Invasive ductal carcinoma - T?N0M? G2-G3 
43 Invasive ductal carcinoma - - G3 
44 Invasive ductal carcinoma - - G2-G3 
45 Invasive ductal carcinoma 54 T1NxMx G3 
46 Invasive ductal carcinoma 79 T1NxMx G2 
47 Invasive ductal carcinoma 74 T2NxMx G3 
48 Invasive ductal carcinoma - - G3 
49 Invasive ductal carcinoma 52 T2NxMx G3 
50 Invasive ductal carcinoma 57 T2NxMx G3 
51 Invasive ductal carcinoma 50 T2NxMx G2 
52 Ductal carcinoma and lobular 
carcinoma 
43 - G2 
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Appendix II: Breast cancer patient’s clinical data.  
IDC: invasive ductal carcinoma, NC: neuroendocrine carcinoma, MC: medullary carcinoma, 
MIDC: metastasis invasive ductal carcinoma, LN: lymph node, NAT: normal adjacent tissue 
Number of 
sample 
Age Organ Pathology 
diagnosis 
TNM Grade Stage Type 
1  53  Breast  IDC T3N0M0  2  IIB  Malignant  
2  44  Breast  IDC T2N0M0  1  IIA  Malignant  
3  63  Breast  IDC T4N0M0  2  IIIB  Malignant  
4  41  Breast  IDC T2N0M0  1--2  IIA  Malignant  
5  43  Breast  IDC T1N0M0  2  I  Malignant  
6  44  Breast  IDC TicA0M0  1  I  Malignant  
7  39  Breast  IDC T2N0M0  1  IIA  Malignant  
8  54  Breast  IDC T3N0M0  2  IIB  Malignant  
9  40  Breast  IDC T4N0M0  1  IIIB  Malignant  
10  44  Breast  IDC T2N1M0  2  IIB  Malignant  
11  55  Breast  IDC T2N0M0  2  IIA  Malignant  
12  63  Breast  IDC T2N0M0  2  IIA  Malignant  
13  70  Breast  IDC T2N0M0  2  IIA  Malignant  
14  50  Breast  IDC T2N1M0  2  IIB  Malignant  
15  60  Breast  IDC T2N0M0  2  IIA  Malignant  
16  38  Breast  IDC T2N0M0  2  IIA  Malignant  
17  48  Breast  IDC T2N0M0  2  IIA  Malignant  
18  75  Breast  IDC T2N1M0  2  IIB  Malignant  
19  40  Breast  IDC T2N0M0  2  IIA  Malignant  
20  49  Breast  IDC T4N1M0  2  IIIB  Malignant  
21  43  Breast  IDC T2N0M0  2  IIA  Malignant  
22  61  Breast  IDC T2N1M0  2  IIB  Malignant  
23  55  Breast  IDC T2N0M0  2  IIA  Malignant  
24  58  Breast  IDC T1N0M0  2  I  Malignant  
25  57  Breast  IDC T4N2M0  2  IIIB  Malignant  
26  45  Breast  IDC T2N0M0  2  IIA  Malignant  
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27  53  Breast  IDC T2N1M0  2  IIB  Malignant  
28  47  Breast  IDC T2N0M0  2  IIA  Malignant  
29  34  Breast  IDC T2N0M0  2  IIA  Malignant  
30  53  Breast  IDC T3N1M0  2  IIB  Malignant  
31  39  Breast  IDC T2N0M0  1  IIA  Malignant  
32  36  Breast  IDC T1N0M0  2  I  Malignant  
33  60  Breast  IDC T2N0M0  3  IIA  Malignant  
34  60  Breast  IDC T2N0M0  2  IIA  Malignant  
35  29  Breast  IDC T2N0M0  3  IIA  Malignant  
36  50  Breast  IDC T2N0M0  -  IIA  Malignant  
37  66  Breast  IDC T2N0M0  2  IIA  Malignant  
38  37  Breast  IDC T2N0M0  2  IIA  Malignant  
39  46  Breast  IDC T2N0M0  2  IIA  Malignant  
40  43  Breast  IDC T2N0M0  2  IIA  Malignant  
41  62  Breast  IDC T4N0M0  3  IIIB  Malignant  
42  46  Breast  IDC T2N0M0  3  IIA  Malignant  
43  45  Breast  IDC T2N0M0  2  IIA  Malignant  
44  49  Breast  IDC T2N0M0  3  IIA  Malignant  
45  52  Breast  IDC T2N1M0  3  IIB  Malignant  
46  32  Breast  NC  T2N3M0  -  IV  Malignant  
47  51  Breast  IDC  T2N0M0  2  IIA  Malignant  
48  40  Breast  MC T3N0M0  -  IIB  Malignant  
49  58  Breast  MC T3N0M0  -  IIB  Malignant  
50  64  Breast  MC T2N0M0  -  IIA  Malignant  
51  49  LN MIDC T1N1M0  -  -  Metastasis  
52  41  LN MIDC -  -  -  Metastasis  
53  50  LN MIDC T2N1M0  -  -  Metastasis  
54  61  LN MIDC T2N1M0  -  -  Metastasis  
55  57  LN MIDC T4N2M0  -  -  Metastasis  
56  38  LN MIDC T2N1M0  -  -  Metastasis  
57  52  LN MIDC T4N1M0  -  IIIB  Metastasis  
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58  46  LN MIDC -  -  -  Metastasis  
59  39  LN MIDC T4N1M0  -  -  Metastasis  
60  48  LN MIDC T3N1M0  -  -  Metastasis  
61  50  LN MIDC T2N1M0  -  -  Metastasis  
62  38  LN MIDC -  -  -  Metastasis  
63  46  LN MIDC T4N2M0  -  IIIB  Metastasis  
64  52  LN MIDC T2N1M0  -  -  Metastasis  
65  57  LN MIDC T2N2M0  -  -  Metastasis  
66  50  LN MIDC T2N2M0  -  -  Metastasis  
67  45  LN MIDC T4N1M0  -  -  Metastasis  
68  58  LN MIDC T4N1M0  -  -  Metastasis  
69  57  LN MIDC T2N1M0  -  -  Metastasis  
70  33  LN MIDC -  -  -  Metastasis  
71  76  LN MIDC -  -  -  Metastasis  
72  48  LN MIDC T2N1M0  -  -  Metastasis  
73  57  LN MIDC T3N1M0  -  IIIA  Metastasis  
74  46  LN MIDC -  -  -  Metastasis  
75  56  LN MIDC -  -  -  Metastasis  
76  42  LN MIDC -  -  -  Metastasis  
77  49  LN MIDC -  -  -  Metastasis  
78  51  LN MIDC -  -  -  Metastasis  
79  47  LN MIDC T3N2M0  -  IIIA  Metastasis  
80  36  LN MIDC T2N2M0  -  -  Metastasis  
81  41  LN MIDC T2N2M0  -  -  Metastasis  
82  39  LN MIDC -  -  -  Metastasis  
83  53  LN MIDC -  -  -  Metastasis  
84  29  LN MIDC -  -  -  Metastasis  
85  34  LN MIDC T2N1M0  -  -  Metastasis  
86  35  LN MIDC T2N1M0  -  -  Metastasis  
87  42  LN MIDC -  -  -  Metastasis  
88  47  LN MIDC -  -  -  Metastasis  
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89  47  LN MIDC -  -  -  Metastasis  
90  53  LN MIDC T2N1M0  -  -  Metastasis  
91  40  Breast  - -  -  -  NAT  
92  43  Breast  - T2N1M0  -  -  NAT  
93  42  Breast  - T1N1M1  -  -  NAT  
94  44  Breast  - -  -  -  NAT  
95  51  Breast  - -  -  -  NAT  
96  43  Breast  - T2N1M0  -  -  NAT  
97  43  Breast  - -  -  -  NAT  
98  35  Breast  - -  -  -  NAT  
99  42  Breast  - -  -  -  NAT  
100  42  Breast  - -  -  -  NAT  
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Appendix III: Representative image of a tissue section 
visualised under an optical microscope at 400x 
magnification with the grid used for the eyepiece 
systemic quantification.  
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Appendix IV: Images of all invasive carcinoma, lymph node metastasis and adjacent 
normal tissue sections stained for TSP1 and IDO1. Representative images of TSP1 
(rabbit) IgG control and IDO1 (mouse) IgG control staining. 
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Appendix V: Tryptophan composition of the different 
VEGFA isoforms (NCBI website) 
Isoform NCBI code N.o of amino 
acids 
N.o of 
tryptophans 
% of 
tryptophan 
a NP_001020537.2 412 7 1.7 
c   NP_001020538.2 389 5 1.3 
d NP_001020539.2 371 5 1.4 
e NP_001020540.2  354 5 1.4 
f NP_001020541.2 327 5 1.5 
g NP_001028928.1 371 5 1.3 
h NP_001165093.1 317 5 1.6 
i NP_001165094.1 232 5 2.2 
j NP_001165095.1 215 4 1.9 
k  NP_001165096.1 209 3 1.4 
l NP_001165097.1 191 3 1.6 
m NP_001165098.1 174 3 1.7 
n NP_001165099.1  147 3 2.0 
o  NP_001165100.1 191 3 1.6 
p NP_001165101.1 137 3 2.2 
q NP_001191313.1 171 4 2.3 
r NP_001191314.1 351 6 1.7 
s NP_001273973.1 163 0 0 
x NP_001303939.1 213 3 1.4 
b NP_003367.4 395 6 1.5 
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